Exhibit 588

| | Page 1 |
|----------|---|
| 1 | IN THE UNITED STATES DISTRICT COURT |
| | FOR THE EASTERN DISTRICT OF NORTH CAROLINA |
| 2 | |
| 3 | IN RE: |
| |) |
| 4 | CAMP LEJEUNE WATER LITIGATION) Case No.: |
| |) 7:23-cv-00897 |
| 5 |) |
| | This Document Relates to:) |
| 6 |) |
| | ALL CASES) |
| 7 | |
| _ | |
| 8 | |
| 9 | VIDEOTAPED DEPOSITION OF MATTHEW COOPER, MD |
| 10 11 | THURSDAY, JULY 10, 2025 |
| L | |
| 12 | |
| 13 | Videotaped deposition of MATTHEW COOPER, MD, |
| 14 | held at Center for Advance Care Building, 8900 West |
| 15 | Doyne Avenue, Wauwatosa, Wisconsin, commencing at |
| 16 | a.m., on the above date, before Juliana F. Zajicek, |
| 17 | Registered Professional Reporter, Certified Shorthand |
| 18 | Reporter, Certified Realtime Reporter. |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | Job No. 7450002 |

Page 2 of 281

| | Page 2 |
|-----|---|
| 1 | APPEARANCES: |
| 2 | ON BEHALF OF THE PLAINTIFFS: |
| 3 | MANDELL, BOISCLAIR & MANDELL, LTD. |
| | One Park Row |
| 4 | Providence, Rhode Island 02903 |
| | 401-273-8330 |
| 5 | BY: MARK MANDELL, ESQ. |
| | mmandell@mbmjustice.com; |
| 6 | |
| 7 | ON BEHALF OF THE DEFENDANT: |
| 8 | U.S. DEPARTMENT OF JUSTICE |
| | Trial Attorney, Civil Division |
| 9 | P.O. Box 340 |
| | Washington, DC 20044 |
| 10 | 202-616-8461 |
| | BY: CARSON M. GARAND, ESQ. |
| 11 | carson.m.garand@usdoj.gov; |
| | ERICK MARQUINA, ESQ. |
| 12 | erick.marquina@usdoj.gov; |
| | JOSHUA CARPENITO, ESQ. (Via Zoom) |
| 13 | joshua.g.carpenito@usdoj.gov |
| 14 | |
| 15 | ALSO PRESENT: |
| 16 | LEXI DOROTINSKY, (Via Zoom) |
| | Mandell, Boisclair & Mandell, Ltd. |
| 17 | |
| 18 | THE VIDEOGRAPHER: |
| 19 | STEPHAN HOOG, |
| | Golkow Technologies, a Veritext Division. |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 2 4 | |

| | | | Page 3 |
|-----|------------|-----------------------------------|----------|
| 1 | | I N D E X | |
| 2 | WITNESS: | 1 | PAGE: |
| 3 | MATTHEW CO | OOPER, MD | |
| 4 | EXAM | BY MR. GARAND | 6 |
| 5 | EXAM | BY MR. MANDELL | 212 |
| 6 | | | |
| 7 | | **** | |
| 8 | | EXHIBITS | |
| 9 | DR. COOPER | EXHIBIT MARKE | O FOR ID |
| 10 | No. 1 | Plaintiffs' Designation and | 15 |
| | | Disclosure of Phase III Expert | |
| 11 | | Witnesses with Respect to Kidney | |
| | | Cancer; Materials Considered List | |
| 12 | | for Matthew Cooper's Report on | |
| | | Plaintiff Frank W. Mousser | |
| 13 | | | |
| | No. 2 | Plaintiffs' Designation and | 16 |
| 14 | | Disclosure of Phase III Expert | |
| | | Witnesses with Respect to Kidney | |
| 15 | | Cancer; Materials Considered List | |
| | | for Matthew Cooper's Report on | |
| 16 | | Plaintiff Jacqueline J. Tukes | |
| 17 | No. 3 | Supplemental Materials Considered | 16 |
| | | List, February 2, 2025 | |
| 18 | | | |
| | No. 4 | Third Supplemental Materials | 17 |
| 19 | | Considered List, February 2, 2025 | |
| 20 | No. 5 | Invoice dated 12/15/2024 | 22 |
| 21 | No. 6 | Fee Schedule dated 8/29/2024 | 34 |
| 22 | No. 7 | Specific Causation Expert Report: | 37 |
| 0.0 | | Frank Mousser, 2/2/2025 | |
| 23 | 27. | | 2.5 |
| 0.4 | No. 8 | Specific Causation Expert Report: | 37 |
| 24 | | Jacqueline Tukes, 2/2/2025 | |
| | | | |

Golkow Technologies, A Veritext Division

| | | | Page 4 |
|----------|------------|--|--------|
| 1 | | EXHIBITS | |
| 2 | DR. COOPER | EXHIBIT MARKED | FOR ID |
| 3 | No. 9 | Laboratory results; | 94 |
| 4 | | 00667_MOUSSER_0000005598 - 5812 | |
| 4 | No. 10 | Dep transcript of Daniel Kevin | 107 |
| 5 | 110. 10 | Flood, M.D., 8/7/2024 | 107 |
| 6 | No. 11 | Progress Note dated 4/18/2022; | 113 |
| | | 00667_MOUSSER_VHA_000000375 | |
| 7 | | | |
| 0 | No. 12 | Mr. Mousser's lab results from | 118 |
| 8 | | March 20, 2023; | |
| 9 | | 0667_MOUSSER_VBA_0000005164 - 5165 | |
| | No. 13 | Progress note dated 5/6/2024; | 122 |
| 10 | | 0667_MOUSSER_VHA_0000001499 - 1504 | |
| 11 | No. 14 | Progress notes dated 11/12/2024; | 123 |
| | | 0667_MOUSSER_VHA_0000001624 - 1626 | |
| 12 | | | |
| 1 2 | No. 15 | Lab results dated 3/22/2016; | 124 |
| 13 14 | No. 16 | 0667_MOUSSER_VHA_0000001567 - 1568 Progress note dated 7/19/2022; | 131 |
| | 100. 10 | 0667_MOUSSER_VHA_0000000327 - 333 | 131 |
| 15 | | | |
| | No. 17 | Progress note dated 12/11/2023; | 134 |
| 16 | | 0667_MOUSSER_VHA_000000111 - 112 | |
| 17 | No. 18 | Progress note dated 12/15/2023; | 138 |
| 1.0 | | 0667_MOUSSER_VHA_000000097 - 103 | |
| 18 | No. 19 | Pages 1, 101 - 103 and 118 of | 144 |
| 19 | NO. 19 | Andrew P. Rockwood, MD, deposition | 144 |
| | | transcript from 7/24/24 | |
| 20 | | - | |
| | No. 20 | Progress notes dated 11/8/2024; | 153 |
| 21 | | 0667_MOUSSER_VHA_0000001631 - 1638 | |
| 22 | No. 21 | Medical records from South Texas | 157 |
| 2.2 | | Cardiovascular Consultants, dated | |
| 23 | | 4/6/2016; | |
| 24 | | 0667_MOUSSER_STCC_000000078 - 80 | |
| | | | |

Page 5 of 281

| | | 1 | Page 5 |
|----|------------|------------------------------------|--------|
| 1 | | EXHIBITS | |
| 2 | DR. COOPER | EXHIBIT MARKED | FOR ID |
| 3 | No. 22 | Medical records from South Texas | 160 |
| | | Cardiovascular Consultants, dated | |
| 4 | | 3/16/2021; | |
| | | 0667_MOUSSER_STCC_000000054 - 57 | |
| 5 | | | |
| | No. 23 | Medical records from South Texas | 162 |
| 6 | | Cardiovascular Consultants, dated | |
| | | 10/24/2021; | |
| 7 | | 0667_MOUSSER_STCC_0000000044 - 47 | |
| | No. 24 | Supplemental Specific Causation | 169 |
| 8 | | Expert Report for Frank Mousser by | |
| | | Armine K. Smith, MD | |
| 9 | | | |
| | No. 25 | Medical records; | 200 |
| 10 | | 00667_MOUSSER_0000007336 - 7366 | |
| 11 | No. 26 | Peterson Health medical records; | 205 |
| | | 00667_MOUSSER_0000008702 through | |
| 12 | | 8732 | |
| 13 | | | |
| 14 | | | |
| 15 | | | |
| 16 | | | |
| 17 | | | |
| 18 | | | |
| 19 | | | |
| 20 | | | |
| 21 | | | |
| 22 | | | |
| 23 | | | |
| 24 | | | |
| | | | |

| 1 | THE VIDEOGRAPHER: We are now on the record. My |
|----|--|
| 2 | name is Stephan Hoog. I am the videographer for |
| 3 | Golkow, a Veritext Division. |
| 4 | Today's date is July 10th, 2025. The time |
| 5 | is 8:50 a.m., as indicated on the video screen. |
| 6 | This video deposition is being held at |
| 7 | 8900 West Doyne Avenue, Wauwatosa, Wisconsin, In the |
| 8 | Matter of In Re: Camp Lejeune Water Litigation. |
| 9 | The deponent today is Dr. Matthew Cooper. |
| 10 | Counsel will be noted on the stenographic |
| 11 | record. |
| 12 | The court reporter is Juliana Zajicek. |
| 13 | Can you please swear in the doctor. |
| 14 | (WHEREUPON, the witness was duly |
| 15 | sworn.) |
| 16 | THE VIDEOGRAPHER: Please proceed. |
| 17 | MATTHEW COOPER, MD, |
| 18 | called as a witness herein, having been first duly |
| 19 | sworn, was examined and testified as follows: |
| 20 | EXAMINATION |
| 21 | BY MR. GARAND: |
| 22 | Q. Dr. Cooper, my name is Carson Garand. I'm |
| 23 | here with my colleague Erick Marquina. We are |
| 24 | attorneys with the Department of Justice, and we |
| | |

Page 7 of 281

Page 7 1 represent the United States in this matter. 2 Do you understand that? 3 Α. I do. Can you please state your full name for 4 Q. 5 the record, please? 6 Α. Matthew Cooper. 7 And can you please state your current 8 business address? 9 Α. 8900 West Wisconsin Avenue, Milwaukee, 10 Wisconsin 53005. 11 Okay. Doctor, you've been deposed before? Ο. I have. 12 Α. 13 Okay. I'm going to go over some ground Ο. 14 rules just to make sure everything goes smoothly 15 It's probably, you know, things you've heard before, but just to make sure we're all on the same 16 17 page. 18 Do you understand that you took an oath to tell the truth today? 19 2.0 Α. T do. 21 Do you understand that this is the same Q. 22 oath that you would take in court subject to the same

23

24

Page 8 of 281

Α.

penalties of perjury?

I do.

| Q. During the deposition the court reporter |
|---|
| is going to record and transcribe everything we say |
| while we're on the record. So to make sure everything |
| gets transcribed properly, I'll ask that you give me |
| verbal responses to my questions. Is that okay? |

- A. I understand.
- Q. If you didn't hear or understand a question, please let me know. I'm going to be asking you a lot today, so some of them might not be worded perfectly. So if you don't understand, certainly let me know and I'd be happy to rephrase. Okay?
 - A. Thank you.
- Q. But if you do answer my question, I'm going to under -- assume that you understood it. Okay?
 - A. Okay.
- Q. Please be sure to let me finish asking my question before you begin to answer, and I'll do my best to allow you to fully answer before I ask my next question. Okay?
 - A. Okay.
- Q. While we're here, you can correct your testimony at any time. So if we talk about something and you want to modify it or add or change an answer

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

Page 9 of 281

that we discussed earlier, please feel free to do that. Okay?

- A. I understand.
- Q. We're going to try to take a break about every hour or so, but if you need to take a break for any reason or no reason at all, you just want to --want to take a five-minute break, please let me know. I'm -- I'm happy to stop at any point. The only caveat there is if I've asked a question, I'll ask that you answer the question before we take the break. Okay?
 - A. Understood.
- Q. During the deposition, you may hear Mr. Mandell object to certain questions. Unless he instructs you not to answer, I'm going to ask that you answer the question, but, of course, if he instructs you not to, then you're -- you're of course able to take his advice there.

Is there any reason why you would be unable to give your most truthful and accurate testimony today?

- A. No.
- Q. Doctor, what did you do to prepare for your deposition today?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

| A. So I reviewed a number of the voluminous |
|---|
| materials as part of this case. Most importantly, I |
| reviewed my expert opinion and had conversations with |
| Mr. Mandell and his office in preparation for today's |
| planned testimony. |

Ο. How did you decide which materials to review in preparation for the deposition?

MR. MANDELL: The only thing I would instruct you is that if it's any information or part of a conversation with me as your attorney here, or anyone else in my office, I'm instructing you not to answer If you can otherwise answer the question as to how you chose what you reviewed, fine, but nothing that we discussed. Okay?

THE WITNESS: Understood.

MR. MANDELL: Thank you.

BY THE WITNESS:

So I reviewed what I believed were the Α. pertinent documents to not only specifically the case but, you know, to my expertise, things that, again, I thought were going to be most relevant to our conversation today, but the specifics of which I can't recall.

BY MR. GARAND:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

| Q. | Okay. | . So | you | don't | recall | what | what |
|---------|---------|------|-----|--------|--------|------|----------|
| records | exactly | that | you | review | wed? | | |

- A. In general I can give you some of the -the big pieces but not all of them. Certainly I
 reviewed, again, the substantive medical histories of
 both of the -- the parties in this case, focused
 certainly on the operative reports and the pathology
 reports, reviewed some of the data following
 nephrectomy for both of the -- the plaintiffs in this
 case, looked at some of the depositions that I believe
 were most important and pertinent to my testimony,
 reviewed the deposition of Dr. Johnstone as I thought
 that would be important, as well as some of the data
 that was in his deposition. And I believe that's the
 substance that I can recall.
- Q. Okay. And you also said that you met with your attorneys, and as Mr. Man- -- Mandell said, I'm not asking for the substance of any of those conversations, but can you tell me which lawyers you consulted with in preparing for your deposition today?
- A. Mr. Mandell and one of -- and one of his associates. Sorry, I don't remember her last name.
- Q. Okay. Do you remember how many times you met to prepare for your deposition today?

2.1

2.3

- Yes. About three or four times over a couple of days, a couple of hours each time.
- And those three or four times, are those within the last week or so?
 - The last couple of weeks. Α.
- Ο. And you said each was about -- each of the three or four times was about a couple of hours each time?
 - That's correct.
- Ο. Were these persons -- or were these meetings in person, over the phone?
 - Α. Video conference, Zoom.
- Ο. Have you had any communications with anyone other than an attorney to prepare for your deposition today?
 - Δ No.
- Have you had any communications with any of the plaintiffs in the Camp Lejeune Water Litigation about your deposition?
 - Α. No.
- Have you had any communications with any of Mr. Mousser's or Ms. Tukes' treating physicians to prepare for your deposition?
 - Α. No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- Q. How did you first become aware of the Camp Lejeune Water Litigation?
 - A. I was contacted by Mr. Mandell.
 - Q. So Mr. Mandell was the -- the person who first contacted you about working in this litigation?
 - A. Yes, that's correct.
 - Q. Do you recall when you were first contacted by Mr. Mandell?
 - A. Boy, I just don't remember the specifics. It was last year, summertime perhaps.
 - O. Okay. So summer of 2024?
- 12 A. That sounds about right.
- Q. Were you provided with any information during this initial contact?
 - A. No, just conversation.
 - Q. So you had been hired as an expert witness in this matter, right?
 - A. Yes, that's correct.
 - Q. You did not execute a retainer agreement with the plaintiffs' leadership group or any of the plaintiffs regarding this liti- -- litigation, though, right?
- 23 A. That's correct.
- 24 O. Is that typical practice for you when

3

4

5

6

8

9

10

11

15

16

17

18

19

20

21

| you're providing expert betvies, | 1 | you're providin | g expert se | rvices |
|----------------------------------|---|-----------------|-------------|--------|
|----------------------------------|---|-----------------|-------------|--------|

A. Yes, sir.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

- Q. Do you recall when you were formally retained then?
 - A. I'm sorry, I don't.
- Q. Presumably after that summer of 2024 conversation?
 - A. Correct, sometime after that conversation.
- Q. Do you recall if it was, you know, pretty quick after, if it was a couple of months later?
 - A. I believe it was pretty quickly after.
- Q. And is it Mr. Mandell's firm that retained you?
 - A. Yes.
- Q. Did you perform any work in connection with the Camp Lejeune Water Litigation prior to being formally retained?
 - A. No.
- Q. What did you -- what was your assignment in this matter?
 - MR. MANDELL: Objection. Again, anything that comes from me or anybody in my firm to you is privileged. You're not to answer that. If you can otherwise explain it, perhaps in terms of what you

generally did, that's -- that would be appropriate, or more appropriate, okay.

BY THE WITNESS:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

A. Yeah, I was -- well, I was provided documentation that included the medical records of the plaintiffs in this case as well as some information surrounding the instances at Camp Lejeune that I was asked to review and to provide my expert opinion.

BY MR. GARAND:

- Q. Do you have any support staff that's helping you with this matter?
 - A. No.
- Q. Okay. Dr. Cooper, we're going to mark a few exhibits here which are your Materials Considered List. So bear with me here while we do this. And we'll go first with the Materials Considered List for Mr. Mousser, the initial list, and we'll mark this as Cooper Exhibit 1.

(WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 1, for identification, as of 07/10/2025.)

THE WITNESS: Thank you.

MR. MANDELL: Thank you.

| 1 | MR. GARAND: Madam Court Reporter, would you |
|----|--|
| 2 | like me to hand you the the record? |
| 3 | THE COURT REPORTER: Sure. |
| 4 | BY MR. GARAND: |
| 5 | Q. Yeah, if you don't mind reviewing that |
| 6 | quickly. |
| 7 | So I'll mark I'll mark as Cooper No. 2 |
| 8 | your Materials Considered List for plaintiff |
| 9 | Jacqueline J. Tukes. |
| 10 | (WHEREUPON, a certain document was |
| 11 | marked Dr. Cooper Deposition Exhibit |
| 12 | No. 2, for identification, as of |
| 13 | 07/10/2025.) |
| 14 | MR. GARAND: I'll mark as Cooper Exhibit 3, the |
| 15 | document entitled Dr. Matthew Cooper, Supplemental |
| 16 | Materials Considered List. |
| 17 | (WHEREUPON, a certain document was |
| 18 | marked Dr. Cooper Deposition Exhibit |
| 19 | No. 3, for identification, as of |
| 20 | 07/10/2025.) |
| 21 | MR. GARAND: And as Cooper Exhibit 4, I'll mark |
| 22 | the document titled Dr. Matthew Cooper, Third |
| 23 | Supplemental Materials Considered List. |
| 24 | (WHEREUPON, a certain document was |
| | |

| 1 | m | ar. | ked | Dr. | Cooper | Deposition | on | Exhibit |
|---|---|-----|------|-------|--------|------------|----|---------|
| 2 | N | э. | 4, | for | identi | fication, | as | of |
| 3 | 0 | 7/ | 10/2 | 2025. | .) | | | |

MR. GARAND: And just for the record, I believe we received a second Third Supplemental Materials Considered List from Ms. Giles of your office. It contained the same information that's in this document there, so I'm just providing this one.

MR. MANDELL: Okay. Thank you.

BY MR. GARAND:

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- Q. And just to make sure I'm not missing anything, there's no second supplemental Materials Considered List, right, that you are aware of?
 - A. Not that I'm aware of.
- Q. Okay. Doctor, do you recognize each of these four documents?
 - A. I do, having seen them in the past.
- Q. Okay. Doctor, did you prepare these documents, or did counsel prepare them?
 - A. Counsel prepared these.
- Q. Okay. In looking between these four exhibits, again, Cooper Exhibits 1 through 4, are they a complete and accurate copy of your lists of materials considered?

| A. Well, there's a lot on he | . A. | ell, t | here's | a i | lot | on | her |
|------------------------------|------|--------|--------|-----|-----|----|-----|
|------------------------------|------|--------|--------|-----|-----|----|-----|

Q. There is.

- A. I believe they are. They -- they look complete to the best of my knowledge, but, again, I'm uncertain of the totality of all of the documents that were provided to me and currently in the DropBox that I think we have available.
- Q. And we'll go through some of those, but if there are any documents we've discussed that are either not on those or you don't recall reviewing, certainly let me know.
 - A. Okay.
- Q. Are there any documents that you reviewed but decided not to rely on?
- A. I am -- oh, boy. I'm sorry, I don't remember that. I'd say I reviewed a lot in here. I can't remember exactly which pieces from sort of what part of this, you know, were used in creating my expert testimony.
- Q. So, Doctor, according to -- to your Materials Considered List, you reviewed over 35,000 documents for Mr. Mousser's case.

Does that sound about right to you?

MR. MANDELL: Objection. Go ahead.

BY THE WITNESS:

- 2 Boy, I don't remember the totality of what 3 I reviewed over the course of these many months, but,
- again, that -- this is the substance of what was put 4
- 5 before me.

1

BY MR. GARAND: 6

- 7 Could you --
- 8 MR. MANDELL: Sorry, can I just ask for
- 9 clarification. When you say "this is the substance,"
- 10 what is "this," just for the record? I'm sure
- 11 Mr. Garand wants that.
- 12 MR. GARAND: Thank you, Mr. Mandell.
- 13 BY THE WITNESS:
- 14 What's actually listed in these documents.
- 15 MR. MANDELL: Do you mean Exhibits 1 through 4?
- BY THE WITNESS: 16
- 17 Exhibits 1 through 4, yes, thank you very
- 18 much.
- 19 MR. GARAND: Thank you, Mr. Mandell, for that.
- 2.0 MR. MANDELL: Yeah, and --
- THE WITNESS: Point taken. 21
- MR. MANDELL: -- I -- I don't mean to impose 22
- 23 myself. I just wanted -- I thought you'd want it
- 24 clear too.

- 1 MR. GARAND: Thank you.
- MR. MANDELL: 2 Okay.
 - BY MR. GARAND:

3

5

10

11

- So according to your Materials Considered 4 O. Lists, you reviewed over 15,000 documents for Ms. --6 Ms. Tukes' case.
- Does that sound about right to you? 8 MR. MANDELL: Objection.
- BY THE WITNESS: 9
 - Same answer to the last question. Α. I -- I believe what's in Exhibits 1 through 4, yeah, was inclusive of what was put before me.
- 13 BY MR. GARAND:
- 14 And I'll represent to you my math is not 15 great. Addition is about the extent of it, but -- but 16 that is, you know, if you total up the amount of 17 records in there, that's about what that looks like, 18 about 35,000 dollars -- 35,000 documents for 19 Mr. Mousser and 15,000 pages of records for Ms. Tukes, 20 okay?
- 21 MR. MANDELL: Objection.
- BY MR. GARAND: 22
- 2.3 Doctor, did you actually review all of Q. those records? 24

| A. I can't remember the specifics of what |
|--|
| contained through Exhibits 1 through 4 I reviewed, but |
| I reviewed what I believed was the important |
| substantive material in order for me to provide what |
| you see in my expert opinion and what we'll talk about |
| today. |

- Q. So, Doctor, let me ask then, given the voluminous records in this case, how did you decide what to review and what to rely on?
- MR. MANDELL: Okay. I'm going to give you the same instruction that I gave you before, that if it's anything to do with conversations between you and me or any other person in my office, you're not to answer that question, but if you can otherwise answer it, go ahead.

BY THE WITNESS:

- A. So I primarily focused on the patient records, the clinical record of the patient as well as materials that I thought were necessary to support information that I had gathered in the patient's records. That's the substance of what, again, I remember in the review of all of these materials.

 BY MR. GARAND:
 - O. Thank you, Doctor. I'm going to show you

1 what I'll mark as Cooper Exhibit 5, I believe we're 2 on.

> (WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 5, for identification, as of 07/10/2025.)

BY MR. GARAND:

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

- Doctor, please review this record and please let me know if this is something you've seen before.
 - Yes, it is. Α.
 - And, Doctor, what is it? Q.
- This is the bill that I submitted, excuse me, to Mr. Mandell's office for some initial work in preparation for this case.
- Was this the first invoice you submitted Q. to Mr. Mandell?
 - I believe, yes, yes, it is. Α.
- Ο. Do you recall if this is the only invoice you've sent to Mr. Mandell?
- 21 It is the only invoice that I've 22 submitted.
- 23 Okay. So, Doctor, this was -- and just Ο. 24 for the record, again, this is a December 15th, 2024,

invoice that Dr. Cooper sent to Mr. Mandell and his law firm for services rendered in this case.

So this document is dated eight months ago, is that right, approximately?

- A. Approximately, yes.
- Q. So you've only sent Mr. Mandell one invoice in the past eight months, is that right?
 - A. That's correct, yes.
- Q. Have you done additional work after this date, after December 15th of 2024?
 - A. I have, yes.
- Q. Is it your typical practice -- or what is your typical billing practice for your expert services?
- A. Well, I do my best to try and stay current with billing. This is not my full-time job. And so, you know, my responsibilities with my current profession oftentimes prevent me from, as much as I want to, to stay current. So I just haven't submitted a supplementary bill, you know, since this in December.
- Q. Can you give me an estimate of how many hours you've spent in the last eight months working on this case and just -- and, Doctor, for the record,

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- 1 just for -- by "this case" --
- 2 A. Yeah.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

- Q. -- I mean Mr. Mousser's case and
 Ms. Tukes' case?
 - A. I'd say approximately 20 additional hours.
 - Q. Okay. And what have you been doing in those 20 additional hours?
 - A. So I was provided additional patient records. I was provided some additional deposition testimony. I was provided particularly information, the testimony of Dr. Johnstone, which I reviewed including some articles that were cited there. And that's I think the extent of what I've done since then; and preparations that we talked about for today.
 - Q. Well, Doctor, I know there's -- well, let me ask. Will -- will you be submitting an additional invoice to Mr. Mandell's firm at -- at some point in the future?
 - A. Yes, I plan to.
- MR. GARAND: Okay. When that happens,

 Mr. Mandell, we're going to request that that invoice

 be produced to us.
- 23 BY MR. GARAND:
- 24 O. So just ballpark again, over the last

| eight months, about 20 approximately 20 additional |
|--|
| hours. Can you, you know, again, give an approximate |
| number as to how many hours you've spent doing which |
| activities that you just discussed? |

- Boy, I think we talked earlier about, you Α. know, five or so hours in preparation for this and then the remaining was in the review of those additional materials and depositions.
- So about 15 hours reviewing the additional materials. Do you know -- and presumably part of that is drafting your expert reports, right?
 - (Nodding head). Α.
- Ο. Do you recall how long it took for you to draft your expert reports?
 - Α. Three or four hours.
- Is that three or four hours total or per O. expert report?
- I've been -- probably between the two of Α. them, it's probably more like five or six hours.
- Okay. So that leaves about nine or ten hours reviewing the additional depositions and records, is that right?
- 23 MR. MANDELL: Objection.
- 2.4 BY THE WITNESS:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

| Α. | That sou | ınds | about | right. | . And | I'm not | а |
|------------|----------|------|-------|--------|-------|---------|---|
| math major | either, | but | that | sounds | about | right. | |
| BY MR. GAR | AND: | | | | | | |

And I know I'm asking you for, you know, Ο. approximations here and guesses, but we don't have another invoice here to go off of, so I'm just trying to understand what you've done over the last eight months.

And so -- so out of that, again, approximate nine or ten hours remaining, how would you divide that between deposition review and record review?

- Α. The majority of it is -- is record review. And I said the additional -- sorry, the deposition of Dr. Johnstone. So it's probably three hours with that deposition and the remainder was record review.
- Q. So three hours with Dr. Johnstone's deposition?
 - Α. Yeah.
 - And the remainder is record review? Ο.
- Α. Yes.
- Okay. And so in looking at this invoice Ο. here, again, Cooper Exhibit 5, it says, "Re: Mousser v. United States of America."

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

1 Do you see that bolded and underlined 2 there?

> Α. I do.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

- This invoice is also for work done in Q. Ms. Tukes' case, is that right?
- That's correct. Α.
 - And the invoice is for \$21,200, right? Ο.
 - Α. That's correct.
- Ο. Okay. Okay. So it looks like this first entry here is record and literature review for 4.5 hours.

Do you recall what percentage of that 4.5 hours was for record review and what percentage was for literature review?

- I'm sorry, I don't.
- Okay. So assuming -- well, so -- well, Ο. okay.

And so this -- so the 4.5 hours of record review here and then the approximately seven hours that we've discussed for record review in the last eight months, that's for both cases, right?

- Α. That's correct, yes.
- So at most, 7 plus 4.5, 11-1/2 hours for 23 24 the approximate 50,000 pages of records in this case,

1 is that right?

MR. MANDELL: Objection.

BY THE WITNESS:

A. Well, again, I -- I didn't admit the

5 | 50,000 --

2

3

4

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

BY MR. GARAND:

0. Oh.

A. -- but that's the amount of time that I spent in the record review of both cases, is what I believe you have.

Q. Okay. Let's look at Cooper Exhibit 1, which is your Materials Considered List for Mr. Mousser, your initial Materials Considered List.

If you look at Page 2 of this record, at the very top, the third line from the top, it says, "Plaintiffs specifically identify the following facts, data, and publications considered by Dr. Cooper in forming his opinions for Frank W. Mousser," right?

A. Correct.

Q. And then No. 2 says, "Transcripts of the depositions of Plaintiff Frank W. Mousser, Heather Mousser, Richard Eugene Mercer, Andrew P. Rockwood, MD, Daniel Kevin Flood, MD, Janet Mueller, PsyD, and all documents marked as exhibits therein."

Is that right?

1

2

3

4

5

6

8

9

13

14

15

16

- A. That's what it says, yes.
- Q. So, and, again, if we look at Exhibit 5, again, which is your December 2024 invoice, it states, lines 3 through 4 -- or sorry, 2 through 4 of this invoice date, you reviewed the deposition of Heather Mousser, Frank Mousser, and Dr. Mueller, is that right?
 - A. Correct.
- Q. Did you review the deposition transcripts of Mr. Richard Eugene Mercer, Dr. Rockwood, and Dr. Flood?
 - A. I don't recall. Those came later.
 - Q. But you don't recall that you've reviewed the -- whether you've reviewed those deposition transcripts?
- 17 A. I don't recall.
- 18 Q. Do you know who Mr. Mercer is?
- 19 A. I don't, no.
- Q. Do you know who Dr. Rockwood is?
- 21 A. No.
- Q. Do you know who Dr. Flood is?
- 23 A. I don't recall.
- O. So Dr. Rockwood is Mr. Mousser's VA

Filed 08/26/25 Page 30 of 281

1 urologist, do you understand -- or do you know that?

- A. Thank you.
- Q. So you did not know that before I told you?
 - A. No.

2

3

4

5

6

7

8

9

10

11

12

13

15

16

- Q. So you did not know that Dr. Rockwood is the urologist that initially found Mr. Mousser's cancer, correct?
- A. I don't know the name associated with the individual.
- Q. Okay. But you're -- you're unaware that he was deposed in this case, is that right?
- MR. MANDELL: Objection.
- 14 BY THE WITNESS:
 - A. I'm not unaware. I just didn't -- don't remember specifically the name and the individual who was Mr. Mousser's urologist.
- 18 BY MR. GARAND:
- Q. And I'm assuming the same is true for
 Dr. Daniel Flood, you don't know that he was deposed
 in this matter either?
- MR. MANDELL: Objection, he didn't testify to that, but go ahead.
- 24 BY MR. GARAND:

| 1 | Q. | Are you | aware | that D | r. Flood | was | depo | se | d |
|---|---------|---------|---------|--------|----------|-------|------|------|---|
| 2 | in this | matter? | | | | | | | |
| 3 | Α. | I do. | | | | | | | |
| 4 | 0. | And k | out vou | don't | recall | wheth | er d | or : | n |

- And -- but you don't recall whether or not Ο. you reviewed Dr. Flood's deposition transcript, right?
- Α. Again, I don't remember the specifics of that.
- And Dr. Flood is Mr. Mousser's VA nephrologist. Do you understand that, or did you know t.hat.?
- 11 MR. MANDELL: Objection.
- BY MR. GARAND: 12

5

6

7

9

10

14

15

16

17

18

19

20

21

22

23

- 13 Ο. Go ahead.
 - I understand he has a nephrologist, but I didn't have a name associated with that.
 - Would the deposition transcripts of Ο. Mr. Mousser's VA neurologist and VA nephrologist be relevant to your opinions today?
 - I believe that the portions of what they -- they say in their deposition may be important, but I relied mostly on the medical direct -- on the medical records following treatment of Mr. Mousser's cancer.
 - Let's go to Cooper Exhibit 2, which Ο. Okay.

is the initial Materials Considered List for Mrs. Tukes. And we'll again look at Page 2, and I'll be asking you a lot of the same questions here.

So if we look at Numbers 4 and 5, it states you reviewed the "Transcripts of the depositions of Plaintiff Jacqueline J. Tukes,

April 11th, 2024, and January 15 of 2025, Nagesh H.

Jayaram, MD, Roc McCarthy, DO, Heather Jones, MD, Mary Katherine Garbarini, MS, CGC, and all documents marked as exhibits therein." And Number 5 says, "Transcripts of the depositions of Willie Tukes, Jr. and K.V.

George Thomas, MD."

And if we go back to Cooper Exhibit 5, which is your December 15, 2024, invoice, it states that you reviewed the depositions of Jayaram, Thomas, McCarthy, and Ms. Tukes, is that right?

- A. Correct.
- Q. And I'm assuming "Tukes" there is Ms. Jacqueline Tukes, not her husband Mr. Tukes?
 - A. Correct.
- Q. So you have -- did you review the deposition transcripts of Heather Jones, Mary Katherine Garbarini, and Mr. Willie Tukes?
 - A. Again, I've looked at them in passing, but

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

| | I | don | 't | remember | the | specifics |
|--|---|-----|----|----------|-----|-----------|
|--|---|-----|----|----------|-----|-----------|

- Would you agree that the deposition transcript of Heather Jones, which is Mrs. Tukes' post-transplant nephrologist, would be relevant to your opinions?
- 6 MR. MANDELL: Objection; go ahead.

7 BY THE WITNESS:

1

2

3

4

5

8

9

14

15

16

17

18

19

2.0

21

2.2

23

- Not necessarily. Like I said, I relied on the medical records to make my determination.
- 10 BY MR. GARAND:
- 11 Okay. The last entry here on Cooper Ο. 12 Exhibit No. 5 is, "Complete Damage Questions -13 3.0 hours."
 - What does this refer to?
 - These were conversations that I had had with Mark and his office about questions, you know, surrounding post nephrectomy, what the outlook would be for Ms. Tukes and Mr. Mousser, of which, you know, I in addition put in my expert report.
 - So the contents of that is in your expert report, is that right?
 - Α. The substance is in the expert report, yes, sir.
 - Doctor, have you received -- or how much Q.

| 1 | compensation have you received to date in this case? |
|----|--|
| 2 | A. Solely what you see on this invoice of |
| 3 | December 15th. |
| 4 | Q. And is it fair to assume the approximately |
| 5 | 20 hours that you've done since this invoice would |
| 6 | also be billed at this 80 or \$800 an hour rate? |
| 7 | A. That's correct. |
| 8 | Q. Does your payment depend on the outcome of |
| 9 | this case at all? |
| 10 | A. No, it does not. |
| 11 | Q. What percentage of your annual income is |
| 12 | earned from serving as an expert witness? |
| 13 | A. Less than 1 percent. |
| 14 | Q. Is your fee schedule in this case the same |
| 15 | as fee schedules you've used in other cases? |
| 16 | A. Yes, sir, most recently. |
| 17 | Q. Okay. I'm going to show you your fee |
| 18 | schedule here, and I will mark this as Cooper |
| 19 | Exhibit 6. |
| 20 | (WHEREUPON, a certain document was |
| 21 | marked Dr. Cooper Deposition Exhibit |
| 22 | No. 6, for identification, as of |
| 23 | 07/10/2025.) |
| 24 | MR. GARAND: Thank you. |
| | |

- THE WITNESS: Thank you. 1
- 2 MR. GARAND: Thank you.
- BY MR. GARAND: 3

6

7

8

9

10

11

12

13

14

15

- Is this an accurate depiction of your 4 Q. 5 current fee schedule?
 - Yes, it is. Well, no. This is a little Α. bit old. The chart review is -- is 800 based upon, like we said here.
 - Ο. So when did the rate change from \$750 an hour to \$800 an hour?
 - I'm sorry, I don't know the specifics of Α. that. Sometime following -- following August and December.
 - Thank you, Doctor. Ο.
 - And for chart review, does that include deposition transcript review as well?
- 17 Α. It does.
- And presumably that includes medical 18 record review as well? 19
- 2.0 That's correct.
- 21 Have you ever served as an expert witness 0. 22 for a defendant?
- 23 Α. Yes.
- 24 Do you recall approximately how many cases Q.

| +ha+ | 1 0 | been' | 2 |
|-------|-----|-------|---|
| LIIaL | ·S | Deen | : |

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- A. Over the course of the last four years, I have been deposed approximately eight times, and for the question about defense, about those eight times, about five for the plaintiff and three for defense.
- Q. Prior to this case, have you ever worked as an expert witness for the Bell Legal Group?
 - A. No.
- Q. Prior to this case, have you ever worked as an expert witness for Keller Postman, LLC?
 - A. Not to my knowledge.
- Q. Prior to this case, have you ever worked as an expert witness for Lieff Cabraser Heimann & Bernstein LLP?
 - A. Not to my knowledge.
- Q. Prior to this case, have you ever worked as an expert witness for the Dowling firm, PLLC?
 - A. Not to my knowledge.
- Q. Prior to this case, have you ever worked as an expert witness for Weitz & Luxenberg, PC?
 - A. Not to my knowledge.
- Q. Prior to this case, have you ever worked as an expert witness for Wallace & Graham, P.A.?
 - A. Not to my knowledge.

| 1 | Q. And we'll talk about this a little bit |
|----|--|
| 2 | later, but is your expert are your expert services |
| 3 | typically in the Milwaukee or Wisconsin area or is it |
| 4 | national? |
| 5 | A. National. |
| 6 | Q. Okay. Dr. Cooper, I'm going to mark your |
| 7 | reports as exhibits now, and we'll start first with |
| 8 | the specific causation expert report for Frank |
| 9 | Mousser, dated February 2nd, 2025, and we'll mark this |
| 10 | as Cooper Exhibit 7. |
| 11 | (WHEREUPON, a certain document was |
| 12 | marked Dr. Cooper Deposition Exhibit |
| 13 | No. 7, for identification, as of |
| 14 | 07/10/2025.) |
| 15 | MR. GARAND: Thank you, Erick. |
| 16 | And then we'll also mark as Cooper |
| 17 | Exhibit 8 your specific causation expert report for |
| 18 | Jacqueline Tukes, dated February 2nd of 2025. |
| 19 | (WHEREUPON, a certain document was |
| 20 | marked Dr. Cooper Deposition Exhibit |
| 21 | No. 8, for identification, as of |
| 22 | 07/10/2025.) |
| 23 | BY MR. GARAND: |
| 24 | Q. And, Doctor, I'll ask that you briefly |
| | |

Page 38 of 281

review the reports in this case. I know that this exhibit also contains your CV, but I just want to make sure this report is the report that you drafted -- or these reports are the reports that you drafted.

- A. It is two-sided?
- O. Yes.
- A. Yes.
- MR. MANDELL: Off the record.

(WHEREUPON, discussion was had off the stenographic record.)

BY MR. GARAND:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- Q. Okay. Doctor, if we could look at Cooper Exhibit 7, which is your Mousser report, and we are going to turn to the CV here, which is directly after the record. And, Doctor, I know your CV is about 100 pages here, so I'll ask you to -- to briefly review it, but it's -- it's been printed off of what you submitted to us, so it should be fully accurate.
 - A. Okay. Yes, it looks complete, yes.
 - Q. Thank you, Doctor.
 - Do you recognize this document as your CV?
 - A. I do, yes.
- Q. Is this the most current version of your CV?

A. I believe I may have updated it with a couple of lectures within the last couple of months.

- Q. Okay. Would the lectures be the only additions within the last few months?
 - A. Yes.

1

2

3

4

5

6

7

8

9

10

11

14

15

- Q. Is this document a complete representation of your educational and employment background?
 - A. It is.
- Q. Does this document contain all of your publications?
- A. It does.
- Q. Is there any information you did not include in your CV?
 - MR. MANDELL: Objection. Could you rephrase that? I mean, it's obvious there's information about his life that he doesn't have in there.
- 17 BY MR. GARAND:
- Q. Is there any professional information
 other than the lectures we've just discussed that are
 included in your CV?
- 21 MR. MANDELL: Thank you.
- 22 BY THE WITNESS:
- 23 A. No.
- 24 BY MR. GARAND:

Q. Okay. Doctor, if we look at Page 1 of your CV, you are a transplant surgeon, is that right?

- A. Yes, sir.
- Q. And your residency was in general surgery?
- A. It was.

1

2

3

4

5

6

7

8

9

10

11

13

14

15

16

17

18

19

20

2.1

- Q. And your fellowship was in transplant surgery, right?
 - A. Yes, sir.
- Q. You are a board certified -- or sorry, you are board certified in surgery only, is that right?
 - A. Board certified general surgery, yes, sir.
- 12 Q. What is your current role?
 - A. So I am the division chief for the division of transplantation here at the Froedtert Memorial Lutheran Hospital. I am also the director for the service line for Froedtert and for Children's Hospital overseeing all of the adult and the pediatric transplant programs.
 - Q. Doctor, you mentioned overseeing. Do you still see patients directly?
 - A. I do.
 - Q. Do you still perform surgeries?
- 23 A. I do.
- 24 O. So can you tell me just generally what

does a transplant surgeon do?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- So we are -- we're fortunate to be the interface between referring doctors with patients who have end organ failure and the decision as to whether or not they meet candidacy for solid organ transplant. Once they are approved for surgery, we are then responsible, particularly from the surgeon's side, for performing the operations and then manage them post-transplant throughout the -- really the entirety of their post-transplant care.
- So you are involved with not just the Ο. surgery but also the post-transplant care, is that right?
 - Pre- and post-transplant, correct. Α.
- Do you typically see patients who are considering or going to be having a transplant surgery?
 - T do. Α.
- Do you typically see patients with, you know, kidney or other organ issues that are less severe?
 - Α. Can you ask that again, please?
- 0. So, for example, a patient with Sure. chronic kidney disease in the earlier stages, would

| you | be | treating | that | type | of | patient? |
|-----|----|----------|------|------|----|----------|
| | | | | | | |

- A. We do. We ask patients to come to us prior to end organ failure to discuss transplant.
- Q. And, Doctor, you said "we do." Is that something that you do as well?
 - A. It is.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- Q. Presurgery and postsurgery, would you be somebody's primary treater regarding their organ issues?
 - A. Yes, I would.
- Q. You're also a professor of surgery, is that right?
 - A. Yes, sir.
- Q. What percentage of your time is spent practicing as a surgeon versus teaching surgery?
- A. Teaching, very little. Our teaching is limited to residents and students that rotate on our service. So it's probably around 5 percent of time.
- Q. And what kind of transplant surgeries do you perform?
- A. Currently kidney and pancreas transplantation.
- Q. Can you give me a ballpark of how many transplant surgeries you do per year?

| | Α. | I | do a | pproximately | 100 | kidneys | and | about |
|----|----------|-----|------|--------------|-----|---------|-----|-------|
| 20 | pancreat | cic | per | year. | | | | |

- Do you see any other kind of patients? O.
- Well, I also see patients pre- and Α. post-transplant that are in need of some general surgical procedures as well that we also care for.
- What are those general surgical procedures? What does that look like?
- Patients that may have a hernia, particularly incisional hernias after their transplants. We put in dialysis access catheters and peritoneal dialysis catheters, and we can do small surgeries, we call them lumps and bumps, lipomas, and sometimes things like gallbladders if we feel comfortable doing that too, and those are the cases that I do.
- Ο. What are -- what percentage of your surgical practice is attributed to this general -these general surgical procedures?
 - Very small, 2 to -- 2 percent.
- How long do you have to meet with a 0. patient before you can render a diagnosis for that patient?
 - Can you be more specific? Any diagnosis? Α.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

| Q. So if you are so if you're going to |
|---|
| determine whether or not a patient needs a kidney |
| transplant, how long would you need to meet or how |
| many times would you need to meet with that patient |
| before you could determine whether they needed a |
| kidney transplant? |

- A. That's very different based upon the individual. Some are more complex than others. I'd say on average, you know, we meet with patients pre-transplant to determine their candidacy about between an hour and an hour-and-a-half, and then it includes some record review thereafter to help make that determination.
- Q. And so after an hour or an hour-and-a-half, you're able to determine whether or not a patient needs a kidney transplant?
 - MR. MANDELL: Objection.

Go ahead.

BY THE WITNESS:

- A. No, that's not what I said.
- 21 BY MR. GARAND:

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

22

23

- Q. My apologies.
- A. We meet with them initially for an hour and a half, and then we have record review and data

| collection that all | has to be put together. | And the |
|---------------------|--------------------------|---------|
| decision is made by | a multidisciplinary team | and not |
| by myself alone. | | |

- Q. Thank you, Doctor. And -- and as we go today, I'm not trying to put any words into your mouth, so if I misstate your testimony, please let me know.
 - A. Okay.

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

24

- Q. So you do treat patients with chronic kidney disease who are not nearing renal failure, is that right?
- A. I deal with patients who have chronic kidney disease whose expectation is that they will eventually potentially develop chronic renal failure.
- Q. When you say their expectation is that they'll get to endstage renal disease or chronic kid -- or kidney failure, what does that type of patient look like in terms of, like, their lab results and symptoms and things of that nature?
 - MR. MANDELL: Objection.

Go ahead.

BY THE WITNESS:

A. So we ask to see patients before they need to make a decision such as transplant, and so we see

patients in CKD, late Stage 3, and certainly CKD Stage 4 to be able to talk about what we would like to perform, is a preemptive kidney transplant. And so we have conversations with they and family about options available before they develop endstage renal disease and -- and potentially need dialysis.

BY MR. GARAND:

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- Q. And so when you say -- when you say late Stage 3, you mean CKD Stage 3b?
 - A. Typically, yes.
- Q. Do you typically see patients in CKD Stage 2 or 3a?
 - A. Not often, no.
 - Q. And why is that?
- A. My services aren't often necessary, although there are some occasional patients that have problems with a kidney that has maybe a somewhat normal GFR that still could benefit from a -- we call it a nephrectomy, an autotransplant, but that's few.
- Q. Okay. Doctor, I'm going to ask you a handful of questions here just to -- to try to understand what exactly the specialty is that you possess and the specialty in which you're -- you're testifying and providing opinions in this matter.

| | | Page 47 |
|-----|-------------|--|
| 1 | | Doctor, you're not an attorney, is that |
| 2 | right? | |
| 3 | Α. | No. |
| 4 | Q. | You are not an epidemiologist, right? |
| 5 | Α. | No, sir. |
| 6 | Q. | And you are not a geneticist, right? |
| 7 | Α. | No, sir. |
| 8 | Q. | You're not a toxicologist, right? |
| 9 | Α. | No, sir. |
| LO | Q. | You're not an oncologist, right? |
| L1 | Α. | No, sir. |
| L2 | Q. | You're not a nephrologist, is that right? |
| L3 | Α. | No, sir. |
| L4 | Q. | And you're not a transplant nephrologist, |
| L 5 | right? | |
| L6 | Α. | No, sir. |
| L 7 | Q. | Can you explain the difference between a |
| L8 | transplant | surgeon like yourself who handles kidney |
| L9 | transplant | s and a nephrologist or a transplant |
| 20 | nephrologia | st? |
| 21 | Α. | The difference primarily is medical versus |
| 22 | surgical s | pecialty. A transplant nephrologist and |
| 23 | transplant | surgeons, really all transplant physicians |
| 24 | and surgeon | ns work collaboratively in the diagnosis and |

care of patients. What primarily distinguishes the 1 2 surgeon from the nephrologist is we have the ability

to perform the surgical procedure, but, again, most of 3

what we do is, you know, collaborative work between 4

5 the two specialties.

6

7

8

13

- Q. And, Doctor, you are not a urologist, is that right?
 - No, sir. Α.

health, is that right?

- 9 Ο. You have no degrees in pharmacology, 10 correct?
- 11 Α. No, sir.
- 12 You have no degrees in environmental Ο.
- 14 Α. No, sir.
- 15 You have no degrees in occupational Ο. 16 medicine?
- 17 Α. No, sir.
- 18 And you have no degrees in statistics, 19 right?
- 20 Α. No, sir.
- 21 Have you ever physically examined Frank Ο. 22 Mousser or Jacqueline Tukes?
- 23 Α. I have not.
- 24 Have you ever met them or spoken with O.

| them | 2 |
|-------|----|
| LHell | lí |

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

- A. I have not.
- Q. Doctor, have you ever been subject to any disciplinary action or censure by any licensing body?
 - A. No, sir.
- Q. Have you ever been subject to any disciplinary action by any court or tribunal?
 - A. No, sir.
- Q. Doctor, in your practice, do you offer any guarantees to your patients?
 - A. Guarantees, no, no.
 - Q. And why is that?
- A. Really, everything is -- I can't guarantee what happens biologically in the field that I practice, so we don't use the word "guarantee."
- Q. Would you agree that medicine is not an exact science?
 - A. No, I wouldn't agree to that.
 - Q. And why is that?
- A. Because I think there's many parts in medicine that we have very good data to be able to provide information to patients that I think is critical for them to make important decisions.
 - Q. Would the treatment and -- or diagnosis,

treatment, and prognosis of chronic kidney disease fall into that category?

- A. Can you say that again, please?
- Q. So would the diagnosis, treatment, and -- and prognosis, determining the prognosis of chronic kidney disease fall into the subset of science -- or of medicine that is an exact science?

MR. MANDELL: Objection; form.

BY THE WITNESS:

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

- A. I think -- I think it's different for every patient. I think we have, fortunately in transplant, decades and decades of data that allow us to be able to look at a patient in front of us and be able to give them information about what their path is expected to be based upon those -- that data that we have a requirement to collect.
- BY MR. GARAND:
- Q. Do we also have significant, you know, decades and decades of data regarding progression of CKD?
- 21 | MR. MANDELL: Objection.
- Go ahead.
- 23 BY THE WITNESS:
- 24 A. We do.

BY MR. GARAND:

1

2

3

4

5

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Q. So, Doctor, like we discussed, typically patients with CKD Stage 2 and 3a -- stable CKD Stage 2 and 3a, don't come to see you, right?
- MR. MANDELL: Objection; go ahead.

6 BY THE WITNESS:

A. Not often.

BY MR. GARAND:

- Q. Do you typically provide a prognosis in your practice?
 - A. Prognosis. Yes, we do.
- Q. Okay. And is that -- what -- at what point in the transplant surgery process do you typically provide a prognosis?
- A. Really, when we have that initial interview with patients and we put the story together with their past medical history, again, the fortunate fact that we have, as I said, decades of data, and with my education, experience, and consistent review of the literature, I've been able to provide that prognosis for patients at the time that I'm seeing them.
- Q. Doctor, CKD staging is measured by looking at the glomerular filtration rate, or GFR, is that

right? 1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- That's part of it, yes. Α.
- Is the other part the level of protein in O. somebody's urine?
 - Α. That's correct.
- Ο. So the GFR is a measure of how well the kidneys are filtering blood, right?
 - In general, yes. Α.
- Is it true that often clinicians will use Ο. the estimated GFR or eGFR to measure kidney function?
- Α. They do. That's the convenient way of measuring a -- not even measuring -- of providing a GFR.
- When you say "convenient," is it typically accurate as well?
 - Α. No. It's actually not accurate.
- Q. Okay. Is it -- so then why is it relied on by doctors?
 - Α. Because it's easy to obtain.
- And why is it not accurate? 0.
 - Because your creatinine ends -- the Α. changes in creatinine are really not reflective of what, in fact, is that kidney's ability to do its filtering mechanism. It can change pretty rapidly and

pretty easily with many different interventions.

- Would you agree that a measure of somebody's creatinine is an accurate assessment of kidney function?
 - Α. No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

- Ο. So how does anybody -- how does any nephrologist measure accurately kidney function?
- Most don't, so they utilize creatinine as an estimate for the GFR, and in following patients, seeing changes in their creatinine, they can get an idea as to whether or not GFR needs to be measured more accurately.
- And what are the ways to measure GFR more O. accurately?
- So we can use radiotracer excretion to be able to measure someone's GFR. We can use something called inulin, which is actually cleared by the kidney as well and that gives, again, a measure of the kidney's function to do that actual clearance part that we just mentioned.
- Those two procedures or -- or tools that you just referenced, is that something you typically use in your practice?
 - We do. Α.

| Q. | . So | typically | a | higher | eGFR | indicates |
|--------|--------|-----------|----|--------|--------|-----------|
| better | kidney | function, | is | that | right? |) |

- A. I'm sorry, can you repeat that?
- Q. Typically a higher eGFR indicates better kidney function, right?
 - A. Comparatively, it does.
- Q. Well, doctor, let me ask, I know in your report -- and we'll get through this and we'll talk about your report in detail. I know you mentioned as part of your bases for why you believe Mr. Mousser will require renal replacement therapy is a creatinine of 1.5 to 1.6 and declining GFR.

If those are not reliable measures, why did you use them in your report?

- A. Because that's the information that I had available based upon his -- review of his medical records.
- Q. The two more reliable methods we just discussed, and I apologize, I don't remember the exact names, were those available in the medical records that you saw for Mr. Mousser?
 - A. Not that I saw, no.
- Q. Okay. So let's discuss the -- the different stages of CKD. The stages of CKD are based

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Page 55 1 primarily on kidney function and secondarily on the 2 amount of albumin in urine, is that right? 3 That's correct. And CKD Stage 1 is when someone has a GFR Ο. 5 of 90 or higher, right? Α. That's correct. 6 7 And this represents normal kidney Ο. 8 function, correct? 9 Α. That's how it's characterized, yes. 10 And CKD Stage 2 is a GFR between 60 and O. 11 89, right? 12 Α. That's correct. 13 Ο. And this represents mild reduction in 14 kidney function, correct? 15 Α. That's correct. 16 Q. CKD Stage 3a is a GFR between 45 and 59, 17 right? 18 Α. Correct. 19 And this represents moderate reduction in 20 kidney function, correct? Again, that's how it's characterized. 21 Α. 22 Q. CKD Stage 3b is a GFR between 30 and 44, 23 right? 24 Α. That's correct.

- O. And this represents moderate to severe reduction in kidney function, right?
 - Α. It does.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

- And CKD Stage 3b is when you stated you Q. typically will begin seeing patients who may need surgery, a transplant surgery, in the future, right?
 - We'd hope to, yes.
- Ο. CKD Stage 4 is a GFR between 15 to 29, right?
 - That's correct. Α.
- And this represents severe reduction in Ο. kidney function, correct?
 - Α. It does, yes.
- And then finally, CKD Stage 5 is a GFR of less than 15, is that right?
 - That's correct. Α.
- Ο. And this represents kidney failure, correct?
 - Α. Endstage renal disease.
- And so whenever somebody gets to Stage 5, that's typically when they would require either dialysis or a kidney transplant, right?
- At some point with endstage. Some people can be in Stage 5 for a period and not need either of

1 those.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- Would you say that the vast majority of the patients you see have either CKD Stage 4 or CKD Stage 5?
 - Α. That's correct.
- Ο. You wouldn't typically put someone on dialysis or suggest that they need a kidney transplant if they have stable CKD Stage 3, is that right?
 - Α. Stage 3, no.
- Can we agree that a single value of O. creatinine is insufficient to estimate GFR in someone's kidney function?
- No. We can see significant abnormalities in someone's creatinine which is a harbinger of believe -- what I believe to be some significant kidney dysfunction which needs to be further evaluated.
- So a single elevated creatinine level or low GFR would be indicative of further tests that need to be done or -- or further monitoring?
 - Α. In my practice, yes.
- If somebody's creatinine or GFR returns to normal limits after those abnormal results, would you still think that those people need to be monitored?

| 1 | A. | Yes. |
|---|----|------|
| | | |

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

- Q. Would you agree that a single value of creatinine or single GFR result is insufficient to stage CKD?
 - A. I do.
- Q. Would you agree that the diagnosis of a CKD stage requires a person to have a persistently elevated creatinine or excessive albumin in the urine or both for at least three months?
 - A. No, I don't think that's necessary.
- Q. Okay. What is necessary to diagnose a CKD stage?
- A. So, again, based upon creatinine as inaccurate as it is, and if we're talking about the patients that are Stage 3b and later, very small changes in creatinine warrants additional testing, i.e., an effort to measure someone's GFR.

And so I believe even single measurements for a couple of measurements within a three-month period still to me indicate that someone could have significant decline in their GFR outside of the numbers that we just talked about.

Q. When diagnosing or determining a patient's CKD stage, would you typically look at, you know, the

last five or six lab results, or would you focus on a single lab result to determine the CKD stage?

- We would often use a -- a number of measurements in order to make that determination.
- And, Doctor, simply I'm asking, would you Q. look at kind of the totality of the circumstances in attempting to stage CKD and determining prognosis?
- If you mean the totality, I would look at, again, the patient's entire medical history, including conditions which we know have significant untoward effects to the kidney as well as estimated and measured GFRs to be able to fully characterize someone's position on that chart that we talked about earlier.
- Ο. Doctor, clinicians also measure the ratio of albumin to creatinine in urine, is that right?
 - Α. We do.
 - And this is called ACR, right? Ο.
 - Α. Albumin creatinine ratio, yes.
 - Thank you. Ο.

A normal ratio is less than 30 milligrams of albumin per gram of creatinine in the urine, is that right?

Α. That's right.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- Q. And that's classified as A1?
- 2 Α. Correct.

1

3

5

6

7

8

9

10

11

12

13

14

20

2.1

- An ACR of 30 to 300 milligrams of albumin 0. per gram creatine is classified as A2, right?
 - Α. Yes, sir.
 - And an ACR of more than 300 milligrams of Ο. albumin per gram creatinine is A3, right?
 - Α. Yes.
 - Proteinuria refers to elevated levels of Ο. protein in the urine, right?
 - Α. Yes, sir.
 - And albu- -- albuminuria refers to Ο. elevated levels of albumin in the urine, right?
 - That's correct. Α.
- 15 And albumin is just an example of a specific protein, right? 16
- 17 Α. That's correct.
- 18 Is albumin the most -- the protein most Ο. 19 likely to appear in the urine?
 - It is. Α.
 - Is it sometimes -- or is proteinuria and Ο. albuminuria, are sometimes those named interchanged?
- 23 Mistakenly, but yes. Α.
- 24 Q. Thank you, Doctor.

And so, again, the only difference between proteinuria and albuminuria is that proteinuria is refer -- is referencing proteins generally and albuminuria is referencing albumin in the urine specifically, right?

- A. That's correct.
- Q. Would you agree that CKD stage is important because it predicts the likelihood a patient with CKD will progress to endstage kidney disease?
- A. I believe it is one of many variables that's important in predicting someone's progression to endstage renal disease.
 - O. What are some of those other variables?
- A. Again, patient's past medical history, including their comorbidities that we know have untoward effects on the kidney and additional lab data potentially reflective of those comorbidities that give us indication of the -- the -- the progression of someone's chronic kidney disease that potentially could lead to endstage renal disease.
- Q. If those comorbidities are controlled or treated with medication, would that impact your prognosis?
 - A. It would, but, again, the definition of

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

"treated" or "controlled" I think is an important one.

- Okay. How would you define "treated" or "controlled"?
- Well, "treated" is, you know, patients are Α. on medications. Whether or not the results of that treatment have developed -- have resulted in that condition being controlled is very different.
- So if a patient is treated and controlled for a co- -- comorbidity that could impact kidney function and kidney progression to endstage renal disease, that would impact your -- your prognosis, right?
- It would be part of the conversation. But, again, even the ability to have someone treated and have independent -- sorry, measures of controlled during whatever time it's being measured, can't confirm that it's been controlled 24/7, 365.
 - Ο. Thank you, Doctor.
- CKD stage is important because it predicts the likelihood a patient with CKD will have a major adverse cardiac event, is that right?
- Again, one -- one of the -- the things Α. that can predict that.
 - And CKD stage is also important because Ο.

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

it's one of the things that predicts a likelihood that a patient with CKD will die from any cause, is that right?

One of many.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- We talked a little bit about this, but Ο. when you're looking to diagnose someone's CKD, temporally what lab results are you looking at? you looking at the most recent? Are you looking at the last couple of years? What are you looking at?
- I personally look at the last couple of Α. years.
 - And why do you do that, Doctor? Ο.
- Because, again, I'm utilizing not only the creatinine measurements, as we talked about being accurate, I also want to be able to look at the progression or change of those numbers, but then factor into the care and the treatment of those comorbidities that I believe also can affect the kidney but aren't reflective in creatinine as we just talked about.
- If creatinine results or GFR results are more stable -- are stable throughout those couple of years, would you agree that that makes it a more accurative -- or accurate reflections on kidney

function?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

- A. I believe it makes me more comfortable that they have potentially more stable renal function than those that do not.
- Q. Is it fair to assume that when you are giving a prognosis for someone's chronic kidney disease, you would also look at lab results from the last, you know, two or three years?
 - A. Yes.
- Q. Are you aware of the Kidney Failure Risk Equation?
 - A. I am.
 - Q. Do you ever use it in your practice?
 - A. I don't.
- Q. Are you aware that this equation can estimate the absolute risk that a patient with CKD will progress to endstage kidney disease based on stable measurements of creatinine and urine ACR?
- A. Again, I -- I know that it is utilized for that purpose, but it, again, is utilizing estimated values.
- Q. Are you aware of whether or not this equation is becoming a standard of care for nephrologists and transplant nephrologists?

1 MR. MANDELL: Objection.

Go ahead.

BY THE WITNESS:

A. I am not aware. We don't use it in our practice.

6 BY MR. GARAND:

2

3

4

5

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

- Q. Is there a -- or why don't you use it in your practice?
 - A. We don't find that valuable.
 - Q. And why not?
- A. We just don't believe that that is the -the appropriate use of data and patient history to be
 able to have an appropriate sort of counseling session
 to be able to speak about, as you asked before, a
 prognosis of someone's progression of kidney disease.
- Q. Two of the most common causes of CKD are diabetes and hypertension, right?
 - A. Two most common, correct.
- Q. Thank you.

You mentioned renal replacement therapy in your reports. Does this refer to dialysis and transplants?

- A. Yes, sir.
- Q. A person will not require dialysis simply

because they have one kidney, assuming that kidney is functioning well, is that right?

- A. Can you ask that again, please?
- Q. So, yes.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

Assuming somebody's kidney is functioning -- lone kidney is functioning well, they won't require dialysis just because they have one kidney, right?

- A. That's correct.
- Q. And same question for transplantation.

 Assuming they have a lone well-functioning kidney,
 they won't require a kidney transplant just because
 they have one kidney, right?
 - A. That's correct.

MR. GARAND: Doctor, I believe we've been going for about an hour. So we'll take a little break here if that's okay.

MR. MANDELL: Before we get off, how long because -- five minutes?

MR. GARAND: Yeah, I'm fine with five minutes.

MR. MANDELL: Perfect.

THE VIDEOGRAPHER: Going off the record at 9:53 a.m.

24 (WHEREUPON, a recess was had

1 | from 9:53 to 10:02 a.m.)

THE VIDEOGRAPHER: We are back on the record at 10:02 a.m.

BY MR. GARAND:

4

5

6

8

9

10

11

15

16

17

18

19

20

21

22

23

- Q. Doctor, you mentioned previously that there's often a transplant team or a team of -- of doctors who are, you know, evaluating and treating a patient, is that right?
 - A. Transplant patient?
- Q. Yes.
 - A. Yes, sir. Yes.
- 12 Q. Thank you.
- How many doctors are typically on that team?
 - A. Can I just clarify, for a particular -- for a single patient, are we talking about?
 - Q. Correct, a single patient?
 - A. So often we have a surgeon, a nephrologist. If we're just talking physicians, that's really the extent of the physicians. We have a whole group of support staff also.
 - Q. And so what's -- why is there both a surgeon and a nephrologist on these teams?
 - A. Well, we -- we compliment each other, we

coordinate care between each other, and we both bring training and expertise and experience to the table that all benefits the care of the individual patient.

- Q. Are there certain areas that you would defer to the nephrologist on, and are there certain areas where the nephrologist would defer to you?
- A. Well, certainly the nephrologist would defer to us on surgical issues pre- and post-transplant. For us, we would defer to the nephrologist on pre-transplant care of primary glomerular disease that may result in endstage renal disease. That's where their expertise is.

And then post-transplant, we -- we both collaborate in the immediate post-transplant care, but then the -- the longer post-transplant care, typically six to -- months to a year, primarily then nephrology takes over.

Q. Doctor, let's look at your Mousser and
Tukes reports, and these are -- we'll look at
Mr. Mousser's report first. It is Cooper Exhibit 7.

So, Doctor, after discussing the scope of your testimony with Mr. Mandell, it's my understanding that there are a number of topics you won't be testifying on, is that correct?

1 A. That's correct.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

- Q. Is it accurate that you won't be testifying on -- as to the cause of Ms. Tukes or Mr. Mousser's cancers?
 - A. That's correct.
- Q. Is it accurate that you won't be testifying or providing an opinion on the toxins present in the water at Camp Lejeune?
 - A. That's correct.
- Q. Is it also accurate that you won't be testifying or providing an opinion on the levels of exposure to these toxins in terms of what causal role the toxins played in the development of their cancers?
 - A. That's correct.
- Q. Okay. Doctor, I want to go through your report real quick, and we'll start on Page 6, and I'd -- I'd like to ask if any of these sections or specific opinions listed in your report are still in play.

So we're on Page 6 of Mr. Mousser's -- or Dr. Cooper's report for Mr. Mousser. It is Cooper Exhibit 7. I'm looking at heading VI, "Risk Factors for UTUC Kidney Cancer" that goes to Page 7.

Is -- is anything in there still in play?

| A. I certainly am aware of these risk |
|--|
| factors, and if there's questions that you'd like to |
| ask, I would, you know, very much like to answer those |
| for you. |

- Q. Will you be providing any opinions on these -- on this topic, risk factors for UTUC kidney cancer at trial?
- A. Again, only -- only if you have questions specifically about me for these -- to these.
- Q. I do not, unless you are going to be offering opinions on these risk factors?

MR. MANDELL: To the extent -- just for the record, to the extent that they may impact Dr. Cooper's opinions about Mr. Mousser, Ms. Tukes' condition and/or need for future medical care, then he may well be giving opinions on that, but not as to the cause of the cancer in the first place.

MR. GARAND: Thank you, Mr. Mandell. I understand.

BY MR. GARAND:

Q. And so -- and so just to make sure, you know, we're on the same page, to the extent -- and I'm just picking an example here. Smoking impacts chronic kidney disease and transplant and things like that.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

| $l \mid I'm$ not asking about that. |
|-------------------------------------|
|-------------------------------------|

2

3

4

5

6

7

8

9

10

11

14

15

16

17

18

19

20

21

22

23

I'm asking, will you be providing any opinions as to the risk factors for kidney cancer, for UTUC kidney cancer?

- A. Not -- not specifically, no.
- Q. Okay. So if we look at heading VII, which is on Page 7 and it goes through Page 10, and it's the -- it's titled, "Mr. Mousser's Exposure at Camp Lejeune."

Are these opinions and analyses still in play?

- 12 A. Not something I'll be providing testimony on.
 - Q. Okay. If we look at Page 10, heading VIII, it says, "Levels of the Toxins Known to Cause Kidney Cancer."

That would fall within the topics we just discussed, correct?

- A. It does, yes, sir.
- Q. And so those opinions are no longer in play, correct?
- A. It is not something that I will be testifying to.
- O. Thank you, Doctor. And so on Page 13,

heading IX is "Differential Diagnosis." And my understanding is that's a differential diagnosis as to the cause of Mr. Mousser's kidney cancer. Is that accurate?

- A. Let me take a quick peek, please.
- O. Sure.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- A. Yes, sir, that's correct.
- Q. And -- and again, Doctor, we'll be going through a bunch of records today. If I ever move too quickly for you, let me know and I'm happy to slow down.
 - A. Okay.
- Q. So from Page 13 to 14, heading IX is no longer in place, is that right?
 - A. I will not be testifying to that, no.
- Q. Okay. And then finally, heading X, on Page 14 to 15, entitled -- or titled "Responses to the Government's Interrogatories," are any of those opinions -- will you be providing testimony as to any of those opinions?
 - A. No, sir.
 - Q. Thank you, Doctor.
- Let's look at Ms. Tukes' report which is

 Cooper Exhibit 8. And we'll start on page -- Page 5

- here. And I appreciate you bearing with me here,
 Doctor.
- 3 A. Okay.

4

5

6

7

8

9

15

16

17

18

19

2.0

21

- Q. So Page 5, there's a heading -- heading
 VI, "Risk Factors for Renal Cell Cancer." That
 opinion is no longer in play, is that right?
 - MR. MANDELL: Objection as -- with the same explanation I gave before as to each of these sections, okay.
- MR. GARAND: Thank you, doc- -- thank you,

 Mr. Mandell.
- 12 BY THE WITNESS:
- 13 A. Yes, that's correct.
- 14 BY MR. GARAND:
 - Q. And then Page 6 to Page 7, there's a heading VII, "Dr. Irving Allen Report," Dr. Irving Allen is a geneticist, is that right?
 - A. That's correct, yes, sir.
 - Q. And so does the -- the opinions in heading VII, will you be testifying or providing opinions regarding the content in heading VII?
 - A. No. No, I will not.
- Q. Headings VIII and IX are discussing
 Ms. Tukes' exposures at different places at

Camp Lejeune. It goes from Pages 7 to 10. 1

> Will you be providing testimony or opinions regarding that -- that content or that heading?

> > No, sir. Α.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

- Ο. Heading -- or Page 10, heading X is "Levels of the Toxins Known to Cause Kidney Cancer," and it goes from Page 10 to 13, will you be providing testimony on these opinions?
 - No, sir. Α.
- And then finally, Page 13 to 15, heading "Differential Diagnosis," it's my understanding that that is a differential diagnosis as to the cause of Ms. Tukes' kidney cancer, is that right?

MR. MANDELL: Again, with the same explanation, that it may relate to the need for future treatment or condition, okay?

MR. GARAND: Yes, of course.

MR. MANDELL: Okay.

BY THE WITNESS:

- I will not be testifying to that either. Α.
- BY MR. GARAND: 22
- 2.3 Q. Okay. Thank you, Doctor.
- 2.4 Let's look again at Cooper Okay.

Exhibit 7, which is Mr. Mousser's report, and we're going to be going through this here.

If we look at Page 16 of the report, please let me know when you're there.

- I'm here. Α.
- Ο. And that's your signature there, right?
- Α. Yes, sir.
- Does this report contain all of the Ο. opinions you've formed to date in this case regarding Mr. Mousser?
- Α. So I -- it contains certainly the -- the four corners of what we're going to talk about today, but if there's questions that come up that result from conversation in this, there may be additional pieces that need to be added.
- Are there any pieces you envision adding O. at this point?
- Not that specifically comes to mind, but Α. certainly it may as we talk more about this.
- At this point in time, you know, through the conversation we've had right now, and through your medical review of -- review of medical records and review of deposition transcripts, do you have any other opinions to add at this point?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

| Α. | Not th | at I car | n think | of. | But, | again, | |
|------------|---------|----------|---------|--------|--------|--------|----|
| reserving | the fac | t that o | during | our co | nvers | ation, | w∈ |
| may need f | urther | explanat | cions b | ased u | ıpon w | hat's | in |
| this docum | ent. | | | | | | |

Q. Of course.

Doctor, does this report, again, at this point in time, contain all of your explanations and analyses to support the opinions contained in your Mousser report?

MR. MANDELL: Objection.

BY THE WITNESS:

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

A. I believe it contains, again, the substance of what is my opinion. There may be additional details that may need to be brought out as we have more conversation.

BY MR. GARAND:

Q. Okay. We'll look at Ms. Tukes' report real quick. I'll just ask the same questions.

If you look at Page 16, which is the last page of the report, that's your signature there, is that correct?

- A. Yes, sir, it is.
- Q. And does this report contain all of the opinions you formed to date in this case regarding

Jacqueline Tukes?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

2.4

- Again, it's the same answer with It contains the substance of what is my Mr. Mousser. opinion, but if there's conversation that requires additional data or additional thoughts around it, I would love to be able to share those as well.
- And I'm assuming your answer is the same regarding the explanations and analyses in these opinions?
 - Yes, sir, that's correct. Α.
- Ο. Do you -- are you planning on forming any additional opinions regarding Ms. Tukes at this point in time?
- Only if it -- only if additional Α. information comes before me.
- In these two reports, you used the more O. likely as not standard when rendering all of your opinions regarding Mr. Mousser and Mrs. Tukes, is that right?
 - That's correct. Α.
- And your opinions were to a reasonable degree of medical certainty?
 - Α. Yes, they are.
 - Did you review the Camp Lejeune Justice Ο.

| Act | in | prepara | a | or | to | before | pro- | before |
|------|------|---------|------|-----|----|------------|------|------------|
| draf | Etin | ıg your | repo | rts | ? | | | |

- A. I -- I don't recall if that's specific.

 Like I said when we talked earlier, there's many

 documents that were put before me. I'm unsure what

 that specific one was.
- Q. Do you know whether or not you've reviewed the Camp Lejeune Justice Act?
- A. I believe that I have. Again, it's a long time ago, but I don't know specifically if that was one of the documents.
- Q. Did anything in the Camp Lejeune Justice Act, any of that language, play any role in you formulating your opinions in this case?
- A. No. My opinions were based upon review of the medical records, my review of the data that was put in front of me, and making conclusions based upon my training, education, experience.
- Q. Okay. Doctor, let's look at Mr. Mousser's report, again, which is Cooper Exhibit 7. If we look at Page 2 of this report under heading IV.
 - A. Yes, sir.
- Q. On the second line there's a sentence that reads, "His past medical history includes

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

| 1 | hypertension, CAD, status post 4v CABG, |
|---|--|
| 2 | hyperlipidemia, chronic back pain status post |
| 3 | discectomy, anxiety, and depression," is that right? |

- A. It is, sir, yes.
- Q. When you say "past medical history," what point in time are you referring to as "past"?
- A. Any time prior to which the records that I was given contain that diagnosis.
- Q. Okay. So -- so essentially you're stating that the records that you've reviewed have those diagnoses in them?
- A. And -- and not only the diagnoses, but the supporting documentation to confirm those diagnoses.
- Q. How did you decide which medical conditions to include here?
- A. Hmm, I believe I included all of the ones that I felt were both pertinent to this case and were a significant risk going forward for, you know, Mr. Mousser specifically here.
- Q. Is there any reason why you didn't include, like, his kidney cancer and nephroureterectomy?
- A. No. This -- this sentence as put in this document was prior to that event. So this was sort

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

of, as you can see, a timeline of events and was not included in that sentence.

- Q. Would severe obstructive sleep apnea be relevant to your opinions in this case at all?
 - A. Not -- no.
- Q. Would overactive bladder or nocturia be relevant to your opinions in this case?
 - A. No.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- Q. Would diabetes be relevant to your opinions in this case?
 - A. Yes.
- Q. Okay. Why is diabetes or prediabetes not listed here?
- A. I forgot to put that in there, but it's mentioned somewhere later in the report. I'm sure we'll get to that.
- Q. Let's look at the last paragraph -- okay. So on Page 3, the last paragraph before heading V?
 - A. Page 3, okay. Page 3, yes.
- Q. And then we're going to look at the first part of this -- this paragraph under heading V. So right above heading V, you write, "Following nephrectomy, however, Mr. Mousser has had a rise in serum creatinine (1.5 to 1.6 mg/dl) with significant

proteinuria, elevated protein/creatinine ratio (287 milligrams/milligrams) and remains under the care of nephrology and psychology."

Is that right?

A. Yes, sir.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

24

- Q. And then this next paragraph, it reads,
 "Based upon Mr. Mousser's decline in GFR following
 unilateral nephrectomy with episodic elevations in
 creatinine as well as the expected hyperfiltration of
 his remaining kidney, Mr. Mousser will to a reasonable
 degree of medical certainty require renal replacement
 therapy in three to five years while in his early
 60s," is that right?
 - A. It says that, yes, sir.
- Q. Okay. So looking at these two sentences, there are four bases that I see for you to determine that he will require renal replacement therapy in three to five years.

MR. MANDELL: Objection.

Go ahead.

BY MR. GARAND:

Q. And I'm looking at one, serum creatinine of 1.5 to 1.6 after his nephroureterectomy, is that right?

1 A. Yes.

2

8

9

10

11

12

13

14

15

16

17

18

19

- Q. A decline in GFR, is that right?
- A. Correct.
 - Q. Significant proteinuria, is that right?
- 5 A. Correct.
- Q. Elevated protein creatinine ratio, is that right?
 - A. Correct.
 - Q. Are there any other reasons that you think Mr. -- or you believe Mr. Mousser will require renal replacement therapy in three to five years?
 - MR. MANDELL: Could -- could I just ask before you said, Carson, please, I'm sorry?
 - MR. GARAND: Yes. So serum creatinine of 1.5 to 1.6, decline in GFR, significant proteinuria, and elevated protein creatinine ratio. And, again, those are in the -- the last two paragraphs on Page 3.
 - MR. MANDELL: So -- okay. So you are leaving out purposefully other things in those two sentences?
- MR. GARAND: No, I'm not. So if he has -- if there are other --
- 22 MR. MANDELL: Okay. All right.
- 23 BY THE WITNESS:
 - A. Yeah, importantly, the most important one

is the unilateral nephrectomy. So the fact that he has had a kidney removed is incredibly important, and with that remaining kidney, the response is going to be the need for that remaining kidney to hyper-filtrate, to work harder than two kidneys normally would work in concert. If we talk about the -- the stress that that puts on that remaining kidney, which eventually can cause injury to the podocytes and glomerular sclerosis in that remaining kidney, in addition to what we know is in the pathology specimen of his nephrectomized kidney that shows evidence of nephrosclerosis as well, we add on top the fact of those comorbidities that we sort of chatted about a few minutes ago.

And so the nephrectomy, the hyperfiltration, the -- the pathology report that shows nephrosclerosis in the kidney that was removed that we know is a bilateral disease and his comorbidities that include, and thank you, the diabetes, hypertension, coronary artery disease, peripheral vascular disease, all of those in combination with the erratic serum creatinine estimated GFR, and that evidence of proteinuria following his nephrectomy in 2020.

2.0

BY MR. GARAND:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

- Doctor, and so you testified Okay. previously that simply having a well-functioning single kidney does not necessarily mean somebody will require renal replacement therapy, correct?
 - That alone, correct. Α.
- I don't see in your report, and please correct me if I'm wrong, that you discuss a path -the pathology report with nephrosclerosis.

Is that in your report anywhere?

- No, it's not in my report, but it is Α. something that I considered in forming this opinion.
- So if that's one of the bases for your O. opinion that he'll need renal replacement therapy in three to five years, why was it not included in your report?
- Α. Again, I -- the information that I used to put this together was as complete as I thought was necessary. The fact that I used that in my discussions or my decisions around his prognosis at three to five years is not because it wasn't considered. It just didn't make it into this report.
- Okay. Is it important, you know, Ο. generally to fully explain the -- the rationales for

1 your opinions?

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

MR. MANDELL: Objection.

BY THE WITNESS:

A. It is, and that's what I think part of today is about.

BY MR. GARAND:

Q. Okay. So other than -- okay. So we listed the four I listed and then the unilateral nephrectomy, hyperfiltration, pathology report with nephrosclerosis, and his comorbidities.

Is there anything else that you're relying on to determine that he will require renal replacement therapy in three to five years?

MR. MANDELL: Objection; asked and answered, but go ahead.

BY THE WITNESS:

A. Well, also his age which is, you know, part of the -- of the equation and, you know, I -- utilizing, you know, some of that data allows us to look at expected kidney survival with all of those comorbidities and in addition my, again, experience and my practice of 25 years that takes care of patients exactly like this.

BY MR. GARAND:

| 1 | Q. Is it fair to assume that the rationales |
|---|--|
| 2 | that are listed in your report are weighted more |
| 3 | heavily in in determining his prognosis? |
| 4 | MR. MANDELL: Objection. |
| 5 | BY THE WITNESS: |
| 6 | A. No. Again, all of the things that we |
| | |

talked about are a component that makes up this

BY MR. GARAND:

opinion.

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

- Q. Are any of these factors weighted more heavily than the others?
- A. They are. The fact that he has one kidney that was removed because of his cancer.
- Q. Is that the only one? Is that the only factor that's weighted more heavily than the others?
- A. His comorbidities would equally be important, but the number one reason is the fact that he had to have a kidney removed because of cancer.
- Q. And his current kidney function is not something that's weighted more heavily than others?
 - A. No.
 - Q. And why is that?
- A. Because, again, when -- in my practice and my experience of evaluating patients, recognizing all

| of the information and the pieces of data that bring |
|--|
| us to currency is more important than kind of where we |
| find ourselves now, because, again, we can normalize |
| someone's kidney function many different ways, but |
| it's really what's underlying that inaccurate |
| measurement of creatinine that I believe has a much |
| higher weight in determining his future kidney care |
| and future kidney needs. |

Q. So if his comorbidities are weighted more heavily, you know, in addition to the unilateral nephrectomy, why is that not discussed in your report really at all as an explanation for why he will require renal replacement therapy?

MR. MANDELL: Objection. I don't think that accurately re- -- reflects the report.

But go ahead.

BY MR. GARAND:

- Q. And, Doctor, if it's in the report, please show me where it is.
- A. Can you just ask that question again, please?
- Q. Sure. So you mentioned that Mr. Mousser's comorbidities is a factor that's weighted more heavily in your -- in determining that he will require renal

replacement therapy in three to five years, is that right?

A. That's fair.

- Q. Can you please show me where in your report you explain why that is, what those comor- -- comorbidities include, anything of that nature?
- A. So later we do talk about his -- his hypertension, and we certainly do talk about the fact that he has had a unilateral nephrectomy in that sense that we talked about. His age is, you know, throughout this document, and the fact that he had these comorbidities is how we started this medical history.

In my practice, and the way that I put together these -- these expert reports, while it might not have it in the sentence, it's contained here in this entirety of this expert opinion and is utilized in my decision-making around the specifics of this timeframe of three to five years.

Q. So if -- again, so can you please show me in your report, is there any analysis as to why, for example, Mr. Mousser's hypertension will -- increases his risk of requiring renal replacement therapy in three to five years?

| A. It's a well-known fact, and it's something |
|--|
| that, again, we understand in the field of transplants |
| and appreciate that that is a significant risk factor |
| as we talked about for developing chronic kidney |
| disease. |

- Q. Doctor, do you understand generally what your role as an expert is?
 - Α. I do.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

2.1

22

2.4

- And what is that? Ο.
- It's to review the medical records and the Α. data in front of me and determine what I believe is the potential course of the records that I review, as well as to provide, as the name implies, expert opinion of, again, the data in front of me based upon my experience as someone who works in this field on a regular basis.
- And who is your reader of the expert report?
- 19 MR. MANDELL: Objection.

20 BY THE WITNESS:

- I believe it's anyone that is involved in, you know, this litigation.
- BY MR. GARAND: 23
 - Would you expect any non-nephrologist or 0.

transplant surgeon to understand or know that hypertension is a major risk factor for somebody progressing to endstage renal disease?

MR. MANDELL: Objection.

BY THE WITNESS:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

A. I would expect a lot of people would know that.

BY MR. GARAND:

Q. On what basis?

MR. MANDELL: Objection.

BY THE WITNESS:

- A. It is a -- it's something that, again, is taught to really every primary care physician about managing hypertension and diabetes as being the number one and two causes of chronic kidney disease, and individuals, again, who have any experience in kidney disease, which infects one in seven people in the United States, it's, again, a very common conversation around controlling hypertension and the risks thereof resulting in chronic kidney disease.
- Q. Yeah, so, I mean, one in seven is -- I can't do the math. It's certainly less than 20 percent of the people, is that right?
 - A. It's a lot of people. That's -- I'll give

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

- Q. So let me ask you, Doctor. Whenever you have -- well, I'll strike that.
- Whether or not somebody's hypertension is controlled or -- yeah, controlled, does that impact your decision -- or impact your determination as to somebody's prognosis?
- A. Yeah, we talked about this before.

 Having -- on medications and whether or not it's controlled at certain time points when it's measured is very different what happens, again, 24/7, 365. So if they're on medications versus not, that's, you know, I think part of the -- the calculus that we utilize in counseling patients, sure.
- Q. Doctor -- okay. So, for example, when you discuss the serum creatinine of 1.5 to 1.6 and a decline in GFR, what records are you relying on to make those determinations?
- A. The -- again, the medical records of Mr. Mousser that were supplied to me.
- Q. Is it your opinion that Mr. Mousser's current creatinine levels are at that -- are at 1.5 to 1.6?
 - A. I don't know what they are currently.

So his current creatinine levels are not Ο. relevant to your -- or -- and let me not -- let me back up.

Is it your opinion that his current creatinine levels are relevant to your -- to his prognosis -- prognosis for chronic kidney disease?

- Yes, they are, again, part of the conversation. And while -- while I didn't have them in front of me, I also had the ability to read Dr. Johnstone's report which actually had information about his current creatinine.
- And, Doctor, when you discussed a decline Ο. in GFR, again, do you recall what records you're -you're referencing?
- Referencing his -- Mr. Mousser's medical records following the nephrectomy in 2020 and the follow-up that he has had at multiple VAs -- or at the VA by multiple physicians, some of which we named earlier.
- Are you aware of his current GFR test Ο. results?
 - I am not. Α.
- And, again, is that something that would be relevant to your determination regarding

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

Mr. Mousser's prognosis?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

2.4

- A. Again, I think they're a part of the -the decision-making for Mr. Mousser and his team going
 forward, but, again, the information that was put in
 this expert opinion based upon the data that I had up
 until February -- or sorry, this was February, up to
 February, is in conjunction with all of these other
 things that I talked about was how I formed this
 opinion specifically around the need for renal
 replacement in three to five years.
- Q. And you've mentioned -- sorry, I didn't mean to cut you -- did I cut you off there?
 - A. (Inaudible response.)
- Q. And, Doctor, so you mentioned serum creatinine levels and GFR are a part of a bigger picture. They're certainly important enough to mention in your report, right?
 - A. Yes.
- Q. Okay. Doctor, we are going to look at Mr. Mousser's serum creatinine levels and GFR from around the time of his surgery through the present day, okay.
 - A. Okay.
 - O. If we can have -- and this is a -- we have

a binder of records here, and we'll be going through some others. I'm going to mark this as -- are we on 9, Erick -- Cooper Exhibit 9. And I will just typically refer to this as "the binder."

- A. The binder, okay.
- Q. This is the only one that has a binder.
- A. Okay. Thank you.

(WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 9, for identification, as of 07/10/2025.)

BY MR. GARAND:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Q. Dr. Cooper, have you reviewed Mr. -- and just for the record, again this is Cooper Exhibit 9. These are Mr. Mousser's VA lab results from June of 2020 through November of 2023, and then I have some -- some more recent ones after that, but this binder, for the record, the records are Bates-stamped 00667_MOUSSER_05598 through 05812.

Doctor --

MR. MANDELL: Can I just object on -- on the record to the lack of foundation. Even though there was no question, it was a prefatory -- it was a preface to questions. So that -- my objection is lack

1 of foundation, but go ahead.

BY MR. GARAND:

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

- Q. And, Doctor, if we look at the very first page here, which is Bates ending in 05598 -- and just I'll ask, do you understand what Bates numbers are?
 - A. Yes, sir, I do.
- Q. Okay. Mr. Mousser's name is here at the -- the top left corner, is that right?
 - A. That's correct.
- Q. And it says "VA Laboratory Results" at the top, right?
 - A. That's correct.
- Q. Okay. Let's turn to -- we're going to be starting towards the end. Let's look at Bates ending in 05778, and we're going to be working our way back up.

Doctor, do you see the date there is August 31st of 2020, in the middle of the page?

- A. I do.
- Q. And this is right around the time when Mr. Mousser was first diagnosed with cancer, is that right?
 - A. Correct, yes.
 - Q. At the bottom of the page, do you see his

Page 96 1 creatinine is 1.2? 2 I do. Α. 3 Ο. And if you turn to Bates ending in 05781? 5781. Okay. 4 Α. 5 Q. The very bottom of the page, his eGFR is 62.4, is that right? 6 7 Yes, sir, that's correct. 8 Ο. What stage of CKD would someone be diagnosed with with a GFR of 62 and a creatinine of 9 1.2? 10 11 Α. Four. 12 Q. Stage 4? 13 Α. Um-hum. 14 Doctor, we just looked previously, we went 15 over the different stages of CKD. 16 Do you remember that? 17 Α. I do. 18 And we determined -- or let me ask, why --19 why is that CKD Stage 4? His creatinine of 62.4. 2.0 21 Where did you see that? Q. 22 Between 60 and 90. eGFR. Am I looking at Α. 23 the wrong page? You said creatinine. I think 24 MR. MANDELL: No.

Page 97 1 you meant the eGFR. 2 BY THE WITNESS: 3 Α. Yeah, the eGFR. eGFR. BY MR. GARAND: 4 5 Q. Is 6 -- so an eGFR of -- of 62 is CKD 6 Stage 4? 7 Α. 60 to 90, yes. 8 Ο. I think we might be getting our numbers 9 mixed up. Is that not CKD Stage 2? 10 Α. I apologize. 11 Okay. I was -- I was -- I was worried we Ο. were going to have to go back a little bit. 12 13 Α. Yep, I apologize. 14 No, no problem. Ο.

- Stage 2. I apologize. Α.
- Okay. So at the outset, assuming stable Q. GFR and creatinine results of 1.2 and 62, would you be -- would you be worried that a patient with these results would need dialysis or a kidney transplant in three to five years, assuming stability?
- Pardon me, I missed the beginning. Could you ask me one more time?
- Assuming stable creatinine levels of 1.2 Ο. and GFR of 62, would it be your opinion that somebody

15

16

17

18

19

2.0

21

22

23

would require renal replacement therapy in three to five years?

MR. MANDELL: Objection; lack of foundation.

Go ahead.

BY THE WITNESS:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

A. I would be significantly worried with someone who has an eGFR of 62.4 without, you know, any expectation of what was to follow, that's an abnormal eGFR. As we mentioned, you know, 90 and above is normal.

So the fact that he has an eGFR of 62 concerns me, but the answer specifically to your question, I wouldn't specifically think that he would have a risk for developing chronic -- sorry, endstage renal disease in three to five years, but based upon this number and the totality of his medical history, I would be very worried about his future with two kidneys as we're talking about right now.

BY MR. GARAND:

Q. Is it abnormal for somebody -- and please let me know if you don't know the answer to this. Is it abnormal for somebody in their late 50s to have CKD Stage 2?

MR. MANDELL: Objection. Go ahead.

1 BY THE WITNESS:

- 2 One more time. Is it ab- --Α.
- 3 BY MR. GARAND:
- Is it abnormal for somebody in their late 4 Q. 5 50s, a patient in their late 50s, to have a CKD 6 Stage 2?
- MR. MANDELL: Objection.

BY THE WITNESS: 8

9

10

11

12

13

14

16

17

18

19

2.0

21

22

- It's -- people in -- as we talked about, can have -- well, chronic kidney disease, even Stage 2, for various reasons, but age is one of the risk factors for developing progressive kidney disease. So I wouldn't say it's abnormal, but it's also not normal.
- 15 BY MR. GARAND:
 - My understanding is that as somebody ages, Q. their kidney function decreases. Is that -- is that accurate?
 - Α. That's correct, but, again, if we're going to talk specifics about where it decreases to, that's a different question.
 - Thank you, Doctor. Ο. Okay. Let's now look at Bates ending in
- 24 05762.

Page 100 1 Α. 057 -- I'm sorry, one more time? 2 5762. 0. 3 Α. 5762, okay. I know we'll be jumping around a little 4 Q. bit --5 6 Okay. Α. 7 -- so I ask that you bear with me here. Ο. 8 Α. I'm here. 9 Q. So at the very bottom of this page, do you see that the date is September 7th of 2020? 10 11 Α. I do. Flip to the next page, which is Bates 12 13 ending in 05763, the third line down, Mr. Mousser's 14 creatinine is 1.0. 15 Do you see that? 16 J do. Α. 17 And if you flip to Bates ending in 05766, his eGFR is 77. 18 19 Do you see that? 2.0 Α. I see that. Okay. Now, let's look at Bates ending in 21 Q. 22 05710. 5710. 23 Α. 24 And please let me know when you're there. Q.

I'm here, sir. 1 Α.

2

3

4

5

6

7

8

9

10

13

14

15

16

17

18

19

- And, Doctor, I apologize if I asked this, Q. but I want to make sure that I have, have you seen these records before?
 - I have. Α.
 - At the bottom of Page 2, do you see that Ο. the date collected there is October 22nd, 2020, right?
 - Α. I do.
 - And this was just two days after his Ο. October 20, 2020, nephroureterectomy, right?
- 11 Α. I believe that's the dates, the -- the PO date, yes. 12
 - So if you flip to the next page, Bates Ο. ending in 05711, his creatinine is 1.2, right?
 - I do see that here, yes.
 - And then if you flip to Bates ending in O. 05713, at the top of the page, again, his eGFR is 62.4, right?
 - Α. Yes.
- 20 Please turn to Bates ending in 0. Okay. 21 05704.
 - Α. Okay.
- 23 Do you see that the date there at the bottom is 28 April 2021? 24

- 1 A. I do, yes.
- Q. If you flip to the next page, it's

 Bates -- Bates ending in 05705. Do you see at the top

 there that Mr. Mousser's creatinine is 1.5?
 - A. I do.

5

8

9

21

Q. And if you flip to page ending in 05707, his eGFR is 48.2 at the very top.

Do you see that?

- A. I do, yes.
- Q. Okay. If you can flip to Bates ending in 05682.
- 12 A. 05682. Okay.
- Q. And these are January 19, 2022, results.

 Do you see that?
- 15 A. I do, sir.
- Q. And his creatinine is 1.5, a few lines down on this page?
- 18 A. I see that.
- Q. And if you flip to Bates ending in 05684, at the very bottom, his eGFR is 48.1, right?
 - A. Correct.
- 22 Q. All right. Let's look at 05671.
- 23 A. 05671. Okay.
- Q. So do you see the date there at the bottom

- of the page is March 9th of 2022?
- 2 A. I do.

6

7

8

9

10

13

14

15

16

- Q. And we're about 17 months, a year and a half, after his nephroureterectomy at this point, right?
 - A. That sounds right, yes, sir.
 - Q. So if we look at the next page, Bates ending in 05672, in the middle of the page his creatinine is 1.9, is that right?
 - A. That's correct.
- Q. If we flip to Bates ending in 05675, his eGFR is 36.6, right?
 - A. Correct.
 - Q. So from October of 2020 where he had a GFR of 62 and a creatinine of 1.2, to March of 2022, he had a GFR of 36 and a creatinine of 1.9, is that right?
- 18 MR. MANDELL: Objection. Based on these records?
- 20 MR. GARAND: Correct, based on these records.
- 21 BY THE WITNESS:
- 22 A. Yes.
- 23 BY MR. GARAND:
- Q. Okay. Please turn to Bates ending in

Page 104 05665. 1 2 5665. Α. Okay. 3 At the very top, the date is April 7th of Ο. 2022. 4 Do you see that? 5 I do, sir. 6 Α. Ο. And the creatinine is 1.4, right? 8 Α. Yes. And if you flip to Bates ending in 05668, 9 Ο. 10 his eGFR is up to 58. 11 Do you see that? 12 Α. I see that. 13 Ο. So from March of 2022 to April of 2022, 14 his GFR went from 36 to 58, right? 15 MR. MANDELL: Again, based on these records? 16 Objection. 17 MR. GARAND: Yes, correct, based on these 18 records. 19 BY THE WITNESS: 20 Α. That's correct, yes. 21 BY MR. GARAND: 22 And based off of these records from March Ο. of 2022 to April of 2022, his creatinine went from 1.9 23 24 back down to 1.4, is that right?

| A. Yes, according to these record | Α. | Yes, | according | tο | tnese | records |
|-----------------------------------|----|------|-----------|----|-------|---------|
|-----------------------------------|----|------|-----------|----|-------|---------|

- Q. Is it typical for somebody's kidney function to increase significantly like that in just one month after it was declining?
- A. Is it typical. Are you talking about for a -- anybody or for --
- Q. Anybody with chronic kidney disease, and what I'm getting at is it was at 1.9 and then it goes back down to 1.4. It was at 36.6 and then, you know, a couple of weeks later it's at 58.

Do you have any explanation as to why that may be?

- A. Yes.
- Q. And what is that?
- A. So it can happen in -- in patients who have, again, chronic kidney disease, particularly those that have significant damage to the organ itself that make it very susceptible to things like volume status and to medications and to, just, general physiology.

So, again, we -- we see that there can be significant fluctuations which, again, are -- are very concerning, especially when you see at this level changes in creatinine and the significant change it

has in just your eGFR. And so that's why to our conversation earlier, the creatinine alone I don't believe is a good measure of someone's true kidney function.

- Ο. And, again, we -- we mentioned -- you mentioned earlier there were a couple of other measures that would more accurately measure kidney function, is that right?
- Α. Well, they truly measure kidney function, yes.
- And we don't have access to any of those Ο. in this -- this case for Mr. Mousser as far as you're aware, right?
 - Not that I saw in the medical record.
- Doctor, let's -- okay. Put that to the side just for a minute.
- 17 MR. MANDELL: Is -- is that the binder?
- MR. GARAND: Yes, the binder. Thank you. 18 19 we'll come back to it, but --
 - MR. MANDELL: That's fine. No, no, I just wanted to influence the binder.
- 22 MR. GARAND: Thank you.
- BY THE WITNESS: 23
- 24 A. Okay.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

2.0

1 MR. GARAND: Erick, can we have Tab 12 here. 2 We are on Cooper Exhibit 10. Let's see. 3 (WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit 5 No. 10, for identification, as of 07/10/2025.) 6

BY MR. GARAND:

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- And, Doctor, we discussed earlier you don't recall whether or not you reviewed the deposition transcript of Dr. Flood, correct?
 - I'm sorry, I don't recall that. Α.
- That's okay. We'll go through it. And Q. you understand that Dr. Flood --
 - Α. Thank you.
- Ο. -- is Mr. Mousser's VA nephrologist, correct?
 - Α. Yes. Thank you.
 - Does a nephrologist -- is a nephrologist typically able to evaluate someone's chronic kidney disease?
 - Yes, they can. Α.
 - Are they -- are they able to provide a Q. prognosis for someone's chronic kidney disease?
- Α. They can, yes.

- Q. Okay. Let's look at Page 87 of this transcript. And we'll look at Line 15 and we'll go to Page 88:17.
 - A. Page 87:15.
 - Q. Okay. So the question:

"And so if we look at the top of Page 3, which is Bates ending in 05146, these are the lab results, and it notes that his creatinine is up to 1.9 in March of 2022.

"Do you see that?"

Answer: "I do."

Question: "Do you have an opinion on what caused the increase from 1.5 in January to 1.9 in March?"

Answer: "So I opined in this that I thought that it was probably due to hemodynamic changes with the low blood pressure and the use of the lisinopril, which is what an ACE inhibitor is, angiotensin-converting-enzyme inhibitor.

"So that's -- that was my suspicion, because his urine was otherwise normal from it, so when -- things being normal the creatinine can go up not because of intrinsic kidney problems, which is decreased flow to the kidney with diminished blood

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

pressure, so if he was on too much of his blood pressure medicine, it would affect that.

"And so that's what I was hoping for, so I recommended making changes to it, and then I think I ordered a follow-up study in April, which confirmed my preclinical -- or excuse me -- my -- my suspicion of the cause because his creatinine improved."

Did I read that correctly?

- A. Yes, sir.
- Q. Okay. Let's go to Page 91. If you look at the bottom of Page 91, you'll see Mr. Garand, and we're -- we're discussing an April 28, 2022, treatment note.

Do you see that?

- A. I do.
- Q. Okay. If we look at Page 92, Line 3, and we'll go through Line 24.

"And if you look at the bottom of Page 1 of this document under the 'Labs' heading, it says creatinine is down to 1.4 in April of 2022, is that right?"

"Yeah, that's correct."

"And then on Page 2, about halfway down the page, you wrote that you 'Reviewed above lab tests

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Page 110 with marked improvement in creatinine from 1.9 to

1.4,' in parentheses, '(baseline) on 20 milligrams lisinopril with well controlled BP.'

"So Mr. Mousser's creatinine had improved significantly since the March 2022 labs, is that right?"

Answer: "Yes. And that creatinine of 1.4 is entirely consistent with somebody that has one kidney that's doing quite well."

Question: "It's not a cause --"

Answer: "So that -- I'm sorry?"

Question: "It's not a -- it's not a cause for concern then?"

Answer: "No, it's reassuring."

Did I read that correctly?

A. Yes, sir.

Q. Lastly, let's go to Page 100 and we'll go from Lines 1 through 9.

"So I think I mentioned it just a moment ago -- and I can go back and look -- but if he was -- he's -- he's no longer receiving IV fluids, if he's on the lisinopril, that can affect the flow to the kidneys, and so that can make the creatinine appear higher and suggest kidney -- worsening kidney

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

Page 111 1 function, when, in fact, it's a reflection of just flow rather than intrinsic disease." 2 3 Did I read that correctly? 4 Α. Yes. 5 Ο. So it was Dr. Flood's opinion that Mr. Mousser's spike in creatinine was not caused by 6 7 intrinsic issues with the kidney but reduced blood 8 flow to the kidney, is that correct? 9 MR. MANDELL: Objection. 10 BY THE WITNESS: 11 Based upon what you've read here, I Α. believe that's what his opinion is, yes. 12 13 BY MR. GARAND: 14 And he found that a creatinine of 1.4 is entirely consistent with somebody that has one kidney 15 16 that's doing quite well, is that correct? 17 MR. MANDELL: Objection. 18 BY THE WITNESS: 19 That's what he stated here in this Α. deposition. 2.0 21 BY MR. GARAND: 22 Do you have any reason to dispute his

23

24

findings there?

Α.

I do.

| 1 | Q. | Okay. | And | what's | that: |
|---|----|-------|-----|--------|-------|
|---|----|-------|-----|--------|-------|

2.4

A. Again, I -- I believe that the lisinopril, speaking specifically about these comments here, can contribute potentially to the changes in creatinine that we've gone through in the binder, but I think it's, again, not taking into account all of the things that we've talked about before.

To look at sort of simply a change in the medication as the only reason why someone who has had a unilateral nephrectomy, secondary to cancer, has that remaining kidney with we know some nephrosclerotic damage to it that we've seen or the biopsy record, with all of the additional comorbidities, to simply say that changing the medication and fixing someone's number is confidence that he has no evidence of intrinsic kidney disease when we know there is intrinsic kidney disease, we know there's nephrosclerosis, is not a complete thought.

Q. Okay. Doctor, let's look at an April 18th, 2022, treatment note. And we'll mark this as Cooper Exhibit 11.

(WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit

Page 113 1 No. 11, for identification, as of 2 07/10/2025.) 3 BY THE WITNESS: Are we coming back to this? 4 Α. 5 BY MR. GARAND: We will come back --6 Ο. 7 I've just got so many papers in front of 8 me. 9 0. We'll come back to it, but not right now. 10 Α. Okay. 11 So, yeah, you can close it and we'll put Ο. it to the side. 12 13 Α. Thank you. 14 I know there's a -- there's a lot of 15 moving pieces here. 16 Α. Yeah, thank you. 17 Ο. I'll try to tell you if we are going to be coming back to an exhibit or not. 18 19 Α. Okay. Okay. Thank you. 2.0 Ο. Again, this is Cooper Exhibit 11. 21 So this is a -- again, an Okay. 22 April 18th, 2022, VA treatment note. This is Bates 00667_MOUSSER_VHA_0375. 23 24 Doctor, at the top do you see that the

| h | ٠ ــ | D-0 | 7 | D = =1 = =1 0 |
|--------|-----------|-----|--------|---------------|
| author | $\perp S$ | Dr. | Anarew | Rockwood? |

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

- A. I -- I do see that, yes.
- Q. And, again, you understand that that's Mr. Mousser's VA urologist, correct?
 - A. Yes, sir, I do.
- Q. The middle of the page, do you see that Dr. Rockwood stated that, "His updated serum creatinine was 1.4 and a 24-hour urine for CrCl calculates out to a 102 cc per minutes..."

Do you see that?

- A. Yes.
- Q. And Dr. Rockwood found that "which is obviously very good for solitary kidney," correct?
 - A. Correct.
- Q. And then if you look at the assessment, the little paragraph beneath that, Dr. Rockwood found that the "current renal function studies showing excellent and preserved renal function," is that right?
 - A. Correct.
- Q. And so it's your opinion -- it's your testimony that you disagree with Mr. Mousser's VA nephrologist and now his VA urologist; is that accurate?

MR. MANDELL: Objection. 1

Go ahead.

BY THE WITNESS:

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

Α. I do.

BY MR. GARAND:

- Ο. And you understand that these are Mr. Mousser's VA treaters in this case?
 - Α. I do.
 - And you understand that they're --Ο.
 - Post -- post-nephrectomy, yes, sir. Α.
- You understand that Dr. Rockwood was the 0. provider who first discovered the mass?
- Α. I do. I'm just talking about what we're speaking about right now.
 - Ο. Thank you, Doctor.

Okay. So we just finished discussing Mr. Mousser's GFR and creatinine results from the time of his surgery in October of '20 through April of 2022. We are going to keep looking at these results.

And, again, I'll just ask, you know, we -we discussed previously that you relied on a dip in GFR and a creatinine of 1.5 to 1.6, correct?

MR. MANDELL: Objection. Objection to the

Page 116 1 preface too. 2 Go ahead. 3 BY THE WITNESS: Amongst other things. 4 Α. 5 BY MR. GARAND: Of course. So I'll ask just that as we 6 Ο. 7 review a bunch of numbers here, you keep those in 8 mind. 9 All right. So we'll go back to the binder 10 here. 11 Okay. Α. I know, there is... 12 Q. 13 Α. I'm just trying to keep my mounds 14 appropriate here. 15 Q. Thank you, Doctor. 16 Α. Okay. 17 Ο. So let's look at Bates ending in 05657. 18 Okay, sir. Α. 19 So at the very top of the page, do you see Ο. that these are July 15 of 2022 results, correct? 2.0 21 Yes, sir. Α. 22 And if you look a few lines down, his creatinine is 1.4, right? 23 24 Α. Correct.

- Q. And if you flip to Bates ending in 05659, his eGFR is 58, is that right?
 - A. Correct.
 - Q. Let's look at Bates ending in 05645.
 - A. Okay.

3

4

5

6

7

8

9

10

15

16

17

- Q. These are September 19, 2022, results. Do you see that at the bottom of the page?
 - A. I do, sir, yes.
 - Q. The next page is 05646 and the creatinine is 1.3.
- 11 Do you see that?
- 12 A. I do, sir.
- Q. If you flip to page Bates ending in 05648, the eGFR is 63, is that right?
 - A. Correct.
 - Q. Okay. We'll look at -- put these to the side, but we're going to come right back to them.
 - A. Okay.
- Q. Thank you. It would be convenient if all of these were right in the same spot, but unfortunately they're not.
- MR. GARAND: I'll mark this as, let's see, we are on 12. I'll mark this as Cooper Exhibit 12.
- 24 (WHEREUPON, a certain document was

| | Page 118 |
|------------|---|
| 1 | marked Dr. Cooper Deposition Exhibit |
| 2 | No. 12, for identification, as of |
| 3 | 07/10/2025.) |
| 4 | BY MR. GARAND: |
| 5 | Q. And for the record, this is a |
| 6 | Mr. Mousser's lab results from March of 20 March 20 |
| 7 | of 2023. |
| 8 | Do you see, Doctor, Mr. Mousser's name in |
| 9 | the top left corner there? |
| L O | A. I do, yes. |
| L1 | Q. And do you see that the date collected is |
| L2 | 3/20/2023? |
| L3 | A. I do, yes, sir. |
| L 4 | Q. Do you see that the third entry is |
| L5 | creatinine, and it's 1.25 in the lab results? |
| L6 | A. I do, sir. |
| L7 | Q. And the eGFR is 66, correct? |
| L8 | A. I see that also, yes. |
| L9 | Q. So at this point from April of 2022 to |
| 20 | March of 2023, we have not seen a seen a creatinine |
| 21 | level of 1.5 to 1.6, right? |
| 22 | MR. MANDELL: Objection. In the records you've |
| 23 | shown so far? |
| 24 | MR. GARAND: Correct, in the records I've shown. |

Page 119 1 BY THE WITNESS: 2 The dates again, I'm -- can you do it one 3 more time just so I'm --BY MR. GARAND: 4 From April of 2022 --5 Q. 6 Α. Yeah. -- to March of 2023. And the records I've 8 shown --9 Α. Yes. 10 -- we have not seen a decline -- or a Ο. 11 creatinine at 1.5 to 1.6, is that right? 12 With what we've shown, yes, sir. Α. 13 Ο. Are you aware of any other lab results 14 during this timeframe that indicate a creatinine level 15 of 1.5 to 1.6? 16 Α. Not that I can recall. 17 Are you aware of any lab results from this Q. same April of 2022 to March of 2023 time -- time 18 19 period that shows a decline in GFR? 20 No, not -- these -- the labs that you've 21 shown me are the ones that I recall. 22 Thank you, Doctor. Ο. 23 All right. Back to the binder we go. 24 Α. Okay.

- Q. And if you could turn to Bates ending in 05623.
 - A. I'm getting closer to the front.
 - O. We're almost done with these.
 - A. Okay.

3

4

5

6

7

8

9

10

11

12

13

14

15

20

- Q. At the bottom of this page, do you see that the date is July 17th of 2023?
 - A. Yes, sir, I do.
 - Q. And if you look at the next page, which is Bates ending in 05624, at the very top Mr. Mousser's creatinine is 1.4, correct?
- A. Correct.
- Q. If you look to the bottom of Bates ending in 05625, his eGFR is 58. Is that accurate?
 - A. It is.
- 16 Q. Okay. Flip to Bates ending in 05618.
- 17 A. Okay.
- Q. And these are July 27, 2023, results. Do you see that at the very bottom of the page?
 - A. I do.
- Q. And this is just ten days after the prior lab results that I just showed you, which is July 17th of 2023, right?
- A. It sounds right, yes, sir.

Page 121 of 281

- 1 O. If you flip to page Bates ending in 05619, 2 the third entry there is creatinine of 1.7, correct?
 - Α. Yes, sir.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

21

22

And then if you flip to Bates ending in Q. 05621, his eGFR is 46.

Do you see that?

- Α. I see that, yes.
- Ο. Please turn to the very first page. We're almost done with the binder.
 - Α. Awesome.
- Bates ending in 05598, you'll see that Ο. these are November 17, 2023, results.

Do you see that?

- I do, sir, yes. Α.
- At the very top of the next page, which is Bates ending in 05599, the creatinine is 1.4, is that right?
 - Α. That's correct.
- And if you flip to Bates ending in 05602, 19 Ο. his eGFR is 58. 2.0

Do you see that?

- I see that, yes. Α.
- 23 Okay. Okay. We're done with this binder, Ο. 24 thankfully.

A. Okay.

1

9

Q. I'll show you what I'll mark as Cooper Exhibit 13.

4 (WHEREUPON, a certain document was
5 marked Dr. Cooper Deposition Exhibit
6 No. 13, for identification, as of
7 07/10/2025.)

8 BY THE WITNESS:

A. Thank you.

10 BY MR. GARAND:

- 11 Q. Doctor, have you seen this record before?
- 12 A. I can't remember specifically, sir, I'm
 13 sorry.
- Q. That's okay. For the record, this is a

 May 6th, 2024, VA treatment note, and it is

 Bates-stamped 00667_MOUSSER_VHA_01499 through 01504.
- 17 Turn to Bates ending in 01501, please.
- 18 A. 01, sir?
- 19 Q. Yes, correct.
- 20 A. Okay. Thank you.
- Q. And at the -- towards the bottom of the page, you'll see that Jan- -- there's a January 12, 2024, creatinine results and it's 1.5.
- 24 Do you see that?

1 Α. I do, sir, yes. 2 All right. I'm going to show you what Ο. 3 I'll mark as Cooper Exhibit 14. (WHEREUPON, a certain document was 4 5 marked Dr. Cooper Deposition Exhibit No. 14, for identification, as of 6 7 07/10/2025.) 8 BY THE WITNESS: 9 Α. Thank you. 10 BY MR. GARAND: 11 And, Doctor, I'll ask if you've seen this O. record before? 12 13 Again, I'm sorry, I don't -- I don't know Α. 14 specifically. 15 Ο. That's okay. 16 For the record, this is a November 12th, 17 2024, VA treatment note for Mr. Mousser. It's 18 Bates-stamped 00667 MOUSSER VHA 01624 through 01626. 19 If you look at this very first page, 2.0 you'll see about two-thirds of the way down the page, 21 you'll see a November 8th, 2024, date and a May 15th, 22 2024, date. 23 Do you see that? 24 I do, yes. Α.

1 O. And if you go over three or four lines, 2 you'll see the creatinine results for those days are 1.4 for -- for each. 3 Do you see that? 4 5 Α. I do, yes. Okay. I'll show you what I'll mark as 6 O. 7 Cooper Exhibit 15. 8 (WHEREUPON, a certain document was 9 marked Dr. Cooper Deposition Exhibit 10 No. 15, for identification, as of 11 07/10/2025.) 12 BY THE WITNESS: 13 Thank you. Α. BY MR. GARAND: 14 15 Doctor, have you seen this record before? Ο. I don't recall, sir. 16 Α. 17 Ο. That's okay. 18 So for the record, this document is 19 Bates-numbered 00667_MOUSSER_VHA_01567 through 01568. And these are, if you see, the "Chem I 2.0 21 Profile Routine" heading. Do you see that there, in the middle of 22 23 the page? 24 Α. I do.

- If you look directly below that, it says 1 O. January 6th of 2025, correct? 2
 - Α. It does.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- Three lines down the creatinine is 1.3, Ο. correct?
 - Α. That's correct.
- And the -- if you flip to the next page, which is Bates ending in 01568, in the middle of the page there, the eGFR is 63. Is that accurate?
 - That's correct. Α.
- Ο. And as we've discussed, an eGFR of 63 is CKD Stage 2, right?
 - Α. That's right.
- Do you have any evidence or information demonstrating that Mr. Mousser's CKD has changed since January of 2025?
 - One more time, please, do I?
- Are you aware of any medical records or anything indicating that his CKD staging has changed since January of 2025?
 - I don't, not based upon lab data, no. Α.
- Okay. So from April of 2023 -- sorry --Ο. April of 2022 through January of 2025, and I'll represent to you in, you know, my review of the

records, these are all of the -- what I've shown you is all of the lab results I've seen for Mr. Mousser for that time period.

A. Okay.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

Q. He has had one instance of a -- of a creatinine at 1.7, one instance of a creatinine at 1.5, and more than -- or he's at 11 instances of a creatinine at 1.4 or lower.

Is that -- I know we just went through a lot of them, but I'll represent to you that that's the case. So Mr. Mousser's creatinine has been consistently been below 1.5 to 1.6, is that accurate --

- MR. MANDELL: Objection --
- MR. GARAND: -- since April of 2022?
- 16 MR. MANDELL: Objection; form and foundation.
- Go ahead.
- 18 BY THE WITNESS:
- A. Based upon the creatinine values that we've looked at, yes --
- 21 BY MR. GARAND:
- 22 Q. So --
- A. -- those numbers.
- Q. And I apologize for jumping in there.

| | | | So | can | you | explain | why | you | listed | l 1.5 | to |
|-----|----|-----|-----|------|------|---------|------|-----|--------|-------|-----|
| 1.6 | as | the | cre | eati | nine | values | in y | our | expert | repoi | ct? |

A. Yeah, because at the time that I wrote the report, the data that I had in front of me was -- included, again, a lot of these numbers, but as we talked about before, I was most interested in the demonstration that his kidney, you know, has the inability to compensate, you know, when we have sort of changes in volume and potential interventions, such as blood pressure medications.

That is, again, the rationale for why I made that conclusion about his longevity of his remaining kidney. So that's why it's in my report as -- because that's what I focused on as being significant and based upon, again, my experience, that contributes to my conclusion.

Q. So the -- so a creatinine value of 1.5 to 1.6 that's over three years old is what's most significant to you in his lab results?

MR. MANDELL: Objection.

BY THE WITNESS:

A. I didn't say that. I said that's a -- I said that's a part of what I considered to be significant in my determination of his chronicity of

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

Page 128 of 281

| 1 | disease | and | the | future | of | his | kidney. |
|---|---------|-----|-----|--------|----|-----|---------|
|---|---------|-----|-----|--------|----|-----|---------|

BY MR. GARAND:

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

Q. So lower, more recent creatinine results is not significant?

MR. MANDELL: Objection.

BY THE WITNESS:

A. No, I didn't say that either. It is a piece -- it's a part of the decision, but it alone is not in my mind the most important determination of, you know, what his future kidney health is going to look like.

BY MR. GARAND:

Q. Yeah, and, Doctor, I'm sure you understand, all I'm trying to do is figure out why 1.5 to 1.6 was listed as the creatinine values in your report, as opposed to lower creatinine values that are more consistent -- or more recent?

MR. MANDELL: Objection; asked and answered.

Go ahead.

BY THE WITNESS:

A. Again, it's because I was at that time putting together all of the information, included all of the things that we talked about, his unilateral nephrectomy, his hyperfiltration of that remaining

kidney, his comorbidities, and the fact that soon after surgery and even sometime following surgery that he had significant rises in creatinine.

So I think it's important, and you've actually laid it out very nicely, minimal changes in creatinine result in significant drops in creatinine clearance.

BY MR. GARAND:

1

2

3

4

5

6

8

9

10

11

12

13

18

19

20

21

- Q. And, Doctor, you didn't explain any of this in your report, is that -- any of the explanation you just gave as to why you picked certain creatinine results, none of that is in your expert report, is that right?
- 14 MR. MANDELL: Objection.
- 15 BY THE WITNESS:
- 16 A. I didn't feel the need to.
- 17 BY MR. GARAND:
 - O. And why is that?
 - A. Because, again, the -- the information that I placed there in addition to the other parts of the expert opinion, and -- and including, you know, my experience, is what allows me to make that conclusion.
- 23 MR. MANDELL: Objection.
- MR. GARAND: Okay. I think we've been going for

about an hour, and I'm at a good stopping point, if 1 that's all right with you, Doctor. 2

> Sure. THE WITNESS:

MR. MANDELL: Five minutes.

MR. GARAND: Sure.

THE VIDEOGRAPHER: Going off the record at 11:04 a.m.

> (WHEREUPON, a recess was had from 11:04 to 11:16 a.m.)

THE VIDEOGRAPHER: We are back on the record at 11:16 a.m.

BY MR. GARAND:

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

Doctor, I just showed you a whole lot of Ο. GFR -- or lab results with GFR results and -- and creatinine levels.

Did you have all of those records when you wrote your initial report?

- I believe I had if -- everything but maybe Α. the last one, sometime in -- with the one in 2024, but I know I had all of the others.
- Okay. Did you consider -- or was there any consideration in drafting a supplemental report with the most updated creatinine and GFR results?
 - Α. No. I didn't believe that was necessary.

It didn't change my opinion that I provided in the initial report.

- Q. Okay. Doctor, you also -- as part of your bases, you also found that Mr. Mousser was likely to require renal replacement therapy in three to five years be- -- because he had significant proteinuria and an elevated protein creatinine ratio, is that right?
 - A. Correct, that's what I have in here.
- Q. And let me just ask generally, what's the difference between significant proteinuria and an elevated protein creatinine ratio?
 - A. Pretty much the same, yeah.
- Q. Okay. Okay. So let's talk about those two pieces. And Erick per usual is ahead of the game. We're going to mark this as Cooper Exhibit 16.

(WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 16, for identification, as of 07/10/2025.)

BY MR. GARAND:

- Q. Doctor, have you seen this exhibit before?
- A. I don't recall specifically whether I had these records.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

2.4

Okay. Just for the record, this is a Ο. July 19, 2022, treatment note from Mr. Mousser, and it's Bates-stamped 0667_MOUSSER_VHA_0327 through 0333.

If you flip to the very last page, which is Bates ending in 0333, you'll see that it's signed by a -- yeah, sorry about that.

- Α. Okav.
- 0. It's signed by a nephrology fellow and a staff nephrologist.

Do you see that?

Α. Yes.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- In the middle of the page? Ο.
- Α. I do, yes.
- And if you flip to just one page earlier, Bates ending in 0332, do you see that the provider assesses CKD Stage G3a A1. Is that right?
 - I see that, yes. Α.
- The last sentence of that first paragraph -- so I guess two -- two or three lines up from the bottom there to the right, it says, "Found to uptrend to 1.6 few months after and has remains stable 1.5 to 1.6 since then and currently at 1.4," is that right?
 - Α. Yes, that's correct.

- Okay. In the middle of the next O. paragraph, the second line from the top, is -- if you see UA in a medical record, is that urinalysis?
 - Yes, sir, most often.
- So it says, "UAs showing now resolved Ο. hematuria with negative proteinuria on dipstick," is that right?
- Α. Give me one second. The second sentence. Yes, yes, it says that.
- So at this point in July of 2022, there Ο. was no proteinuria, correct?
- According -- according to this record, Α. correct.
- Yes. And, Doctor, of course, yeah, if we Ο. are referencing a record, I'll assume that you mean according to this record and, you know, not that there is some other record out there that would contradict it.

So if we flip to the very last page, which is Bates ending in 0333, do you see the "Plan" heading at the top of the page, towards the top?

- I do. Α.
- The second -- the second --0.
- 24 Α. The last page.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

| 1 | MR. MANDELL: No, it's just go ahead, I've |
|----|---|
| 2 | got it. |
| 3 | BY MR. GARAND: |
| 4 | Q. The second line there says, "UACR |
| 5 | undetected at this time with UPCR 0.07 changing his |
| 6 | grade to Al kidney disease. Continue with ACEi," |
| 7 | which is ACE inhibitor, right? |
| 8 | A. Yes, sir. |
| 9 | Q. And as we discussed earlier, UACR means |
| 10 | urine albumin-to-creatinine ratio, right? |
| 11 | A. It does. |
| 12 | Q. So undetected UACR and 0.07 UPCR is not |
| 13 | evidence of elevated protein creatinine ratio, right? |
| 14 | A. That's correct. |
| 15 | Q. Okay. Let's look at another exhibit here, |
| 16 | which I'll mark as Cooper Exhibit 17. |
| 17 | (WHEREUPON, a certain document was |
| 18 | marked Dr. Cooper Deposition Exhibit |
| 19 | No. 17, for identification, as of |
| 20 | 07/10/2025.) |
| 21 | BY THE WITNESS: |

And, Doctor, I'll ask if you've seen this

22

23

24

Α.

Q.

BY MR. GARAND:

Thank you.

record before?

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

- A. Again, I had these records. I don't remember this specifically.
- Q. Okay. Just for the record, this is a December 11th, 2023, VA treatment note for Mr. Mousser. It is Bates-stamped 00667_MOUSSER_VHA_0111 through 0112.

Do you see that this is a nephrology consult at the very top of the page?

- A. Yes, sir, I do.
- Q. And do you see that the author is Jay Bucci?
 - A. I do, yes.
- Q. I hope I'm pronouncing that correctly.

 But if you flip to the second page at the very top,
 the signature line shows that Jay Bucci is a staff
 nephrologist with the VA, right?
 - A. Yes, sir.
- Q. Okay. Do you see the findings on Page 1 of this record, which is Bates ending in 0111, Dr. Bucci found that "Mr. Mousser is a 60-year-old male with hypertension, CAD status post CABG, urothelial cell carcinoma mall status post nephroureterectomy in October of 2020 and CKD G3a A1

1 | (creatinine 1.4 to 1.5) attributed to reduced renal

- 2 mass from the nephrectomy. He previously had
- 3 proteinuria prior to his nephrectomy, but it has
- 4 resolved. He has managed with lisinopril and
- 5 empagliflozin. He has no complications of CKD."
- 6 Did I read that correctly?
- 7 A. You did.

8

9

10

11

15

16

17

18

19

- Q. So just like in July of 2022, in December of 2023, Mr. Mousser again was found not to have proteinuria, is that right?
- A. Correct.
- Q. And, in fact, this -- this examiner -- or provider found that the proteinuria had resolved, right?
 - A. Correct.
 - Q. Okay. If we look at the "Impression" heading on the same page, Dr. Bucci again found that Mr. Mousser had stable CKD -- and sorry, we're looking at 0111. Sorry about that.
 - A. I was flipping the page. I apologize.
- 21 Q. That's okay.
- 22 A. Okay.
- 23 Q. So the "Impression" tab -- or heading,
- 24 Dr. Bucci found that Mr. Mousser had "stable CKD G3a

Al from reduced renal mass status post nephrectomy three years ago, "right?

> Α. Yes.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

- He also notes right beneath that that "Patients with stable CKD attributed to a nephrectomy without albuminuria and without complications of CKD generally do not require long-term nephrology follow-up unless there is evidence of disease in the remaining kidney, " is that right?
 - That's right, that's what it says. Α.
- And then under the "Recommendations" Ο. heading, the fourth entry there, Dr. Bucci stated that Mr. Mousser "is discharged from the nephrology clinic," is that correct?
 - Yes, sir, that's what it says.
- And as discussed, that's because he had O. CKD Stage G3 A1 and Dr. Bucci found that it was stable, is that right?
- MR. MANDELL: Objection.
- 20 BY THE WITNESS:
- 2.1 That's what he states here in his note. Α. 22 BY MR. GARAND:
- 2.3 And he also found that the proteinuria had Ο. resolved, right? 24

1 Α. That's what's in his note, yes. Okay. I'll show you what I'll mark as 2 3 Mousser -- or Cooper Exhibit 18. (WHEREUPON, a certain document was 5 marked Dr. Cooper Deposition Exhibit No. 18, for identification, as of 6 7 07/10/2025.) 8 BY THE WITNESS: 9 Α. Thank you. 10 BY MR. GARAND: 11 O. Thank you. 12 Doctor, again, I'll ask if you've seen 13 this record before? 14 Again, not specifically, but I did have 15 these in my possession. 16 So, and, again, this is a December 15th, Ο. 17 2023, VA treatment note. It's Bates-stamped 18 00667_MOUSSER_VHA_097 through 0103. And so this is 19 just a few days after the December 11th, 2023, 20 treatment that we just looked at, is that right? 2.1 That's right. Α. 22 Q. And this is a different VA provider, 23 right, Katherine Adams-Krick? 24 Α. Correct.

| Q. | Okay. | Please t | urn to P | age 6 d | of thi | İs | |
|------------|-----------|-----------|----------|---------|--------|---------|----|
| document, | which is | Bates e | nding in | 0102. | If y | you see | |
| the "Asses | ssment/P] | an" head | ing ther | e in th | ne mid | ddle of | |
| the page, | if you] | ook at N | umber 1, | she as | gain d | diagnos | es |
| chronic k | idney dis | sease Sta | ge G3 A1 | , is th | nat ri | ight? | |

- A. That's correct, yes.
- Q. The second bullet under Number 1 is "Serum creatinine stable at baseline at 1.4," is that right?
 - A. That's right.
- Q. And the Number 2 under the Assessment/Plan heading is that, "Proteinuria: Controlled," is that right?
 - A. Yes, sir.
- Q. Do you understand that to mean that she found that his proteinuria was controlled?
 - A. Based upon her note, yes.
- Q. Okay. Doctor, we're going to look back at Exhibit 14, which I hope is one of the ones that I told you to keep.
 - A. Yes, I have it.
- Q. Okay. If we look at Page 2 of this document, which is Bates ending in 01625, right after the -- that double dotted line in the middle of the page, this provider states, "Your kidney function

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

remains stable as reflected by the serum creatinine at 1 your baseline of 1.4," is that right? 2

> Α. I see that.

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

- And if you skip to the next paragraph, she states that, "Additional evidence for stable kidney function is the microalbumin in your urine or protein in your urine remains undetectable at less than 7.0 mg/L," is that right?
 - Yes, sir, that's what it says.
- So, again, as of November -- or in November of 2024, this provider found that Mr. Mousser's microalbumin in the urine was undetectable, correct?
 - Α. That's correct. Excuse me.
- Okay. So let's look at Dr. Flood's Ο. deposition transcript, which is Exhibit 10.
- Α. Ten, okay.
- We'll look at Page 41. And take your time getting there, Doctor. I know there's a lot of documents flying around.
- I'm trying to get these close. I'm sorry, Α. page...?
- Q. 41.
- 24 Α. God bless you.

Q. We'll look at lines 2 to 6. And Dr. Flood stated:

"So he had kidney disease by virtue of single kidney, longstanding proteinuria/albuminuria, which interestingly is resolved on the current medication, which is wonderful for him."

Did I read that correctly?

A. You did.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

Q. We'll look at Page 43. We'll look at again Lines 1 through 8. Dr. Flood testified that:

"His albumin level in 2022 and his urine was under 30, so that was okay by 2022. So he had some proteinuria on one test in 2020, so, yeah, I've got to restate what -- what I wrote as -- at least based on that, unless I was able to find older data, he had proteinuria on one episode, and actually's been doing just fine since that time," correct?

- A. That's correct.
- Q. Is there any reason why you did not include these more recent medical records in your report that indicate that there is no pro- -- that the proteinuria has resolved and that the pro- -- protein creatinine ratio was undetectable?
 - A. Yes, because at -- at the time that I -- I

wrote this report, again, I was, you know, evaluating the, as I said before, the totality of Mr. Mousser and additional data that, again, none of those talked about, that he has had the ability to look at his other kidney.

It's just surprising to me that the nephrologist say that he has no evidence of intrinsic disease when they could look at his pathology and know that he does. And the fact that he had proteinuria and elevated urine creatinine ratio after his nephrectomy at any time to me is incredibly significant.

You said it yourself. He's on medications now to control his proteinuria. So his providers themselves know that he has proteinuria and they're controlling it with the medications, which, again, is an indication that this kidney has injury associated with it and they're treating.

And so your question earlier about does control matter? Sure, it matters, but there still is the demonstration that that single kidney secondary to having a nephrectomy that's hyper-filtrating with all of his co- -- multiple comorbidities is damaged and is going to have problems in the future.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

| Q. And I appreciate that, Doctor. My |
|--|
| question was, why didn't you discuss specifically |
| those more recent results that contradict your finding |
| of elevated proteinuria or significant significant |
| proteinuria and an elevated protein creatinine ratio? |

A. They don't con- --

MR. MANDELL: Objection; asked and answered.

Go ahead.

BY THE WITNESS:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

24

A. They don't contradict what I said. I said that the fact that he has had that following his nephrectomy is part of my equation in calculating those three to five years.

BY MR. GARAND:

- Q. Doctor, are you aware of what medications Mr. Mousser is on that protect his kidney function?
 - A. Currently?
 - O. Currently.
- A. I -- I don't remember specifically. He has been on several medications including like the ACE inhibitors and the ARBs, but what he's on currently right now, I am unfamiliar.
- Q. Do you know whether the medications that protect his kidney, whether he's on those medications

| specifically | , to | protec | t his | kidney | or | he's | on | those |
|--------------|------|--------|--------|--------|----|------|----|-------|
| medications | for | other | purpos | ses? | | | | |

- Α. No, he's on those medications to protect his kidney.
- Q. Okay. Okay. And, again, you don't remember what medication -- or you don't know specifically what medications those are?
- Again, I -- they're under the class that are renal protective agents.
- And he was prescribed those medications to O. protect his kidneys?
 - Α. Correct.
- Ο. Okay. Doctor, again, I think I asked you about this earlier, but you don't recall reviewing Dr. Andrew Rockwood's deposition transcript in this matter, do you?
 - Α. I don't specifically recall, I'm sorry. (WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 19, for identification, as of 07/10/2025.)

BY MR. GARAND:

This is a portion of Dr. Rockwood's 0. deposition transcript.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

2.2

23

| 1 | A. Excuse me. |
|----|---|
| 2 | Q. And, Doctor, if you flip to Page 101 for |
| 3 | me, please. |
| 4 | And, again, you understand that |
| 5 | Dr. Rockwood is Mr. Mousser's VA urologist? |
| 6 | A. I do. |
| 7 | Q. Okay. Let's look at Page 101, Lines 4 to |
| 8 | 15. |
| 9 | Question: "Does Mr. Mousser being |
| 10 | diagnosed with chronic kidney disease change your |
| 11 | opinion of his life expectancy?" |
| 12 | Answer: "No." |
| 13 | Question: "Why doesn't that change your |
| 14 | opinion?" |
| 15 | "It's a very minimal risk factor, the fact |
| 16 | that his or at least based on the last renal |
| 17 | function assessment, his creatinine was 1.4, but that |
| 18 | would have a very minimal impact on his life |
| 19 | expectancy." |
| 20 | Did I read that correctly? |
| 21 | A. You did. |
| 22 | Q. And if you will turn to Page 103 for me. |
| 23 | We'll look at Lines 5 through 8 And Dr Rockwood |

testifies that "...if his kidney function remains

where it is, it should have essentially zero impact on 1 2 his ability to function normal daily activities..." And then at Lines 11 through 12, "... but 3

in terms of his working inside in an office-type setting, it should have zero impact, " is that right?

- Α. That's what it says, yes, sir.
- So Dr. Rockwood's opinion is that Mr. Mousser's CKD would not impact Mr. Mousser's life expectancy, correct?
- 10 MR. MANDELL: Objection.
- BY THE WITNESS: 11

4

5

6

7

8

9

- 12 I believe that's his opinion, yes.
- 13 BY MR. GARAND:
- 14 Okay. Let's look back at Dr. Flood's 15 transcript, which is --
- 16 Δ Ten.
- 17 -- Cooper Exhibit 10. Thank you. Q.
- 18 We'll look at Page 70 of his transcript,
- 19 please. Specifically we'll look at Lines 18 to 20.
 - Α. Okay.
- 21 And you'll see that Dr. Flood stated that,
- 22 "But as of 2024, I can see he's," meaning Mr. Mousser,
- "doing really, really well, which is great." 23
- 24 Do you see that?

1 A. I do.

2

4

5

6

7

8

9

10

2.0

21

22

23

24

- Q. Look at Page 92 for me, please.
- A. Yes, sir.
 - Q. And I'll -- we'll just look at Lines 17 to -- through 19 which again we discussed. You say that, "And that creatinine of 1.4 is entirely consistent with somebody that has one kidney that's doing quite well," is that right?
 - A. Yes, sir, that's what it says.
 - Q. Look at Page 23 for me.
- 11 A. 20 -- 20 --
- 12 Q. 23?
- A. We are back to 23?
- 14 Q. Yes. Sorry about that.
- 15 A. Yep. One second.
- 16 Q. Sure, yeah, no problem.
- 17 A. Okay.
- 18 Q. We're looking at Lines 5 through 18.
- 19 Dr. Flood testified that:

"And I just looked at his recent labs, and actually for somebody that only has one kidney, the creatinine is fairly well preserved, and he no longer has albuminuria, meaning that the filter units are no longer damaged.

Page 148 of 281

"When I saw him in 2022, he was having some albumin or protein, which is a reflection of damage to either the kidney with the albumin or tubules with the protein.

"But that all seems to have resolved, and his urine -- urine looks good. So he's actually doing quite well from my perspective, looking at his current numbers."

Is that what -- did I read that correctly?

- You did. Α.
- 0. Let's go to line -- page 114.
- 12 Α. One more. Okay.
 - And we agreed earlier that a nephrologist O. is in an acceptable position to opine on somebody's prognosis, is that correct, with chronic kidney disease?
 - Α. Yes.
 - Take a look at 114, Line 3. Are you there, Doctor?
 - Α. I am, yes, sir.
 - He says -- Dr. Flood testifies, "He's got one kidney, but he is doing very, very well."
- "So -- and just in line with 23 Ouestion: 24 this, Doctor, what would you say Mr. Mousser's

1

2

3

4

5

6

8

9

10

11

13

14

15

16

17

18

19

20

21

prognosis is related to his chronic kidney disease at this time?"

He answers: "I think it's -- I think it's excellent. He's got one kidney which needs to be protected all the more because he only has one kidney, but with good blood pressure control and avoiding nephrotoxins, things that might hurt the kidney, like Motrin, Advil, that type of thing, and then taking medicines that help protect the kidney, so the lisinopril and the empagliflozin, he has an outstanding lifelong -- barring some unforeseen serious injury or, you know, ill -- critical illness or something that causes acute kidney injury within the kidney itself, I mean, it's an excellent prognosis."

Did I read that correctly?

- Α. You did.
- And so, you know, we've just looked at four or five different passages from Dr. Flood who is, again, Mr. Mousser's -- one of Mr. Mousser's VA treating nephrologists, correct?
 - Correct. Α.
- And, you know, his essential sentiment is Mr. Mousser's prognosis is excellent, correct?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- With a lot of "ifs" in there, yes. Α.
 - And, Doctor, you're aware that doctor --Q. well, maybe you aren't. Do you know that Dr. Flood utilized the Kidney Failure Risk Equation here with Mr. Mousser?
 - Α. I don't recall that specifically, I'm sorry.
 - Q. Let's flip to Page 113, which we're very close.
 - Okay. Α.
 - Okay. So 113, Line 14, Dr. Flood Ο. testified, "Okay. So for -- for a 61-year-old man who has a GFR of 57, with an albumin-to-creatinine that's very low because it's undetectable right now, so less than 5, his risk of going on dialysis in five years is 0.12 percent."

He continues, "And that's from the kidney" -- sorry. "And that's -- that's from the Kidney Failure Risk Equation. It's -- it is well-accepted in the literature; in fact, it's becoming a standard of care for reference in management for it."

Did I read that correctly?

You did. A.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- And based off our prior discussion, you 1 Ο. 2 disagree with Dr. Flood's analysis there, correct? 3 Α. I do.
 - Ο. Doctor, let me -- okay. Doctor, let's look at one more. If we look at Page 124 here.
 - 124? Α.
 - Yes, 124. Q.
 - Α. Okay.

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- We're looking at Line 12 through 19. Ο.
- Α. Okay.
- Dr. Flood again testified, "I mean, this Ο. is pretty incred- -- you know, 1.4, no albumin in his urine would be pretty normal and expected for somebody that even donated a kidney. That would be very normal.
- "So a healthy individual that donated a kidney, these are the kind of numbers we would see." Is that correct?
 - That's what he says, yes. Α.
- Doctor, would you agree that achieving Ο. good blood pressure control can reduced the five-year risk of requiring renal replacement therapy?
 - Compared to not controlling it, yes. Α.

Q. So if Mr. Mousser's hypertension is well controlled, it will reduce his risk of progressing to endstage renal disease, is that correct?

MR. MANDELL: Objection.

Go ahead.

BY THE WITNESS:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

20

21

22

23

2.4

A. He has a better chance than if it's uncontrolled.

BY MR. GARAND:

- Q. Are you aware whether or not Mr. Mousser's hypertension is well controlled at this point?
- A. So he has intermittent fluctuations of some elevation in his blood pressure, but it's better with the medication that he's on than if he was not.
- Q. Are you aware whether or not it's controlled at this time?
- MR. MANDELL: Objection.

Go ahead.

19 BY THE WITNESS:

A. I believe I answered that. Like I said, I believe he's on medication, but he still has elevations at times of that blood pressure above what would be considered normal. So it's better than if it wasn't -- he wasn't on medication, but the definition

Page 153 1 of controlled is, again, extremely variable. BY MR. GARAND: 2 3 Q. Okay. Doctor, let's look at --MR. GARAND: Tab 23. 5 BY MR. GARAND: And I'll mark this as Cooper Exhibit 20. 6 0. 7 (WHEREUPON, a certain document was 8 marked Dr. Cooper Deposition Exhibit 9 No. 20, for identification, as of 10 07/10/2025.) 11 MR. GARAND: Thank you, Erick. 12 THE WITNESS: Thank you very much. 13 MR. GARAND: Of course. 14 BY MR. GARAND: 15 And, Doctor, I'll ask if you've seen this record before? 16 17 Α. Again, I'm sorry, I don't remember the 18 specifics of this one, but I know it was in my 19 possession. 20 Okay. Doctor, just for the record, this 2.1 is a November 8th, 2024, nephrology note for 22 Mr. Mousser. It's Bates stamped 0 -- sorry,

If you'll flip to Bates ending in 01637.

00667_MOUSSER_VHA_01631 through 01638.

23

| 1 | A. | Okay. |
|----|-------------|---|
| 2 | Q. | If you'll look at No. 3 under the |
| 3 | "Assessmen | t/Plan" heading, you'll see that it says, |
| 4 | "Hypertens: | ion-CKD: Controlled." |
| 5 | | Do you see that? |
| 6 | Α. | I do. |
| 7 | Q. | Okay. Doctor, would you also agree that |
| 8 | an ACE inh | ibitor or ARB can reduce the five-year risk |
| 9 | of needing | renal replacement therapy? |
| 10 | Α. | It can, yes. That's why folks are put on |
| 11 | it, partic | alarly those with a demonstrable CKD. |
| 12 | Q. | Are you you're aware that Mr. Mousser |
| 13 | is on lisi | no is taking lisinopril, correct? |
| 14 | Α. | Yes sir. |
| 15 | Q. | And lisinopril is an ACE inhibitor, right? |
| 16 | Α. | That's correct. |
| 17 | Q. | Do you know whether Mr. Mousser was placed |
| 18 | on lisinop | ril for his cardiovascular issues or his |
| 19 | kidney iss | ies? |
| 20 | Α. | He was put on it for both. |
| | | |

an SGLT2 inhibitor can reduce the five-year risk of

21

22

23

24

Q.

For both.

requiring renal replacement therapy?

Okay. Doctor, would you also agree that

- A. The newer data, that's not my area of expertise, but it's certainly proffered as one.
 - Q. Are you aware that Mr. Mousser is taking empagliflozin?
 - A. I am, yes.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

- Q. And that's an SGLT2 inhibitor, correct?
- A. That's correct.
- Q. Okay. Let's go back to your expert report for Mr. Mousser. I know we went through a whole bunch of records and now we're circling back.
 - A. Okay. Okay.
 - Q. If you look at Page 3 for me.
 - A. The Mousser report, Page 3. Yes, sir.
- Q. You write that, "In addition to the risk of CKD/ESRD" -- and, sorry, this is at the very bottom of the page.
 - A. Yes.
- Q. "In addition to the risk of CKD/ESRD, Mr. Mousser has an increased risk of hypertension with decreased glomerular mass."
- When you say -- what do you mean by an increased risk of hypertension?
- A. So one of the roles of our kidneys is to help regulate volume, and when patients have either a

loss of glomerular mass or a loss of a kidney, in both these respects, they have more challenges with regulating blood pressure.

So the fact that he has lost a kidney means that he has increased challenges with regulating his blood pressure compared to what he had before his nephrectomy for cancer.

- And you're aware that Mr. Mousser had stents placed in 2012, correct?
 - Cardiac stents. Α.
 - Ο. Correct.
 - Α. I am, yes.
- Are you aware that he had a quadruple Ο. bypass surgery in 2016?
 - Α. I'm aware, yes.
- Are you aware that he was -- he has been Ο. diagnosed with hypertension at least since 2016?
- I don't know when it started, but I know Α. he has been diagnosed for some time.
- Okay. So it's not your opinion that the chronic kidney disease could cause the hypertension that preexisted before his kidney cancer, right?
 - Α. I'm sorry, one more time.
 - Ο. So his hypertension predates his kidney

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

2.4

| cancer, correct, and I | i'll s | show you | . a record? |
|------------------------|--------|----------|-------------|
|------------------------|--------|----------|-------------|

- A. It does. Yes, it does.
- Q. So your opinion is not that his chronic kidney disease can cause hypertension. It already exist -- he's already being treated for it, correct?
 - A. Correct. It can worsen his hypertension.
- Q. Okay, yeah. That's what I wanted to make sure I understood.
 - A. Okay.
 - Q. Okay. I'm going to show you --
- MR. GARAND: We'll go Tab 24.
- 12 BY MR. GARAND:

1

2

3

4

5

6

7

8

9

10

11

13

14

15

16

17

19

20

21

22

23

24

Q. -- what I'll mark as Cooper Exhibit 21.

(WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 21, for identification, as of 07/10/2025.)

18 BY MR. GARAND:

Q. And, Doctor, I'm assuming you have not seen these records before. This is records from South Texas Cardiovascular Consultants. We just obtained them. We produced them on Monday. It took us forever to actually get them. So you haven't seen them, so if you need to take a minute to, you know, review it,

- 1 | please do so, and just let me know when you're ready.
 - A. Okay. Thank you.
 - Q. And I'll just state for the record that this is an April 6th, 2016, treatment note for Mr. Mousser from South Texas Cardiovascular Consultants, and it's Bates-stamped
 - A. Okay. I think I'm good.

00667_MOUSSER_STCC_078 through 080.

- Q. Doctor, first I want to ask you, again, so this is a -- you see the top right, it's Mousser, Frank?
- 12 A. Yes.

2

3

4

5

6

7

8

9

10

11

15

16

17

18

19

2.0

21

- Q. And then to the left, there's an April 6th, 2016, date there, correct?
 - A. Yes, sir.
 - Q. Are you aware of any kidney problems or issues Mr. Mousser was having in April of 2016?
 - A. Am I aware of any kidney -- no.
 - Q. Okay. Do you see under the current medications, one, two, three, the fourth one down is lisinopril, correct?
 - A. I see that, yes, sir.
- Q. Is it -- so Mr. Mousser was prescribed lisinopril prior -- over four years before he was

- diagnosed with kidney cancer, correct? 1
- That sounds about right. I don't know 2 3 when exactly it started, but yes.
 - Okay. So if you'll look at, again, Ο. Page 1, this is Bates ending in 078, the "Previous Cardiology Testing" heading, do you see that?
 - Α. Yes, sir.
 - Ο. The second paragraph under there, the last sentence states, "He has developed labile hypertension which is controlled on his beta blockade and ACE-I, which we were initially -- which were initially started after his initial presentation."

Is that right?

- Α. Yes, sir.
- And if you flip to Page 2, which is Bates ending in 079, do you see the "Assessments" tab at the top of the page there?
 - I do, sir, yes. Α.
- 19 Ο. And Number 3 under there is "Essential hypertension, correct? 20
 - Α. Correct.
 - And then under the "Treatment" heading, Ο. Number 3 is again "Essential hypertension," right?
 - It does. Α.

4

5

6

8

9

10

11

12

13

14

15

16

17

18

2.1

22

23

| 1 | Q. And the provider here states, "Blood |
|----|---|
| 2 | pressures are borderline controlled on today's |
| 3 | examination. No change in his medical routine is |
| 4 | recommended at this time, "right? |
| 5 | A. Yes, sir. |
| 6 | Q. Okay. I'm going to show you what |
| 7 | MR. GARAND: Tab 25. |
| 8 | BY MR. GARAND: |
| 9 | Q what I'll mark as exhibit Cooper |
| 10 | Exhibit 22. And, again, this is another South Texas |
| 11 | Cardiovascular Consultants record, so if you need to |
| 12 | take a minute to review it, please do so. |
| 13 | A. Thank you. |
| 14 | (WHEREUPON, a certain document was |
| 15 | marked Dr. Cooper Deposition Exhibit |
| 16 | No. 22, for identification, as of |
| 17 | 07/10/2025.) |
| 18 | BY MR. GARAND: |
| 19 | Q. And just let me know when you're ready, |
| 20 | Doctor. |
| 21 | A. Okay. |
| 22 | Q. And I'll just note for the record, this is |
| 23 | a March 16, 2021, treatment note for Mr. Mousser from |
| 24 | South Texas Cardiovascular Consultants, and it's |

1 | Bates-numbered 00667_MOUSSER_STCC_054 through 057.

- A. Okay. I think I'm good.
- Q. Okay. Doctor, under the previous cardiology history -- let me make sure I'm looking at the right one here. Yes, okay.

So the "Previous Cardiology History" heading there in the very middle of the page, the last sentence of that paragraph states that, "He has developed labile hypertension after his CABG," is that correct?

- A. Yes, sir.
- Q. And CABG refers to the 2016 quadruple bypass surgery, correct?
 - A. It does, sir, yes.
- Q. If you'll flip to the second page, which is Bates ending in 055, under the "Assessments" heading, Number 6, he is again diagnosed with "essential hypertension," right?
 - A. Yes, sir.
- Q. And Number 3 under the "Treatment" tab is again "essential hypertension," right?
 - A. Right.
- Q. And on that second line, it says, "Well controlled and he will continue to monitor at least

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

Page 162 weekly with the goal of pressures 130/80 or below," 1 2 correct? 3 It says that, yes, sir. Α. Okay. I'll show you what I'll mark as Ο. 4 Cooper Exhibit 23. 5 6 Α. Exhibit 23. And, again, this is another South Texas 8 Cardiovascular Consultants record, so please feel free to review and let me know when you're ready. 9 10 (WHEREUPON, a certain document was 11 marked Dr. Cooper Deposition Exhibit 12 No. 23, for identification, as of 13 07/10/2025.) 14 BY THE WITNESS: 15 Can you just tell me what the date is on 16 t.hat.? 17 MR. MANDELL: Yes, what is the date? 18 BY MR. GARAND: 19 Yeah, sorry. It's -- so the date -- if 20 you look at the top right, it says date of service is 2.1 10/24/2024. 22 Α. Okay. That's easier to read. 23 Q. 24 Α. Thank you.

1 Okay.

2

3

4

5

6

8

9

10

11

12

13

14

15

17

18

19

20

21

22

2.3

2.4

- Q. Okay. Doctor, so we'll look at Page 1 of this record, which is Bates ending in 044, under the "History of Present Illness" paragraph, the third line down states that, "Blood pressure as far as he knows his," I think it meant "is," "well-controlled, 130/80 or below," is that right?
 - A. Yes, yes.
- Q. And I also just want to point out again if you look at the medications he is taking to the left there in the left column, he is -- four and five down, I believe, so he's still taking the lisinopril, correct?
 - A. Yes.
 - Q. And he is taking Jardiance?
- 16 A. Jardiance.
 - Q. And do you understand that that's em- -- empagliflozin?
 - A. Um-hum.
 - Q. What is -- what's the -- what -- what are some of the reasons why someone would be prescribed Jardiance or empagliflozin?
 - A. Diabetes most commonly.
 - O. Okay. Doctor, let me make sure there's

Page 164 nothing on here that I wanted to discuss. 1 Doctor, let's go back to your 2 Okay. 3 report --Α. 4 Okay. -- for Mr. Mousser, which is Cooper 5 6 Exhibit 7, I believe, and we're looking at Page 4. Α. Okay. 8 So in that big paragraph in the middle of the page, six lines down, there's a -- to the right of 9 10 the -- of the page, there's a sentence that starts "The ability." 11 12 Do you see that? 13 Α. I am there, yes, sir. 14 It reads, "The ability to main -- maintain 15 full-time employment for dialysis patients is 16 difficult despite the interest," is that right? 17 Α. That's correct. And it's your opinion that Mr. Mousser --18 19 Mr. Mousser will need renal replacement therapy in 20 three to five years, correct? 2.1 It is. Α. 22 Do you know what age Mr. Mousser testified he would retire at? 23 24 Oh, I don't know that. Α.

| Q. | Mr. Mousser I'll Mr. Mousser testified |
|-----------|--|
| and then | admitted in a in a separate pleading that |
| he would | retire at age 65. If he required renal |
| replaceme | ent in therapy in three years, he'd be 65, |
| is that o | correct? |

MR. MANDELL: Objection. Foundation and form. BY THE WITNESS:

A. It seems like the right math, yeah.

BY MR. GARAND:

Q. I know, that's -- that's again about the extent of my math skills there.

So if he began renal replacement therapy at 65, it would have little impact on his ability to maintain employment because he'd be retired, correct?

MR. MANDELL: Objection.

BY THE WITNESS:

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

A. I don't know how we're connecting those two. If he goes on dialysis, my -- my point still sticks here that most folks have difficulty even if he changes his mind that he wants to work, that he'd be able to gain meaningful employment, but I don't know how I can put those two together.

BY MR. GARAND:

Q. Sure. Doctor, let's look at Page 5 of

1 your report.

2

3

4

5

6

8

9

10

11

12

13

14

15

16

2.1

22

- A. Okay.
- Q. And we're looking at the middle paragraph that begins "The reality."

Do you see that?

- A. I do.
- Q. The third line down all of the way to the right side, there is a para -- a sentence that says, "If Mr. Mousser suffers a recurrence now more than four years following surgery for the original cancer, his prognosis would be extremely poor as it would more likely than not be a metastatic site not appreciated in early follow-up bones, lungs, liver and brain."

 Did I read that correctly?

- A. That's correct.
- Q. Doctor, again, we've discussed this.
- 17 You're not an oncologist, correct?
- 18 A. No, sir.
- 19 Q. You don't treat people for their kidney 20 cancer, correct?
 - A. I do not.
 - Q. What is the basis of this statement?
- A. Really knowing the -- the pathophysiology of cancerous lesions if they recur in a metastatic

fashion, these are the most common, renal cell cancer is something that we see all of the time in our practice as causative for nephrectomy and potentially transplant, and this is some of the workup that we do in order to assure that somebody meets candidacy for kidney transplantation.

- Q. Are you aware that Mr. Mousser had a second cancer?
 - A. I am.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- Q. Do you know when that second cancer occurred?
- A. Sometime I think it was after -- soon after this report. It was like in March -- February, March. I think it's around that time.
- Q. Doctor, why did you -- is there any reason why you decided not to draft a supplemental report?

 MR. MANDELL: Objection.

Don't -- listen, in terms of anything that comes from conversations we've had or anybody at my -- at my office has had with you, do not answer that question. If you can answer it otherwise, fine. But the question is why didn't you do a redraft. So that's my objection.

BY THE WITNESS:

1 Α. The answer is as it was before, it 2 didn't -- it didn't change this opinion at all. 3 BY MR. GARAND: So in your expert opinion, Mr. Mousser's 4 Q. 5 second cancer did not impact his chronic kidney disease prognosis? 6 7 MR. MANDELL: Objection. 8 BY THE WITNESS: 9 Α. That -- that's correct. 10 BY MR. GARAND: 11 Are you aware that Mr. Mousser was O. 12 diagnosed with low-grade papillary urothelial 13 carcinoma? 14 MR. MANDELL: Objection. 15 BY THE WITNESS: 16 Yes, sir. Α. 17 MR. MANDELL: Go ahead. 18 BY THE WITNESS: 19 A. Yes, sir. BY MR. GARAND: 2.0 21 And, again, you don't treat patients with 22 this specific type of cancer, correct? I do not. 23 Α. 24 MR. MANDELL: When you say "treat," you mean for

| | Tage 107 |
|----|--|
| 1 | that cancer? |
| 2 | MR. GARAND: Correct, for that cancer. |
| 3 | MR. MANDELL: That's what I thought you meant. |
| 4 | MR. GARAND: Thank you. |
| 5 | BY MR. GARAND: |
| 6 | Q. Doctor, did you review the expert report |
| 7 | of Dr. Armine Smith in this matter? |
| 8 | A. I I don't recall that specifically, |
| 9 | Armine Smith. |
| 10 | Q. Do you know do you have any familiarity |
| 11 | with what her expert opinion would be on? |
| 12 | A. Again, connecting names and professions at |
| 13 | this point, there's just so many names here. I'm |
| 14 | sorry, I don't. |
| 15 | Q. I'll make it easier for us, Doctor. I'll |
| 16 | show you what I'll mark as Cooper Exhibit 24. |
| 17 | (WHEREUPON, a certain document was |
| 18 | marked Dr. Cooper Deposition Exhibit |
| 19 | No. 24, for identification, as of |
| 20 | 07/10/2025.) |
| 21 | BY MR. GARAND: |
| 22 | Q. And, Doctor, I'll represent to you that |
| 23 | she is a specific causation expert on behalf of |
| 24 | Mr. Mousser. |

1 Α. Okay.

2

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- She issued an initial opinion and then a Q. supplemental opinion after Mr. Mousser's second cancer.
 - Α. Okay.
- Ο. And so I'm going to show you her supplemental specific causation expert report.

MR. GARAND: Thank you.

BY THE WITNESS: 9

> Α. Thank you.

BY MR. GARAND:

- And, Doctor, if you have not had a chance O. to review this, please feel free to do so. It's -it's not long, so just let me know when you're ready.
 - Α. Okay.
- So, Doctor, if we'll look at the second Ο. main paragraph, the very last sentence states that, "In Mr. Mousser's case, this new bladder tumor is best understood as part of the continuum of his existing urothelial disease process, not as a new or unrelated malignancy."

Did I read that correctly?

- Α. Yes.
- If we look at her -- if you see then the O.

next line is, "Based on my review of the updated clinical documentation, I conclude the following," and she lists three reports -- or three opinions there, right?

A. She does.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

- Q. All right. Number 3 states that, "The development of low-grade bladder cancer does not independently impact or worsen Mr. Mousser's overall prognosis, which remains governed by his prior high-grade UTUC and the associated nephroureterectomy," is that correct?
 - A. That's correct, sir.
- Q. So if we go back to your expert report for Mr. Mousser. Again, we're looking at Page 4.

So Mr. Mousser did, in fact, have a recurrence more than four years after his surgery, is that correct?

- A. That's correct.
- Q. Would you agree -- so his -- as stated by Dr. Smith, which, again, is Mr. Mousser's specific causation expert, she found that his prognosis is still governed by the original UTUC, correct?
 - A. That's correct.
 - Q. And his cancer was not a metastatic site

that appeared in the bones, lungs, liver, or brain,
correct?

- A. That's correct.
- Q. Okay. Let's look at the last paragraph -- or at the bottom of Page 5 of your Mousser report, the third line down, Mr. -- you write in your report that, "Mr. Mousser also calls himself a 'slave' to his employment schedule making the opportunity for gainful employment impossible," is that correct?
 - A. That's correct, sir.
- Q. Is the "making the opportunity for gainful employment impossible" part of that sentence, is that Mr. Mousser's statement or your opinion?
 - A. I apologize, one more time.
- Q. So you -- is the "making the opportunity for gainful employment impossible" part of that sentence Mr. Mousser's statement or your opinion?
- A. So you're talking about previously what was said, not that statement?
- Q. No. So I'm asking, what you wrote in here is that, "He calls himself a 'slave' to his appointment schedule" --
- A. Yeah, I know that, but we -- the gainful employment we talked about elsewhere.

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

- Q. But I'm -- I'm asking, is that your opinion or did Mr. Mousser say his -- did you see in some record that his appointment schedule makes it impossible for him to maintain employment?
- A. Yeah, I just want to make sure I have my statements correct.
 - O. Of course.
- A. So just -- just to be clear, my statement says, the ability to maintain full-time employment is difficult, not impossible, despite his interest. And then we go over here, we talk about "slave to his appointment schedule, the opportunity for gainful employment impossible." That's what I interpreted his statement to be based upon his deposition that I read.
- Q. Okay. So that's not your opinion, that's your recitation of his statement?
- A. Correct. My -- my opinion is several paragraphs earlier that we talked about.
- Q. Okay. Okay. If you look at this, again,
 Page 5 in the bottom, the sentence immediately
 following what we were just discussing, you write,
 "His psychological concerns have resulted in
 significant insomnia which contributes to his ongoing
 feelings of fatigue," is that correct?

| Α. | That's | correct. |
|----|--------|----------|
|----|--------|----------|

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

- Q. Again, is this your opinion, or was it based off Mr. Mousser's deposition testimony or medical records or anything like that?
- A. Both. I mean, based -- based upon his medical records from the VA, including the -- the psychologist who is caring for him, as well as Mr. Mousser's deposition.
- Q. Are you aware that Mr. Mousser has severe obstructed sleep apnea that impacts his ability to sleep?
 - A. I am, yes.
- Q. Are you aware that Mr. Mousser's musculoskeletal pain significantly impacts his sleep?
 - A. I don't know that part specifically.
- Q. Are you aware that Mr. Mousser's nocturia causes him to wake up five to six times a night to use the bathroom?
- A. I recall that being as part of his history, yes.
- Q. Are you aware that Mr. Mousser has stated that his tinnitus interferes with his ability to sleep?
 - A. I don't recall that specifically, no.

Q. Okay. So there are many possible reasons or bases for him feeling fatigued, correct?

MR. MANDELL: Objection.

BY THE WITNESS:

4

5

6

8

9

10

11

12

13

14

15

16

19

20

21

A. According to Mr. Mousser, he believes that the -- you know, the most concerning reason for why he has an inability to work is his constant concern about recurrence of his cancer and, you know, the fact that he has so many now appointments. So he doesn't specifically call out to those other things.

BY MR. GARAND:

- Q. Okay. And, again, I was just asking about his fatigue, not -- not his overall ability to work?
 - A. Same.
- Q. So are you aware that there's, yeah, many different reasons for Mr. Mousser's fatigue?
- 17 MR. MANDELL: Objection.

18 BY THE WITNESS:

- A. So there are reasons. Those aren't the ones that Mr. Mousser calls as to why he is so fatigued.
- 22 BY MR. GARAND:
- Q. Okay. Again, looking at his deposition transcript, correct?

- And in the records when he's speaking with 1 a psychologist. 2
 - Okay. All right. And then that last O. sentence in this last full paragraph on Page 5 of your Mousser report, you write, "Based on review of Mr. Mousser's postsurgical records, he has significant stress and illness anxiety disorder and will require lifetime psychological counseling and support, " is that correct?
 - That's correct. Α.
- 11 Doctor, you're not a psychologist, Ο. 12 correct?
 - Α. I'm not.
 - And you're not a psychiatrist? Ο.
- 15 I am not. Α.
- 16 You're not a mental health professional of O. 17 any kind, correct?
- 18 No, sir. Α.
- 19 Ο. You don't treat patients for mental health 20 conditions?
 - Not primarily, no. Α.
 - Is this a diagnosis of significant stress Ο. and illness anxiety disorder?
- 24 Α. Say what again?

3

4

5

6

8

9

10

13

14

21

22

- Q. Is that a -- is that a specific diagnosis you're making?
 - A. It is, it is. That's found in the medical record.
 - Q. So there is a medical record that diagnoses him with stress and illness anxiety disorder?
 - A. There is, his psychologist.
 - Q. Okay. And so that's not your diagnosis; you're just quoting what someone else has diagnosed him with?
 - A. That's correct.
 - Q. Do you have an opinion on the cause of his mental health issues?
 - A. Again, based upon the medical records and treating similar patients, I can certainly understand why he feels the way that he does.
 - Q. Do you have a complete -- or -- or a full understanding of Mr. Mousser's personal and professional background that could contribute to mental health conditions?
- MR. MANDELL: Objection.
- 23 BY THE WITNESS:
 - A. I believe I've read a lot of records and

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

notes about Mr. Mousser and following the nephrectomy
for cancer and everything that followed, I, again, see
a lot of these patients and I can certainly understand
why he describes the way that he does.

5 BY MR. GARAND:

6

7

8

9

10

12

13

14

Q. Doctor, do you have any knowledge regarding Mr. Mousser's relationship with his parents?

MR. MANDELL: Objection.

BY THE WITNESS:

A. I don't know.

11 BY MR. GARAND:

- Q. Do you have any knowledge of any traumatic events that Mr. Mousser or his family members experienced when he was a kid?
- 15 MR. MANDELL: Objection.
- 16 BY THE WITNESS:
- 17 A. No, I don't.
- 18 BY MR. GARAND:
- 19 Q. Do you have any knowledge regarding
- 20 whether Mr. Mousser was abused as a child?
- 21 MR. MANDELL: Objection.
- 22 BY THE WITNESS:
- 23 A. I don't.
- 24 BY MR. GARAND:

| 1 | Q. Do you have any knowledge regarding his |
|----|---|
| 2 | marital history? |
| 3 | MR. MANDELL: Objection. |
| 4 | BY THE WITNESS: |
| 5 | A. I don't. |
| 6 | BY MR. GARAND: |
| 7 | Q. Do you have any knowledge regarding his |
| 8 | relationship with his own children? |
| 9 | MR. MANDELL: Objection. |
| LO | BY THE WITNESS: |
| L1 | A. I don't. |
| L2 | BY MR. GARAND: |
| L3 | Q. Do you have any knowledge regarding |
| L4 | Mr. Mousser's work dynamic before he stopped working? |
| L5 | MR. MANDELL: Objection. |
| L6 | BY THE WITNESS: |
| L7 | A. Could you just could you be more his |
| L8 | work dynamic? |
| L9 | BY MR. GARAND: |
| 20 | Q. Sure. He do you know who he last |
| 21 | worked for before he retired in October of 2023? |
| 22 | A. I know he worked at a car agency. |
| 23 | Q. Okay. Do you understand or do you have |
| 24 | any knowledge about the professional dynamic at this |

| 1 | car | auto | dealership? |
|---|-----|------|-------------|
|---|-----|------|-------------|

- No, not specifically, no. Α.
- Do you have any knowledge regarding O.
- Mr. Mousser's use of opioids? 4
- MR. MANDELL: Objection. 5
- 6 BY THE WITNESS:

2

3

- Α. I don't, no.
- BY MR. GARAND: 8
- 9 Do you have any knowledge regarding 10 Mr. Mousser's severe obstructive sleep apnea, which we've discussed a little bit today? 11
- 12 MR. MANDELL: Objection.
- 13 BY THE WITNESS:
- 14 Just that he had the diagnosis.
- 15 BY MR. GARAND:
- 16 Did you know that he had the diagnosis O. 17 before this deposition today?
- 18 Α. Yes.
 - Ο. Doctor, can you also explain how you're able to determine that Mr. Mousser will require lifetime psychological counseling and -- and support?
 - That's, again, in his notes from his Α. psychologist. He's on disability and his psychologist says that that's what he's -- going to be necessary.

19

20

21

22

23

- Q. And by "his psychologist," do you mean Dr. Mueller?
 - A. Those are the -- I believe that's the name.
 - Q. Have you -- did you look at Dr. Roger Moore's expert opinion in this case?
 - A. Again, I don't remember specifically his name.
 - Q. Do you recall reviewing an expert psychologist report on behalf of Mr. Mousser?
 - A. I don't remember that specifically, no.
 - Q. Okay. Doctor, let's look at Jacqueline
 Tukes' report, which is Exhibit 8. I'm happy to say
 we're done with Mr. Mousser, or at least for a few
 minutes.
 - MR. MANDELL: Well, that was quick.
- 17 MR. GARAND: Yeah, you know.
- 18 BY MR. GARAND:

3

4

5

6

7

8

9

10

11

12

13

14

15

16

21

22

- Q. Okay. Doctor, Ms. Tukes received a deceased donor kidney transplant, correct?
 - A. Yes, sir, she did.
 - Q. And the transplant occurred on April 23rd of 2024, is that right?
- A. I believe that's the right date, April 24,

Page 182 1 yes. 2 And she was 59 years old at the time? 0. 3 Α. She was. Okay. Let's look at Page 3 of your Tukes 4 Q. 5 The first paragraph under heading V? report. Yes. 6 Α. 7 The first line all of the way to the 8 right, you write, "The half-life (mean survival) for 9 DD transplants is 13 years." 10 Did I read that correctly? 11 Α. That's correct. So you'd agree by definition if 13 years 12 Q. 13 is the median graft survival, that's just an average, 14 not a maximum, correct? 15 Correct, but it's the mean, not median. 16 Q. Okay. Okay. Thank you, Doctor. 17 So it's true that some deceased donor 18 kidney transplants last well beyond 13 years, is that 19 right? 2.0 Α. They do. 21 So it's a possibility that Ms. Tukes' Q.

I believe it's unlikely based upon the

transplant can last longer than 13 years, is that

22

23

24

Α.

right?

deceased donor that -- that she received and, again, the facts of -- or the number that we're talking about here is based upon the quality of all grafts. believe based upon the information that we know about her graft that it's more likely than not that she'll have 13 or less years for her kidney transplant.

- Delayed graft function is the need for hemodialysis in the first week after transplant surgery, right?
 - That's the standard definition, yes, sir. Α.
- Delayed graft function is a major risk factor for early transplant graft loss, is that right?
- Α. It -- not necessarily. It is a -- a potential complication that occurs after transplant that if folks develop delayed graft function that can then go on to become primary non-function, yes.
- Ms. Tukes did not experience delayed graft Q. function, correct?
 - Α. Not according to the records, no.
- And at worst, it's at least not a bad It doesn't thing that that happened, correct? negatively impact her prognosis, right?
 - Α. That's correct.
 - Are you aware that as of January 2025 O.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

| ${\tt Ms.}$ | Tukes | had | not | shown | any | signs | of | rejection | of | the |
|-------------|-------|-----|-----|-------|-----|-------|----|-----------|----|-----|
| transplant? | | | | | | | | | | |

- A. I'm aware that she didn't show any signs of acute rejection based upon the fact that she hasn't had a biopsy.
- Q. Are there any -- and I appreciate the distinction between acute and chronic. Thanks for that clarification, Doctor.

Are there any signs that you're aware of of acute rejection?

- A. Not that I saw in the medical record.
- Q. Are you aware that as of January 2025, Ms. Tukes had not shown any signs of cancer recurrence?
 - A. Yes, sir, I do not.
- Q. As of January 2025, none of Ms. Tukes' healthcare providers had expressed concerns about her kidney function since the transplant, is that right?
 - A. That's correct.
- Q. As of January 2025, Ms. Tukes had not had any issues with infections, is that right?
- A. She had CMV uremia, so she had some viral particles in her blood and urine that required a changing of her immunosuppression.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- Q. Okay. Were there any other infections other than that instance?
 - A. Not that I saw.
 - Q. Are you aware of any more recent records indicating signs of rejection, cancer recurrence, or infections?
 - A. Not that I am aware of, no.
 - Q. Would you agree that risk of acute rejection is highest in the first year?
 - A. Highest comparatively to years thereafter, yes.
 - Q. Would you agree that early transplant stability is generally associated with better long-term outcomes?
 - A. As one of the factors that can help determine long-term outcomes, yes, I do.
 - Q. Acute rejection negatively affects long-term survival of the graft, is that right?
 - A. Any acute rejection, yes.
 - Q. Are you aware of an instance of -- of acute rejection since Ms. Tukes' kidney transplant in April of 2004?
- A. No.
- Q. And we're over a year removed from that

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

transplant, correct?

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- A. That's correct.
- Q. After a kidney transplant, what would you consider a positive creatinine level?
- A. One more time? A positive creatinine, you mean --
- Q. Yeah, so in terms of, like, what -- that is demonstrating that the kidney func- -- you know, the graft and the kidney function is operating well.
- A. All based upon the kidney -- the quality of the kidney that the patient received. I'd certainly like to see creatinines, you know, somewhere below 1.5 milligrams per deciliter.
- Q. Okay. And so for the quality of kidney transplant that Ms. Tukes received, would that same creatinine level still hold true?
- A. It would. Again, as we've talked about before, we're utilizing a poor man's measure of kidney function in creatinines. We use those only as a marker for how well we need to -- or closely need to follow these patients and what to look out for.
- Q. And, Doctor, I know we've -- we've -- yeah, we've talked about the creatinine and the GFR.

 That is the standard -- or what nephrologists rely on

and look at to, again, determine endstage kid --1 chronic kidney disease, correct? 2

MR. MANDELL: Objection.

BY THE WITNESS:

3

4

5

6

9

10

11

14

15

16

17

18

19

20

2.1

22

Post-transplant, yes, but it's a little Α. different in a post-transplant patient. So very small changes in creatinine are something we respond to very aggressively.

BY MR. GARAND:

- Doctor, are you aware of Ms. Tukes' O. post-transplant creatinine levels?
- 12 I -- again, what I had in the records that Α. 13 I reviewed, yes.
 - Are you aware that her creatinine level was 14 -- was over 14 on the date of her transplant?
 - I don't remember that number specifically. Α. That's probably right.
 - Do you recall that it was high on the --Ο.
 - Α. It was high.
 - Are you aware that it was below 1 in March Ο. of 2025?
 - That sounds about right. Α.
- 2.3 Would you agree that creatinine in the Ο. low 1s is generally viewed as a favorable sign for a 24

transplant recipient at her stage?

- At this stage that she's in, yes, I believe that's a good creatinine.
- Would you agree that generally patients Ο. with kidney transplants live longer than patients on dialysis?
 - Α. The data supports that, yes.
- Ο. Would you agree that generally patients with kidney transplants have a better functional status compared to those patients on dialysis?
 - Α. On average, yes.
- You're aware that Ms. Tukes' Ο. post-transplant nephrologist Heather Jones stated that Ms. Tukes has a good prognosis in terms of her kidney function, correct?
- I don't remember that comment Δ specifically, but I'm -- I'm sure that that's what their team has said.
- Ο. Doctor, there's no standard age limit for kidney transplantation, correct?
- It depends on where you are. Different Α. programs do have absolute age limits for transplant.
- What would an absolute age limit for a Q. transplant look like?

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

2.3

- Α. Some are above 65, some are above 70.
 - Are you aware of an age limitation in North Carolina where Ms. Tukes resides?
 - I don't -- I'm not sure what their -- if Α. they have one.
 - Is it true that chronological age is less 0. important that physiologic age?
 - As one -- as one of the factors -- and I assume we're talking with candidacy for transplant?
 - O. Correct.
 - Sure. I mean, if we were to look at one versus the other, we'd try and take in more than just a number at our program.
 - Ms. Tukes does not have diabetes, correct?
 - She does. So she has what's often referred to as prediabetes or early diabetes and -and is currently on medication for it.
 - But not diabetes, not diabetes 1 or 2, Ο. correct?
 - Well, that would be diabetes. Α.
 - Q. Prediabetes?
 - Α. Yes.
- Okay. Does she have a known 23 Ο. 24 cardiovascular disease?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

- 1 Α. I don't know if she has a diagnosis of 2 cardiovascular disease, no. 3
 - Okay. Doctor, I think we've been going for about an hour. If we can take another quick break, and then I should be able to wrap up.
 - Α. Okay.
 - There are just a couple of other topics that I would like to discuss.
 - Α. Okay.
 - THE VIDEOGRAPHER: Going off the record at 12:20 p.m.
- 12 (WHEREUPON, a recess was had
- 13 from 12:20 to 12:27 p.m.)
- 14 THE VIDEOGRAPHER: We are back on the record at 15 12:27 p.m.
- 16 BY MR. GARAND:

4

5

6

7

8

9

10

11

17

18

19

2.0

21

2.2

23

- Ο. Doctor, in each of your reports, and we can look at -- which one do you have in front of you?
 - Α. I have Tukes still open.
- Okay. Let's look at Page 16 of Tukes, just for ease of reference.
- Okay. So Number 2, you write, "The treatment and care Ms. Tukes has received and is now receiving is reasonable and medically necessary."

And you write the same thing essentially for Mr. Mousser; is that right? And I can --

- A. I do, yes, sir.
- O. Yeah, it's Page 15 --
- A. Just make sure they're in the same order -- yeah.
- Q. What medical treatment are you referring to for Ms. Tukes when you make that statement?
- A. The entirety of her medical -- I mean, the entirety of her medical. So her -- the fact that -- and we've discussed some of this. Her treatment for her kidney cancers, the -- I guess the ongoing care of her while then on dialysis was appropriate, the transition to peritoneal dialysis I think is a better thing, the kidney transplant certainly is a better thing than dialysis and, you know, the care that she has received from her transplant team is, again, I think reasonable and medically necessary.
- Q. And, Doctor, when you make that statement for Mr. Mousser, what medical treatment are you referring to for him?
- A. Again, the diagnosis of his cancer, the treatment of his ongoing comorbidities, the post-nephrectomy management by his team at the VA.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Page 192 of 281

I -- you know, I would hesitate in only that discharging him from a nephrology clinic, I think is a mistake because, as we've talked about, I still think he has risks.

But, again, I think the fact that he's receiving care for his comorbidities that we know and have talked about, potentially reduced the impact of his injured kidney following a nephrectomy for cancer that's hyper-filtrating, I -- I think that's appropriate.

- Are you aware whether or not Mr. Mousser has seen a nephrologist since he was discharged by Dr. Bucci, I believe?
 - I -- no, I'm sorry, I don't know that.
- Doctor, why did you opine on Mr. Mousser's and Mrs. Tukes' past and future medical treatment? MR. MANDELL: Objection.

To the extent that it results from any conversations that we've had or anybody else from my office had with you, that I'm instructing you not to answer. But if you can otherwise answer independently, please do.

BY THE WITNESS:

Α. So, again, my role as an expert was to

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

look at the totality of the information that I had, which included the medical records and, as talked about, some of these depositions, and to determine whether or not where Ms. Tukes and Mr. Mousser currently were following their nephrectomy was, you know, appropriate. And as one has been transplanted, my area of expertise, and as one as approaching the need for transplant, was, again, what I believe my role was in reviewing these records.

BY MR. GARAND:

1

2

3

4

5

6

8

9

10

11

12

13

14

18

19

20

21

- Q. Is -- do you typically opine on the reasonable -- reasonableness and necessity of medical treatment?
- MR. MANDELL: Objection.
- 15 BY THE WITNESS:
- 16 A. I do, yes.
- 17 BY MR. GARAND:
 - Q. Okay. Also in each report, again,

 Mousser's report Page 15 and Tukes's on Page 16, you

 state that the harms and injuries and damages suffered

 by Mr. Mousser or Ms. Tukes that are described in this

 report are permanent. Is that right?
- A. Correct.
- Q. So in regards to Mr. Mousser, when you

| mention | n harr | ns, | injuri | es, | or | damag | ges | are | permanent, | |
|---------|--------|-----|---------|-----|-----|-------|-----|-----|------------|-----|
| what ha | arms, | inj | juries, | or | dan | nages | are | you | referring | to? |

- He'll never get that kidney back because Α. of his cancer.
- Q. Is that the only permanent harm, injury, or damage?
- And the fact that he has now only one Α. kidney and all of the things that we continue to talk about, the hyper-filtration of that kidney that has to work, and an individual who has multiple comorbidities that we know cause and worsen chronic kidney disease, to my opinion, stated earlier, it is expected that kidney is going to be long lost in three to five years.
- And Mr. Mousser's VA nephrologists have described his chronic kidney disease as stable CKD Stage G3a A1, correct?
- MR. MANDELL: Objection.
- BY THE WITNESS: 19

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

- That's -- that's their statement. Α.
- 2.1 BY MR. GARAND:
- 22 And his hypertension according to his Ο. VA -- his VA -- I guess, yeah, his VA team as well as 23 his cardiology team at South Texas -- South Texas 24

Cardiovascular Consultants have found that his hypertension is well controlled as well, correct? MR. MANDELL: Objection.

BY THE WITNESS:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- Α. Currently, yes, but at times borderline. BY MR. GARAND:
- And what are the permanent harms, injuries, or damages suffered by Ms. Tukes?
- So Ms. Tukes is now absent two kidneys, you know, secondary to the -- the cancer and the bilateral nephrectomies, completion nephrectomies that were necessary for the identification and treatment. She then has the risk associated with long-term immunosuppression that increases both infections and malignancies. And we know despite the fact that her lifespan is better than dialysis, it still is reduced because of the need to receive renal replacement therapy.
- Doctor, on Page 16 of both reports, you Ο. also found that the care costs Mr. Mousser or Ms. Tukes incurred for past treatment and care are fair, reasonable, and medically necessary, is that right?
 - Α. That's correct.

| Q. | • | What | for | Mr. | Mous | sser, | what | is | the | |
|--------|-----|------|--------|-----|------|-------|-------|------|------|-----|
| what's | the | past | treatm | ent | that | you': | re re | feri | ring | to? |

- Again, as we talked about before, his, you Α. know, identification of his cancer, the workup of that, the nephrectomy, the post-transplant care, you know, all of that that leads us up to today.
- And what's the past treatment that you're referring to for Ms. Tukes?
- And, again, the identification of the multiple renal cancers that led to her bilateral nephrectomies, the interventions and the postsurgical care that was necessary for that, her institution of dialysis, both in center and then home peritoneal dialysis, and the successful transplant in 2024 and the management of that allograft thereafter.
- What methodology did you use to determine Ο. that their medical bill -- bills were fair, reasonable, and medically necessary?

MR. MANDELL: Objection.

BY THE WITNESS:

I received a copy of their medical bills and just briefly reviewed all of those. And, again, based upon what we just talked about and, you know, again, a cursory comparison of those activities that I

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- believe were appropriate and what those billings were, 1
- I came to that conclusion. 2
- BY MR. GARAND: 3
- 4 In your practice as a transplant surgeon, 0.
- do you typically review medical bills? 5
- 6 MR. MANDELL: Objection.
- 7 BY THE WITNESS:
- 8 As a transplant surgeon. Can you ask that 9 one more time?
- BY MR. GARAND: 10
- 11 Ο. Sure. In your practice --
- 12 Yeah. Α.
- 13 -- as a transplant surgeon, are you 14 ordinarily responsible for evaluating and reviewing 15 medical bills?
- 16 MR. MANDELL: Objection.
- 17 BY THE WITNESS:
- 18 Not routinely, but if asked to. So I --
- I -- as the chief of this division, I'm routinely 19
- 20 asked to look at finances, and those include sometimes
- patients who are sort of dissatisfied with the cost of 21
- 22 their care.
- 23 BY MR. GARAND:
- 2.4 And how often do you review the -- you 0.

1 know, the bills for the patients that are dissatisfied with their care?

- A. Maybe one or two a year.
- Q. Does your hospital have a separate department that manages medical billing to patients?
 - A. We do.

3

4

5

6

8

9

10

11

12

13

14

15

16

17

- Q. Do you oversee that office at all?
- A. I do not.
- Q. In prior cases where you served as an expert witness, have you opined on whether a party's medical bills were reasonable and medical -- medically necessary?
 - A. I don't recall. I'm sorry, I don't.
- Q. So you don't know one way or the other whether you have?
 - A. I don't recall. I don't know.
- Q. It's not a part of your typical practice as an expert?
- 19 MR. MANDELL: Objection.
- 20 BY THE WITNESS:
- A. Different asks are -- you know, have
 different requests. So I -- I've been asked in the
 past, but I don't know the frequency.
- 24 BY MR. GARAND:

- Okay. If we look at your initial -- and O. we don't -- we don't have to, but your initial MCL for Mr. Mousser, which is Cooper Exhibit 1.
 - Α. MCL?
 - Q. Yes.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Α. Oh, gosh, I've got to find one.
 - Ο. I know, we're going -- going back there.

MR. MANDELL: I've got it right here for you.

THE WITNESS: God bless you. Thank you, thank you.

BY MR. GARAND:

- And if we look at Page 3. O.
- Α. Yes, sir.
- And we look at Number 10, it states that, "Frank W. Mousser's medical expenses," and then you -sorry. And so this is what you've reviewed and what you considered. And it says, "Frank W. Mousser's medical expenses, " and you list some Bates numbers there, right?
 - Α. Yes, sir.
- If we look at this, the first range, you have Bates ending in 07362 to 7336. That doesn't seem to make sense to me in terms of just -- is -- do you -- do you recall or know what those Bates should

| | Page 200 |
|------------|--|
| 1 | have been? |
| 2 | A. I don't, sir, I'm sorry. |
| 3 | Q. Okay. And I'll show |
| 4 | A. That's obviously a misprint. |
| 5 | Q you these records. Sure. |
| 6 | Do these two Bates ranges that you list |
| 7 | here include all of the invoices that you are aware of |
| 8 | for Mr. Mousser's past medical expenses? |
| 9 | A. I don't know that for sure. |
| L O | Q. Okay. As you're sitting here right now, |
| L1 | though, you are not aware of any or and I'm going |
| L2 | to show you these medical records, but you're not |
| L3 | aware of any other outstanding invoices that you're |
| L 4 | providing this opinion on? |
| L5 | A. Not that I'm aware of, no. |
| L6 | Q. Okay. Let's see. We'll mark this as |
| L7 | Cooper Exhibit 25. |
| L8 | (WHEREUPON, a certain document was |
| L9 | marked Dr. Cooper Deposition Exhibit |
| 20 | No. 25, for identification, as of |
| 21 | 07/10/2025.) |
| | |

BY THE WITNESS:

A. Thank you.

24 BY MR. GARAND:

Q. And, Doctor, I'll allow you to review that briefly and let me know if you've seen these records before.

And just for the record, this is that first subset of records that you listed, which is 00667_MOUSSER_07336 through 07362. I wasn't 100 percent sure what records, so I just included all of them.

- A. I don't remember these specifically, sir, but, again, I had all of the information that was in materials reviewed in my possession.
- Q. Okay. So let's start at the very beginning, and I apologize that some of these numbers are cut off, but we should be able to work through them here.

I'll ask that you flip through 07336 through 07356, so about those first 20 pages here, and then I'll ask you a few questions whenever you are ready.

- A. Okay.
- Q. Okay. So anything that you just saw from 7336 to 7356, are any of those invoices?
 - A. No.
 - Q. And these are treatment records from the

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

- 1 | Franklin Clinic, is that correct?
 - A. They are.

2

3

4

5

6

7

8

9

10

11

12

13

14

18

19

2.0

21

22

- Q. Are you aware of Mr. Mousser being treated for his kidney cancer at the Franklin Clinic?
 - A. I don't believe so, no.
- Q. And I'll note, if you look at the dates, they are from 2012 to 2015. Did Mr. Mousser have kidney cancer during those dates, during those years?
- A. I don't -- it certainly wasn't diagnosed at that time.
- Q. You're aware that he had gross hematuria in 2017, correct?
 - A. I do recall that, yes.
 - Q. And he had a workup at that time, right?
- 15 A. He did.
- Q. And there was no -- he did not have cancer at that time, correct?
 - A. There was no diagnosis made of cancer, no, not at that time.
 - Q. Okay. So if we look at 7357 through 7361. Take a minute to review those and let me know when you're ready.
 - A. Okay.
- Q. So these are invoices from May of 2021,

- 1 and if you just look through -- sorry, from May 17 --2 of 2017 through May of 2021, is that right? 3 see any dates outside of that?
 - Tell me those dates again, I'm sorry, what Α. you said.
 - May of '17 through May of 2021. O.
 - Yes, I see that.
 - Mr. Mousser wasn't diagnosed with kidney cancer until late August and September of 2020, is that right?
 - Α. Correct.
 - And he had no treatment for the kidney cancer until October 2020 when he had his nephroureterectomy, is that right?
 - Α. That's correct.
 - And that was done at VA, a VA facility? Q.
 - Α. It was, yes, sir.
 - And his postsurgery treatment for the medical conditions, you know, his kidney cancer, chronic kidney disease, that's all been done at VA as well, right?
 - It has, yes. Α.
- 23 Do you have any knowledge that he was 24 treated at the Franklin Clinic for his kidney cancer?

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

1 Α. No.

2

3

4

5

6

8

9

10

- So you would agree that these medical Q. records are unrelated to Mr. Mousser's UTUC treatment?
 - That's correct. Α.
 - They're also unrelated to his second Q. bladder cancer diagnosis in 2025, correct?
 - Α. That's correct.
 - Why did you include invoices from the Franklin Clinic in your Materials Considered List as evidence of Mr. Mousser's medical expenses?
 - Α. They were the wrong numbers.
- 12 Okay. So these -- these are all incorrect Ο. 13 then?
- 14 Objection. MR. MANDELL:
- 15 BY THE WITNESS:
- 16 Α. These -- these are the incorrect records.
- 17 BY MR. GARAND:
- 18 Ο. Okay.
- 19 MR. MANDELL: And just so it's clear for the 20 record, you're talking about Exhibit No. 25?
- THE WITNESS: Correct, Exhibit 25. 2.1
- Thank you, Mr. Mandell. 22 MR. GARAND:
- BY MR. GARAND: 23
- 24 I'm going to show you what I hope Ο. Okay.

| 1 | is | our | last | exhibit | here. |
|---|----|-----|------|---------|-------|
| | | | | | |

- Erick is cheering over there. Α.
- He -- he's excited. Ο.

And we are going to mark it as Cooper Exhibit 26.

(WHEREUPON, a certain document was marked Dr. Cooper Deposition Exhibit No. 26, for identification, as of 07/10/2025.)

10 BY THE WITNESS:

2

3

4

5

6

7

8

9

11

14

15

16

17

18

19

2.0

21

22

- Thank you. Α.
- BY MR. GARAND: 12
- 13 Ο. Thank you.

Doctor, I'll represent to you that this is the second set of Bates ranges that's listed in your initial Materials Considered List for Mr. Mousser and it's Bates-stamped 00667_MOUSSER_08702 through 8732.

- Α. Okay.
- And, again, Mr. Mousser was not diagnosed with kidney cancer until August or September of 2020, correct?
 - Yes, sir. Α.
- 23 And his nephroureterectomy was in October of 2020, right? 24

1 A. Yes, sir.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

- Q. Okay. And if you flip through these records, they're all from the -- from Peterson Health, is that right?
 - A. Yes, that appears correct.
- Q. And as we discussed, all of Mr. Mousser's care for his kidney cancer and related disabilities was done at VA, correct?
 - A. That's correct.
- Q. Okay. So let's look at Pages 8 -- Bates ending in 08702 through 14, 8 -- 087114. And specifically, Doctor, I'll ask you to look at the dates of those invoices, and so please take your time reviewing.
 - A. Okay.
- Q. These invoices are all from 2012 to 2019, correct?
 - A. That's correct.
- Q. And he was not diagnosed -- Mr. Mousser was not diagnosed with kidney cancer until 2020, right?
 - A. Yes, sir.
- Q. So can we agree that all of those records, meaning Bates ending in 08702 through 08714 predate

- 1 his kidney cancer diagnosis, right?
 - A. Yes, sir, that's correct.
 - Q. Can you tell me why you included these invoices, please?
 - A. I believe these are the wrong Bates numbers also.
 - Q. Okay. So let's look at Bates ending in 08715 -- well, actually, Doctor, so can you look through those records and tell me what the correct -- if any of them are the correct invoices that you meant to cite?
- 12 A. No, these I believe are the wrong Bates numbers.
- MR. MANDELL: Up to 14, you're talking about?
- 15 THE WITNESS: Yeah, I looked --
- MR. GARAND: Well, so I'm asking for the
- 17 entire --

2

3

4

5

6

8

9

10

- 18 THE WITNESS: I looked through the rest of them.
- 19 MR. MANDELL: Okay. Fine.
- 20 BY THE WITNESS:
- A. Yeah, I did. These are, I think, are the -- the wrong Bates numbers and the wrong records.
- 23 BY MR. GARAND:
- Q. Can you describe to me what the right

records were? Again, most of Mr. Mousser's treatment for his cancer, I think all of his treatment for his cancer and other disabilities or other conditions have been at VA at no cost to Mr. Mousser. So I'm curious what the records you meant to -- to cite were.

- A. So, yeah, it has been a while since I looked at those. So I had records that were shared with me that I'm -- I don't remember exactly where they were from, but, they, again -- they -- they were costs associated with care. I don't believe they were all from the VA. I think they were from other locations.
 - Q. Do you --
- A. But I'm sorry, I don't remember specifically what those were.
- Q. Okay. Doctor, you've testified at deposition or trial before, right?
 - A. I have, sir, yes.
- Q. Okay. Let's look at -- let's look at Cooper Exhibit 7, which is Mr. Mousser's report, and I'm looking at the very -- let's see -- last page.

THE VIDEOGRAPHER: Mr. Mandell, your microphone.

BY THE WITNESS:

A. Mr. Mousser's, sir, the last?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.4

BY MR. GARAND:

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

- Yes, the very last page which is a list of your testimony history, is that right?
 - Yes, sir. Α.
- Ο. Have you ever served as an expert in a case on behalf of the United States?
 - Α. I have not.
- 0. Have you ever served as an expert in a case against the United States?
 - No, sir. Α.
- Is this an accurate list of the cases in which you provided a deposition or trial testimony?
- Α. I'm looking at the wrong thing. Oh, at the end of my CV.
 - Sorry about that. Ο.
- Yes, I apologize. It is, yes. Α. Ι apologize.
- So is the first time you served -- was August 2018 the first time you served as an expert, or is that just the first listed?
- That -- it's the first listed. believe -- I believe I began expert review soon after the completion of my fellowship, so in the mid 2000s.
 - Ο. Doctor, I'll just ask generally, are

these -- are they predominantly one kind of case, like
medical malpractice or anything like that?

- A. Predominantly, yes.
- Q. Medical malpractice?
- A. Correct.

3

4

5

6

7

9

10

11

12

13

14

15

16

17

18

19

20

21

22

- Q. Can you identify which cases are not medical malpractice?
 - A. On -- on this list?
 - Q. Yes, to the extent you remember.
 - A. I believe these are all medical malpractice cases.
 - Q. Okay. Have you provided testimony either at deposition or at trial in a toxic or environmental tort case other than this one?
 - A. No, sir, I have not.
 - Q. In any of these cases did you provide an opinion as to someone's chronic kidney disease, prognosis or whether they'll require a transplant or dialysis?
 - A. Yes.
 - Q. Okay. Do you recall which ones those are?
 - A. I'm sorry, any of these cases?
- Q. Any of these cases.
- A. I'll have to look at these. But I've

Page 211 of 281

certainly reviewed cases that have asked that 1 question. I don't know whether they actually went to 2 3 deposition or to trial.

I'm sorry, sir, this is so long ago I don't remember these specifically as to whether or not that was the issue in question.

- Do you recall generally what your opinions were in those cases?
- I don't recall that either. It has been a long time.
- Ο. Doctor, have you ever been involved in litigation in your personal capacity?
 - Α. No.
- Doctor, if we could just take a Ο. Okay. two-minute break, I should be able to wrap up and then I'll hand it over to Mr. Mandell.
- Thank you. Α.
- MR. MANDELL: We're just going to stay.
- 19 MR. GARAND: We'll step out real quick. 20 just going to chat and then we'll be good.
- 2.1 THE VIDEOGRAPHER: Going off the record at 12:50 p.m. 22
- 23 (WHEREUPON, a recess was had 2.4 from 12:50 to 12:53 p.m.)

4

5

6

8

9

10

11

12

13

14

15

16

17

THE VIDEOGRAPHER: We are back on the record at 12:53 p.m.

MR. GARAND: All right. Doctor, I have no further questions. I appreciate your time this afternoon -- or this morning.

THE WITNESS: Thank you. Thank you very much.

MR. MANDELL: I just have one question -- actually maybe two.

EXAMINATION

BY MR. MANDELL:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

2.4

Q. Dr. Cooper, you were asked questions about creatinine levels after Mr. Mousser's nephrectomy in terms of whether they were normal and/or reassuring.

Do you have an opinion to a reasonable degree of medical certainty as to whether or not the creatinine levels that were identified for Mr. Mousser after his nephrectomy were normal and/or reassuring?

So the first question is, do you have an opinion to a reasonable degree of medical certainty about that subject, yes or no?

- A. I do.
- Q. All right. What is that opinion to a reasonable degree of medical certainty?
 - A. So, again, my opinion is, and the

definition of normal, if we want to use what's considered the standard reference values for normal creatinine, above 1.3 we can consider that to be abnormal. And the majority of Mr. Mousser's creatinines were almost all above that.

And I'm -- I guess I'm shocked when we talked about the -- the various individuals that provided care for Mr. Mousser after that, with all of the things that really everybody knows about the inaccuracies of creatinine plus all of the additional information that is readily available to utilize that abnormal number and get a true assessment of that remaining kidney, i.e., the -- the fact that that kidney is having to work much harder than a single kidney -- or sorry, than two kidneys would have to, the fact that we have a pathology report that shows that there's some underlying damage based upon his comorbidities, I mean, all of that information to me is demonstrable of an abnormal kidney.

I take care of a lot of people who have a kidney removed. We asked earlier about can people live a normal life with a single kidney. We're -we're blessed that we have living donors that want to come forward and they want to donate a kidney, and we

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

Page 214 of 281

do all of those tests. We measure their GFR, we check for protein in the urine, and we clear them to donate an organ.

And then they donate a kidney and their kidney, yes, it does hyper-filtrate for a short period of time and corrects and they go back to have a normal creatinines. They have creatinines of .9, 1.0. have no evidence of albuminuria. But we have -- if there's ever any question, we even biopsy people that want to donate a kidney because that's the -- the -the gold standard of what the kidney looks like regardless of a normal creatinine.

And I've also been blessed, you know, we have a number of people who are deceased donors, and the majority of them have normal creatinines, but when you go in and remove their kidney and look at it under the microscope, because we often take a biopsy, you see that they have significant injury and we can't use those kidneys.

So even in the face of a normal creatinine, we're saying those kidneys are not better than people being on dialysis.

- Q. Okay.
- Because we know that they aren't going to Α.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

| | Page 215 |
|----|--|
| 1 | do well. |
| 2 | MR. MANDELL: I have no further questions. |
| 3 | Thank you. |
| 4 | MR. GARAND: Yeah, no further questions. |
| 5 | MR. MANDELL: Great. |
| 6 | THE VIDEOGRAPHER: Going off the record at |
| 7 | 12:56 p.m. That concludes today's testimony of |
| 8 | Dr. Cooper. |
| 9 | |
| 10 | Thereupon, at 12:56 p.m., on Thursday, |
| 11 | July 10, 2025, the deposition was concluded. |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| | |

Page 216

REPORTER'S CERTIFICATE

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

1

I, JULIANA F. ZAJICEK, a Registered Professional Reporter and Certified Shorthand Reporter, do hereby certify that prior to the commencement of the examination of the witness herein, the witness was duly sworn by me to testify to the truth, the whole truth and nothing but the truth.

I DO FURTHER CERTIFY that the foregoing is a verbatim transcript of the testimony as taken stenographically by me at the time, place and on the date hereinbefore set forth, to the best of my availability.

I DO FURTHER CERTIFY that I am neither a relative nor employee nor attorney nor counsel of any of the parties to this action, and that I am neither a relative nor employee of such attorney or counsel, and that I am not interested directly or indirectly in the outcome of this action.

IN WITNESS WHEREOF, I do hereunto set my hand on this 22nd day of July, 2025.

2.3

pelune 7. Zgicil

2.4

JULIANA F. ZAJICEK, Certified Reporter

| | Page 217 |
|----|--|
| 1 | DEPOSITION ERRATA SHEET |
| 2 | |
| 3 | Assignment No. 7450002 |
| 4 | Case Caption: In Re: Camp Lejeune Water Litigation |
| 5 | |
| 6 | DECLARATION UNDER PENALTY OF PERJURY |
| 7 | |
| 8 | I declare under penalty of perjury that I |
| 9 | have read the entire transcript of my Deposition taken |
| 10 | in the captioned matter or the same has been read to |
| 11 | me, and the same is true and accurate, save and except |
| 12 | for changes and/or corrections, if any, as indicated |
| 13 | by me on the DEPOSITION ERRATA SHEET hereof, with the |
| 14 | understanding that I offer these changes as if still |
| 15 | under oath. |
| 16 | |
| 17 | MATTHEW COOPER, MD |
| 18 | |
| 19 | |
| 20 | SUBSCRIBED AND SWORN TO |
| 21 | before me this day |
| 22 | of , A.D. 20 |
| 23 | |
| 24 | Notary Public |
| | |

| | | Page 218 |
|----|--------------------------|----------|
| 1 | DEPOSITION ERRATA SHEET | |
| 2 | Page NoLine NoChange to: | |
| 3 | | |
| 4 | Reason for change: | |
| 5 | Page NoLine NoChange to: | |
| 6 | | |
| 7 | Reason for change: | |
| 8 | Page NoLine NoChange to: | |
| 9 | | |
| 10 | Reason for change: | |
| 11 | Page NoLine NoChange to: | |
| 12 | | |
| 13 | Reason for change: | |
| 14 | Page NoLine NoChange to: | |
| 15 | | |
| 16 | Reason for change: | |
| 17 | Page NoLine NoChange to: | |
| 18 | | |
| 19 | Reason for change: | |
| 20 | Page NoLine NoChange to: | |
| 21 | | |
| 22 | Reason for change: | |
| 23 | SIGNATURE:DATE: | |
| 24 | MATTHEW COOPER, MD | |
| | | |

| | | Page 219 |
|----|--------------------------|----------|
| 1 | DEPOSITION ERRATA SHEET | |
| 2 | Page NoLine NoChange to: | |
| 3 | | |
| 4 | Reason for change: | |
| 5 | Page NoLine NoChange to: | |
| 6 | | |
| 7 | Reason for change: | |
| 8 | Page NoLine NoChange to: | |
| 9 | | |
| 10 | Reason for change: | |
| 11 | Page NoLine NoChange to: | |
| 12 | | |
| 13 | Reason for change: | |
| 14 | Page NoLine NoChange to: | |
| 15 | | |
| 16 | Reason for change: | |
| 17 | Page NoLine NoChange to: | |
| 18 | | |
| 19 | Reason for change: | |
| 20 | Page NoLine NoChange to: | |
| 21 | | |
| 22 | Reason for change: | |
| 23 | SIGNATURE:DATE: | |
| 24 | MATTHEW COOPER, MD | |

[& - 079] Page 1

| & | 00667 4:3,6 | 044 163:3 | 05710 100:22 |
|---------------------------|----------------------|---------------------|-----------------------|
| & 2:3,16 36:13 | 5:10,11 94:19 | 05146 108:7 | 05711 101:14 |
| 36:20,23 | 113:23 122:16 | 054 161:1 | 05713 101:17 |
| | 123:18 124:19 | 055 161:16 | 05762 99:24 |
| 0 | 135:7 138:18 | 05598 94:19 | 05763 100:13 |
| 0 153:22 | 153:23 158:7 | 95:4 121:11 | 05766 100:17 |
| 0.07 134:5,12 | 161:1 201:6 | 05599 121:16 | 05778 95:15 |
| 0.12 150:16 | 205:17 | 05602 121:19 | 05781 96:3 |
| 0000000044 5:7 | 00897 1:4 | 05618 120:16 | 05812 94:19 |
| 0000000054 5:4 | 01 122:18 | 05619 121:1 | 0667 4:8,10,11 |
| 000000078 | 0102 139:2 | 05621 121:5 | 4:13,14,16,17 |
| 4:23 | 0103 138:18 | 05623 120:2 | 4:21,23 5:4,7 |
| 000000097 | 0111 135:7,20 | 05624 120:10 | 132:3 |
| 4:17 | 136:19 | 05625 120:14 | 07/10/2025 |
| 000000111 | 0112 135:7 | 05645 117:4 | 15:22 16:13,20 |
| 4:16 | 01499 122:16 | 05646 117:9 | 17:3 22:6 |
| 000000327 | 01501 122:17 | 05648 117:13 | 34:23 37:14,22 |
| 4:14 | 01504 122:16 | 05657 116:17 | 94:11 107:6 |
| 0000000375 4:6 | 01567 124:19 | 05659 117:1 | 113:2 118:3 |
| 0000001499 | 01568 124:19 | 05665 104:1 | 122:7 123:7 |
| 4:10 | 125:8 | 05668 104:9 | 124:11 131:20 |
| 0000001567 | 01624 123:18 | 05671 102:22 | 134:20 138:7 |
| 4:13 | 01625 139:22 | 102:23 | 144:21 153:10 |
| 0000001624 | 01626 123:18 | 05672 103:8 | 157:17 160:17 |
| 4:11 | 01631 153:23 | 05675 103:11 | 162:13 169:20 |
| 0000001631 | 01637 153:24 | 05682 102:11 | 200:21 205:9 |
| 4:21 | 01638 153:23 | 102:12 | 07336 201:6,16 |
| 0000005164 4:8 | 02903 2:4 | 05684 102:19 | 07356 201:17 |
| 0000005598 4:3 | 0327 132:3 | 057 100:1 | 07362 199:22 |
| 0000007336 | 0332 132:15 | 161:1 | 201:6 |
| 5:10 | 0333 132:3,5 | 05704 101:21 | 078 158:7 |
| 0000008702 | 133:20 | 05705 102:3 | 159:5 |
| 5:11 | 0375 113:23 | 05707 102:6 | 079 159:16 |
| | | | |
| | | | |

Golkow Technologies, A Veritext Division

Filed 08/26/25

Document 507-9

www.veritext.com

[**080 - 14**] Page 2

| 080 158:7 | 136:1 139:8 | 10/24/2024 | 12/15/2023 |
|------------------------------|------------------------|------------------------|-----------------------|
| 08702 205:17 | 140:2 145:17 | 162:21 | 4:17 |
| 206:11,24 | 147:6 151:13 | 100 38:15 43:1 | 12/15/2024 |
| 087114 206:11 | 1.4. 105:9 | 110:17 201:7 | 3:20 |
| 08714 206:24 | 1.5 54:12 80:24 | 101 4:18 145:2 | 122 4:9 |
| 08715 207:8 | 81:23 82:14 | 145:7 | 123 4:11 |
| 097 138:18 | 91:16,22 102:4 | 102 114:9 | 124 4:12 151:6 |
| 1 | 102:16 108:13 | 103 4:17,18 | 151:7,8 |
| _ | 115:23 118:21 | 145:22 | 12:20 190:11 |
| 1 3:10 4:18 | 119:11,15 | 107 4:4 | 190:13 |
| 15:18,21 17:22 | 126:7,12 127:1 | 10:02 67:1,3 | 12:27 190:13 |
| 19:15,17 20:11 21:2 28:11 | 127:17 128:14 | 10th 6:4 | 190:15 |
| 34:13 40:1 | 132:22 136:1 | 11 4:6 112:22 | 12:50 211:22 |
| 55:4 109:18 | 186:13 | 113:1,20 126:7 | 211:24 |
| 110:18 135:19 | 1.5. 122:23 | 146:3 | 12:53 211:24 |
| 139:4,7 141:10 | 1.6 54:12 80:24 | 11-1/2 27:23 | 212:2 |
| 159:5 163:2 | 81:23 82:15 | 11/12/2024 | 12:56 215:7,10 |
| 187:20 189:18 | 91:16,23 | 4:11 | 12th 123:16 |
| 199:3 | 115:23 118:21 | 11/8/2024 4:20 | 13 4:9 71:24 |
| 1.0. 100:14 | 119:11,15 | 112 4:16 | 72:13 74:8,11 |
| 214:7 | 126:12 127:2 | 113 4:6 150:8 | 122:3,6 182:9 |
| 1.2 96:1,10 | 127:18 128:15 | 150:11 | 182:12,18,22 |
| 97:17,23 | 132:21,22 | 114 148:11,18 | 183:6 |
| 101:14 103:15 | 1.7 121:2 126:6 | 118 4:7,18 | 130/80 162:1 |
| 1.25 118:15 | 1.9 103:9,16 | 11:04 130:7,9 | 163:6 |
| 1.3 125:4 213:3 | 104:23 105:8 | 11:16 130:9,11 | 131 4:14 |
| 1.3. 117:10 | 108:8,13 110:1 | 11th 32:7 135:5 | 134 4:15 |
| 1.4 104:7,24 | 10 1:10 4:4 | 138:19 | 138 4:17 |
| 109:20 110:2,7 | 71:7,14 74:1,6 | 12 4:7 107:1 | 14 4:11 72:13 |
| 111:14 114:8 | 74:8 107:2,5 | 117:23,23 | 72:17 123:3,6 |
| 116:23 120:11 | 140:16 146:17 | 118:2 122:22 | 139:18 150:11 |
| 121:16 124:3 | 199:14 215:11 | 146:3 151:10 | 187:15,15 |
| 126:8 132:22 | 10/24/2021 5:6 | 12/11/2023 | 206:11 207:14 |
| | | 4:15 | |

[144 - 205] Page 3

| 144 4:18 15 3:10 4:12 25:9 32:7,14 56:8,15 72:17 74:11 108:2 116:20 124:7 124:10 145:8 191:4 193:19 15,000 20:5,19 1504 4:10 153 4:20 1568 4:13 157 4:22 15th 22:24 23:10 34:3 123:21 138:16 16 3:13,17 4:14 75:3 76:19 131:16,19 160:23 190:20 193:19 195:19 160 5:3 162 5:5 1626 4:11 1638 4:21 169 5:7 17 3:18 4:15 103:3 121:12 134:16,19 147:4 203:1,6 17th 120:7,22 18 4:17 138:3,6 | 18th 112:21 113:22 19 4:18 102:13 117:6 132:2 144:20 147:5 151:10 1s 187:24 2 2 3:13,17,19 16:7,12 28:14 28:20 29:5 31:24 32:2 43:20,20 46:12 51:3,3 55:10 78:21 97:9,15 98:23 99:6,11 101:6 109:23 125:12 139:10 139:21 141:1 159:15 189:18 190:22 2/2/2025 3:22 3:24 20 4:8,20 24:5 24:7 25:1,1 34:5 43:2 90:23 101:10 110:2 115:18 118:6,6 146:19 147:11,11 153:6,9 201:17 | 200 5:9 2000s 209:23 2004 185:22 20044 2:9 2012 156:9 202:7 206:16 2015 202:7 2016 156:14,17 158:4,14,17 161:12 2017 202:12 203:2 2018 209:19 2019 206:16 202-616-8461 2:10 2020 83:24 92:16 94:16 95:18 100:10 101:7,10 103:14 135:24 141:13 203:9 203:13 205:20 205:24 206:20 2011 101:24 160:23 202:24 203:2,6 2022 102:13 103:1,15 104:4 104:13,13,23 104:23 108:9 109:12,20 | 116:20 117:6 118:19 119:5 119:18 125:23 126:15 132:2 133:10 136:8 141:11,12 148:1 2023 4:8 94:16 118:7,20 119:7 119:18 120:7 120:18,23 121:12 125:22 135:5 136:9 138:17,19 179:21 2024 13:11 14:6 22:24 23:10 29:4 32:7,14 122:15 122:23 123:17 123:21,22 130:19 140:11 146:22 153:21 181:23 196:14 2025 1:10 3:17 3:19 6:4 32:7 37:9,18 125:2 125:16,20,23 183:24 184:12 184:16,20 187:21 204:6 215:11 216:22 |
|---|--|--|---|
| 147:4 203:1,6 | 147:11,11 | 104:13,13,23 | 184:16,20 |

Golkow Technologies,

www.veritext.com

877-370-3377

[21 - 62] Page 4

| 21 4:22 157:13 | 57:8,9 80:18 | 4 | 165:24 172:5 |
|------------------------|------------------------|------------------------|------------------------|
| 157:16 | 80:19,19 82:17 | 4 3:18 16:21 | 173:20 176:4 |
| 21,200 27:7 | 108:6 109:16 | 17:2,22 19:15 | 5/6/2024 4:9 |
| 212 3:5 | 148:18 154:2 | 19:17 20:11 | 50,000 27:24 |
| 22 3:20 5:3 | 155:12,13 | 21:2 29:5,5 | 28:5 |
| 160:10,16 | 159:19,23 | 32:4 46:2 56:8 | 50s 98:22 99:5 |
| 22nd 101:7 | 161:20 171:6 | 57:3 96:12,19 | 99:5 |
| 216:22 | 182:4 199:12 | 97:6 145:7 | 5165 4:8 |
| 23 5:5 147:10 | 3.0 33:13 | 164:6 171:14 | 53005 7:10 |
| 147:12,13 | 3/16/2021 5:4 | 4.5 27:11,13,18 | 56 100:1 |
| 153:4 162:5,6 | 3/20/2023 | 27:23 | 5665 104:2 |
| 162:12 | 118:12 | 4/18/2022 4:6 | 57 5:4 150:13 |
| 23rd 181:22 | 3/22/2016 4:12 | 4/6/2016 4:23 | 5710 100:23 |
| 24 5:7 109:17 | 30 55:22 59:21 | 401-273-8330 | 5762 100:2,3 |
| 114:8 157:11 | 60:3 141:12 | 2:4 | 5781 96:4 |
| 169:16,19 | 300 60:3,6 | 41 140:18,23 | 58 104:10,14 |
| 181:24 | 31563 216:23 | 43 141:9 | 105:10 117:2 |
| 24/7 62:17 | 31st 95:18 | 44 55:22 | 120:14 121:20 |
| 91:11 | 333 4:14 | 45 55:16 | 5812 4:3 |
| 25 5:9 85:22 | 34 3:21 | 46 121:5 | 59 55:16 182:2 |
| 160:7 200:17 | 340 2:9 | 47 5:7 | 6 |
| 200:20 204:20 | 35,000 18:21 | 48.1 102:20 | 6 3:4,21 34:19 |
| 204:21 | 20:18,18 | 48.2 102:7 | 34:22 69:16,20 |
| 26 5:11 205:5,8 | 36 103:16 | 4v 79:1 | 73:15 97:5 |
| 27 120:18 | 104:14 | 5 | 139:1 141:1 |
| 28 101:24 | 36.6 103:12 | _ | 161:17 |
| 109:12 | 105:9 | 5 3:20 22:1,5 | 60 55:10 96:22 |
| 287 81:1 | 365 62:17 | 26:23 29:3 | 97:7 135:21 |
| 29 56:8 | 91:11 | 32:4,10,13 | 60s 81:13 |
| 2nd 37:9,18 | 37 3:22,23 | 33:12 42:18 | 61 150:12 |
| 3 | 3a 46:12 51:3,4 | 56:14,20,24 | 62 96:9 97:5,17 |
| 3 3:17 16:14,19 | 55:16 | 57:4 72:24 | 97:24 98:11 |
| 29:5 46:1,9 | 3b 46:9 55:22 | 73:4 145:23 | 103:15 |
| 40.1,7 | 56:4 58:15 | 147:18 150:15 | 103.13 |
| | | | 1 |

Golkow Technologies, A Veritext Division

Document 507-9

| | I | I | I _ |
|--|------------------------|---------------------------------|----------------------|
| 62.4 96:6 98:7 | 77 100:18 | 92 109:16 | abnormal |
| 101:18 | 7:23 1:4 | 147:2 | 57:23 98:8,20 |
| 62.4. 96:20 | 7th 100:10 | 94 4:3 | 98:22 99:4,13 |
| 63 117:14 | 104:3 | 9:53 66:23 67:1 | 213:4,12,19 |
| 125:9,11 | 8 | 9th 103:1 | abnormalities |
| 65 165:3,4,13 | 8 3:23 37:17,21 | a | 57:13 |
| 189:1 | 72:24 141:10 | a.d. 217:22 | above 1:16 |
| 66 118:17 | 145:23 181:13 | a.m. 1:16 6:5 | 80:22 98:9 |
| 6th 122:15 | 206:10,11 | 66:23 67:1,3 | 109:24 152:22 |
| 125:2 158:4,14 | 8/29/2024 3:21 | 130:7,9,11 | 189:1,1 213:3 |
| 7 | 8/7/2024 4:5 | a1 60:1 132:16 | 213:5 |
| 7 3:22 27:23 | 80 4:23 34:6 | 134:6 135:24 | absent 195:9 |
| 37:10,13 38:13 | 800 34:6 35:7 | 137:1,17 139:5 | absolute 64:16 |
| 68:20 69:22,23 | 35:10 | 194:17 | 188:22,23 |
| 71:7 73:15 | 87 108:1 | a2 60:4 | abused 178:20 |
| 74:1 75:13 | 8732 5:12 | a3 60:7 | acceptable |
| 78:20 164:6 | 205:17 | ab 99:2 | 148:14 |
| 208:20 | 87:15 108:4 | ability 48:2 | accepted |
| 7.0 140:7 | 88:17 108:3 | 52:23 62:14 | 150:20 |
| 7/19/2022 4:14 | 89 55:11 | 92:9 142:4 | access 43:11 |
| 7/24/24 4:19 | 8900 1:14 6:7 | 146:2 164:11 | 106:11 |
| 70 146:18 | 7:9 | 164:14 165:13 | account 112:6 |
| 189:1 | 8:50 6:5 | 173:9 174:10 | accurate 9:20 |
| 7336 199:22 | 8th 123:21 | 174:22 175:13 | 17:23 35:4 |
| 201:22 | 153:21 | able 9:17 44:15 | 38:18 52:15,16 |
| 7356 201:22 | | 46:2 49:21 | 52:20 53:3 |
| 7350 201:22 7357 202:20 | 9 | 50:13,14 51:20 | 63:15,24 69:2 |
| 7361 202:20 | 9 4:3 94:3,3,10 | 53:16 59:12 | 69:6,10 72:4 |
| 7366 5:10 | 94:14 110:18 | | 99:18 114:24 |
| 7450002 1:24 | 214:7 | 63:15 65:13,14 | 120:14 125:9 |
| | 90 55:5 96:22 | 77:6 107:19,22 141:15 165:21 | 126:13 209:11 |
| 217:3 | 97:7 98:9 | | 217:11 |
| 750 35:9 | 91 109:10,11 | 180:20 190:5 | accurately 53:7 |
| | | 201:14 211:15 | 53:12,14 87:15 |
| | Golkow Te | | I . |

| 1067 | 11 1 75 15 | 100.2.67 | 1.00 17 |
|----------------------|------------------------|-----------------------|---------------------|
| 106:7 | added 75:15 | 189:2,6,7 | 168:17 |
| accurative | adding 75:16 | agency 179:22 | albu 60:12 |
| 63:24 | addition 20:15 | agents 144:9 | albumin 55:2 |
| ace 108:18 | 33:19 83:10 | ages 99:16 | 58:8 59:16,19 |
| 134:7 143:20 | 85:21 87:10 | aggressively | 59:22 60:3,7 |
| 154:8,15 | 129:20 155:14 | 187:8 | 60:13,15,18 |
| 159:10 | 155:18 | ago 23:4 78:10 | 61:4 134:10 |
| acei 134:6 | additional 23:9 | 83:14 110:20 | 141:11 148:2,3 |
| achieving | 24:5,7,8,9,16 | 137:2 211:4 | 150:13 151:13 |
| 151:21 | 25:1,8,9,21 | agree 33:2 | albuminuria |
| acr 59:18 60:3 | 26:14 58:16 | 49:16,18 53:2 | 60:12,22 61:2 |
| 60:6 64:18 | 61:16 75:14 | 57:10 58:2,6 | 61:4 137:6 |
| act 78:1,8,13 | 76:14 77:5,5 | 61:7 63:23 | 141:4 147:23 |
| action 49:4,7 | 77:12,14 | 151:21 154:7 | 214:8 |
| 216:17,20 | 112:13 140:5 | 154:22 171:19 | allen 73:16,17 |
| activities 25:4 | 142:3 213:10 | 182:12 185:8 | allograft |
| 146:2 196:24 | additions 39:4 | 185:12 187:23 | 196:15 |
| actual 53:19 | address 7:8 | 188:4,8 204:2 | allow 8:19 |
| actually 19:14 | admit 28:4 | 206:23 | 50:12 201:1 |
| 20:23 52:16 | admitted 165:2 | agreed 148:13 | allows 85:19 |
| 53:17 92:10 | adult 40:17 | agreement | 129:22 |
| 129:5 147:21 | advance 1:14 | 13:19 | america 26:24 |
| 148:6 157:23 | adverse 62:21 | ahead 18:24 | amount 20:16 |
| 207:8 211:2 | advice 9:18 | 21:15 30:23 | 28:8 55:2 |
| 212:8 | advil 149:8 | 31:13 33:6 | analyses 71:10 |
| actually's | affect 63:18 | 44:18 45:21 | 76:8 77:8 |
| 141:16 | 109:2 110:22 | 50:22 51:5 | analysis 88:21 |
| acute 149:13 | affects 185:17 | 65:2 81:20 | 151:2 |
| 184:4,7,10 | afternoon | 85:15 87:16 | andrew 4:19 |
| 185:8,17,19,21 | 212:5 | 95:1 98:4,24 | 28:22 114:1 |
| adams 138:23 | age 85:17 88:10 | 115:2 116:2 | 144:15 |
| add 8:24 75:24 | 99:11 164:22 | 126:17 128:19 | angiotensin |
| 83:12 | 165:3 188:19 | 131:15 134:1 | 108:19 |
| | 188:22,23 | 143:8 152:5,18 | |

[annual - august] Page 7

| annual 34:11 | appeared 172:1 | 112:21 113:22 | 139:3,10 |
|---------------------|-----------------|------------------------|---------------------|
| answer 8:13,18 | appears 206:5 | 115:18 118:19 | 145:17 154:3 |
| 8:19,24 9:10 | appointment | 119:5,18 | 213:12 |
| 9:15,16 10:11 | 172:22 173:3 | 125:22,23 | assessments |
| 10:12 14:23 | 173:12 | 126:15 158:4 | 159:16 161:16 |
| 20:10 21:13,14 | appointments | 158:14,17 | assignment |
| 70:3 77:2,7 | 175:9 | 181:22,24 | 14:19 217:3 |
| 91:1 98:12,21 | appreciate 73:1 | 185:22 | associated 30:9 |
| 108:11,15 | 89:3 143:1 | arb 154:8 | 31:15 142:17 |
| 110:7,11,14 | 184:6 212:4 | arbs 143:21 | 171:10 185:13 |
| 145:12 167:20 | appreciated | area 37:3 155:1 | 195:13 208:10 |
| 167:21 168:1 | 166:12 | 193:7 | associates |
| 192:21,21 | approaching | areas 68:4,6 | 11:22 |
| answered | 193:7 | armine 5:8 | assume 8:14 |
| 85:14 128:18 | appropriate | 169:7,9 | 34:4 64:5 86:1 |
| 143:7 152:20 | 15:1,2 65:12 | artery 83:20 | 133:15 189:9 |
| answers 149:3 | 65:13 116:14 | articles 24:12 | assuming 27:16 |
| anxiety 79:3 | 191:13 192:10 | asked 9:9 15:8 | 30:19 32:18 |
| 176:7,23 177:6 | 193:6 197:1 | 65:14 85:14 | 66:1,5,11 77:7 |
| anybody 14:22 | approved 41:6 | 101:2 128:18 | 97:16,20,23 |
| 53:6 105:6,7 | approximate | 143:7 144:13 | 157:19 |
| 167:19 192:19 | 25:2 26:10 | 197:18,20 | assure 167:5 |
| apnea 80:3 | 27:24 | 198:22 211:1 | attempting |
| 174:10 180:10 | approximately | 212:11 213:21 | 59:7 |
| apologies 44:22 | | asking 8:8,17 | attorney 2:8 |
| apologize 54:19 | 25:1 27:19 | 11:18 26:4 | 10:10 12:14 |
| 97:10,13,15 | 34:4 35:24 | 32:3 59:5 71:1 | 47:1 216:16,18 |
| 101:2 126:24 | 36:3 43:1 | 71:2 172:20 | attorneys 6:24 |
| 136:20 172:14 | approximatio | 173:1 175:12 | 11:17 |
| 201:13 209:16 | 26:5 | 207:16 | attributed |
| 209:17 | april 32:7 | asks 198:21 | 43:18 136:1 |
| appear 60:19 | 101:24 104:3 | assesses 132:16 | 137:5 |
| 110:23 | 104:13,23 | assessment | august 35:12 |
| | 109:5,12,20 | 53:3 114:15 | 95:18 203:9 |

Golkow Technologies, A Veritext Division

Page 227 of 281

| 205:20 209:19 | 188:12 189:2 | 93:5 98:15 | 124:19 125:8 |
|------------------------|-----------------------|--------------------|---------------------|
| author 114:1 | 192:11 200:7 | 103:18,20 | 132:3,5,15 |
| 135:11 | 200:11,13,15 | 104:15,17,22 | 133:20 135:6 |
| auto 180:1 | 202:3,11 | 111:11 125:21 | 135:20 138:17 |
| autotransplant | awesome | 126:19 127:15 | 139:2,22 |
| 46:19 | 121:10 | 139:16 141:15 | 153:22,24 |
| availability | b | 145:16 151:1 | 158:6 159:5,15 |
| 216:14 | b 3:8 4:1 5:1 | 171:1 173:14 | 161:1,16 163:3 |
| available 18:7 | back 32:13 | 174:3,5,5 | 199:18,22,24 |
| 46:5 54:16,20 | 67:2 79:2 92:3 | 176:5 177:15 | 200:6 205:15 |
| 213:11 | 95:15 97:12 | 182:24 183:3,4 | 205:17 206:10 |
| avenue 1:15 6:7 | 104:24 105:9 | 184:4 186:10 | 206:24 207:5,7 |
| 7:9 | 104.24 103.7 | 196:23 213:17 | 207:12,22 |
| average 44:9 | 113:4,6,9,18 | baseline 110:2 | bathroom |
| 182:13 188:11 | 116:9 117:17 | 139:8 140:2 | 174:18 |
| avoiding 149:6 | 119:23 130:10 | bases 54:10 | bear 15:15 |
| aware 13:1 | 139:17 146:14 | 81:16 84:13 | 100:7 |
| 17:13,14 31:1 | 147:13 155:8 | 131:4 175:2 | bearing 73:1 |
| 64:10,15,22 | 155:10 164:2 | basis 89:16 | becoming |
| 65:4 70:1 | 171:13 190:14 | 90:9 166:22 | 64:23 150:21 |
| 92:20 106:13 | 194:3 199:7 | bates 94:18 | began 165:12 |
| 119:13,17 | 212:1 214:6 | 95:4,5,14 96:3 | 209:22 |
| 125:18 143:15 | background | 99:23 100:12 | beginning |
| 150:2 152:10 | 39:7 177:20 | 100:17,21 | 97:21 201:13 |
| 152:15 154:12 | bad 183:20 | 101:13,16,20 | begins 166:4 |
| 155:3 156:8,13 | ballpark 24:24 | 102:3,3,10,19 | behalf 2:2,7 |
| 156:15,16 | 42:23 | 103:7,11,24 | 169:23 181:10 |
| 158:16,18 | barring 149:11 | 104:9 108:7 | 209:6 |
| 167:7 168:11 | based 35:7 44:7 | 113:22 116:17 | believe 11:10 |
| 174:9,13,16,21 | 50:15 54:16,24 | 117:1,4,13 | 11:14 14:11 |
| 175:15 183:24 | 58:13 64:17 | 120:1,10,13,16 | 17:4 18:3 |
| 184:3,9,12 | 76:3 78:15,17 | 121:1,4,11,16 | 20:11 22:1,18 |
| 185:4,7,20 | 81:7 89:14 | 121:19 122:16 | 28:10 31:19 |
| 187:10,14,20 | 01.7 07.14 | 122:17 123:18 | 39:1 54:10 |
| | Collran To | | 1 |

[believe - cabraser] Page 9

| 57.15 15 50.10 | hotton 54.2.4 | 204:6 | how 2.0 |
|-------------------------------|-----------------------------|-----------------------|---------------------------------|
| 57:15,15 58:18 61:10 63:18 | better 54:2,4 | | box 2:9 |
| | 152:7,13,23 185:13 188:9 | bless 140:24 | boy 13:9 18:15 19:2 25:5 |
| 64:2 65:11 | | 199:9 | |
| 66:15 76:12 | 191:14,15 | blessed 213:23 | bp 110:3 |
| 78:9 79:16 | 195:16 214:21 | 214:13 | brain 166:13 |
| 82:10 87:6 | beyond 182:18 | blockade | 172:1 |
| 89:11,21 | big 11:4 164:8 | 159:10 | break 9:4,5,7 |
| 101:11 106:3 | bigger 93:15 | blood 52:7 | 9:10 66:16 |
| 111:12 112:2 | bilateral 83:18 | 108:17,24 | 190:5 211:15 |
| 130:18,24 | 195:11 196:10 | 109:1 111:7 | briefly 37:24 |
| 146:12 152:20 | bill 22:13 23:20 | 127:10 149:6 | 38:16 196:22 |
| 152:21 163:12 | 196:17 | 151:22 152:13 | 201:2 |
| 164:6 177:24 | billed 34:6 | 152:22 156:3,6 | bring 68:1 87:1 |
| 181:3,24 | billing 23:13,16 | 160:1 163:5 | brought 76:14 |
| 182:24 183:4 | 198:5 | 184:23 | bucci 135:12,16 |
| 188:3 192:13 | billings 197:1 | board 40:9,10 | 135:21 136:17 |
| 193:8 197:1 | bills 196:17,21 | 40:11 | 136:24 137:12 |
| 202:5 207:5,12 | 197:5,15 198:1 | body 49:4 | 137:17 192:13 |
| 208:10 209:22 | 198:11 | boisclair 2:3,16 | building 1:14 |
| 209:22 210:10 | binder 94:1,4,5 | bolded 27:1 | bullet 139:7 |
| believed 10:18 | 94:6,18 106:17 | bones 166:13 | bumps 43:13 |
| 21:3 | 106:18,21 | 172:1 | bunch 72:9 |
| believes 175:5 | 112:5 116:9 | borderline | 116:7 155:9 |
| bell 36:7 | 119:23 121:9 | 160:2 195:5 | business 7:8 |
| beneath 114:16 | 121:23 | bottom 95:24 | bypass 156:14 |
| 137:4 | biologically | 96:5 100:9 | 161:13 |
| benefit 46:18 | 49:14 | 101:6,24 | c |
| benefits 68:3 | biopsy 112:13 | 102:20,24 | |
| bernstein 36:14 | 184:5 214:9,17 | 109:11,18 | c 2:1 |
| best 8:19 18:4 | bit 35:7 37:1 | 117:7 120:6,13 | cabg 79:1 |
| 23:15 170:18 | 63:5 97:12 | 120:19 122:21 | 135:22 161:9 |
| 216:13 | 100:5 180:11 | 132:20 155:15 | 161:12 |
| beta 159:10 | bladder 80:6 | 172:5 173:20 | cabraser 36:13 |
| | 170:18 171:7 | | |
| | Collraw To | | |

[cad - causes] Page 10

| | T | I | |
|-----------------------|------------------------|-----------------|------------------------|
| cad 79:1 | 191:22 192:8 | 189:24 190:2 | 36:22 38:1 |
| 135:22 | 194:4 195:10 | 195:1 | 75:9 76:24 |
| calculates | 196:4 202:4,8 | care 1:14 41:10 | 78:14 79:17 |
| 114:9 | 202:16,18 | 41:12 43:6 | 80:4,7,10 |
| calculating | 203:9,13,19,24 | 48:1 63:17 | 106:12 115:7 |
| 143:12 | 204:6 205:20 | 64:23 68:1,3 | 126:11 170:18 |
| calculus 91:13 | 206:7,20 207:1 | 68:10,14,15 | 181:6 209:6,9 |
| call 43:13 | 208:2,3 | 70:15 81:2 | 210:1,14 217:4 |
| 46:18 175:10 | cancerous | 85:22 87:7 | cases 1:6 27:21 |
| called 6:18 | 166:24 | 90:13 150:21 | 28:9 34:15 |
| 53:17 59:18 | cancers 69:4,13 | 190:23 191:12 | 35:24 43:15 |
| calls 172:7,21 | 191:12 196:10 | 191:16 192:6 | 198:9 209:11 |
| 175:20 | candidacy 41:5 | 195:20,21 | 210:6,11,16,22 |
| camp 1:4 6:8 | 44:10 167:5 | 196:5,12 | 210:23 211:1,8 |
| 12:18 13:1 | 189:9 | 197:22 198:2 | category 50:2 |
| 14:16 15:7 | capacity | 206:7 208:10 | catheters 43:11 |
| 69:8 71:9 74:1 | 211:12 | 213:8,20 | 43:12 |
| 77:24 78:8,12 | caption 217:4 | caring 174:7 | causal 69:12 |
| 217:4 | captioned | carolina 1:1 | causation 3:22 |
| cancer 3:11,15 | 217:10 | 189:3 | 3:23 5:7 37:8 |
| 30:8 31:23 | car 179:22 | carpenito 2:12 | 37:17 169:23 |
| 69:23 70:7,17 | 180:1 | carson 2:10 | 170:7 171:21 |
| 71:3,4,16 72:3 | carcinoma | 6:22 82:13 | causative 167:3 |
| 73:5 74:7,14 | 135:23 168:13 | carson.m.gar | cause 63:2 69:3 |
| 79:21 86:13,18 | cardiac 62:21 | 2:11 | 70:17 71:15 |
| 95:21 112:10 | 156:10 | case 1:4 10:2 | 72:3 74:7,13 |
| 156:7,22 157:1 | cardiology | 10:19 11:6,10 | 83:8 109:7 |
| 159:1 166:10 | 159:6 161:4,6 | 15:6 18:22 | 110:10,12 |
| 166:20 167:1,8 | 194:24 | 20:6 21:8 | 156:21 157:4 |
| 167:10 168:5 | cardiovascular | 22:15 23:2,24 | 177:13 194:11 |
| 168:22 169:1,2 | 4:22 5:3,6 | 24:1,3,4 27:5 | caused 108:13 |
| 170:4 171:7,24 | 154:18 157:21 | 27:24 30:12 | 111:6 |
| | I . | | |
| 175:8 178:2 | 158:5 160:11 | 34:1,9,14 36:6 | causes 65:16 |

[causes - ckd] Page 11

| 174:17 | 212:19,23 | 165:20 187:7 | 156:21 157:3 |
|------------------|-------------------------|----------------------|------------------------|
| caveat 9:9 | certificate | 217:12,14 | 168:5 184:7 |
| cc 114:9 | 216:1 | changing | 187:2 194:11 |
| cell 73:5 135:23 | certified 1:17 | 112:14 134:5 | 194:16 203:20 |
| 167:1 | 1:18 40:9,10 | 184:24 | 210:17 |
| censure 49:4 | 40:11 216:4,24 | characterize | chronicity |
| center 1:14 | certify 216:5,10 | 59:12 | 127:24 |
| 196:13 | 216:15 | characterized | chronological |
| certain 9:14 | cgc 32:9 | 55:9,21 | 189:6 |
| 15:19 16:10,17 | challenges | chart 35:7,15 | circling 155:10 |
| 16:24 22:3 | 156:2,5 | 59:13 | circumstances |
| 34:20 37:11,19 | chance 152:7 | chat 211:20 | 59:6 |
| 68:4,5 91:10 | 170:12 | chatted 83:14 | cite 207:11 |
| 94:8 107:3 | change 8:24 | check 214:1 | 208:5 |
| 112:23 117:24 | 35:9 52:24 | cheering 205:2 | cited 24:12 |
| 122:4 123:4 | 63:16 105:24 | chem 124:20 | civil 2:8 |
| 124:8 129:11 | 112:8 131:1 | chief 40:13 | ckd 46:1,1,9,11 |
| 131:17 134:17 | 145:10,13 | 197:19 | 50:20 51:3,3 |
| 138:4 144:18 | 160:3 168:2 | child 178:20 | 51:23 54:24,24 |
| 153:7 157:14 | 218:2,4,5,7,8 | children 179:8 | 55:4,10,16,22 |
| 160:14 162:10 | 218:10,11,13 | children's | 56:4,8,14 57:3 |
| 169:17 200:18 | 218:14,16,17 | 40:16 | 57:3,8 58:4,7 |
| 205:6 | 218:19,20,22 | chose 10:13 | 58:11,24 59:2 |
| certainly 8:10 | 219:2,4,5,7,8 | chronic 41:24 | 59:7 61:7,9 |
| 11:4,7 18:11 | 219:10,11,13 | 45:9,12,14,16 | 62:19,20,24 |
| 46:1 68:7 70:1 | 219:14,16,17 | 50:1,5 61:19 | 63:2,6 64:16 |
| 75:11,19 88:8 | 219:19,20,22 | 64:6 70:23 | 65:16 96:8,15 |
| 90:22 93:16 | changed | 79:2 89:4 | 96:19 97:5,9 |
| 155:2 177:16 | 125:15,19 | 90:15,20 92:6 | 98:22 99:5 |
| 178:3 186:12 | changes 52:22 | 98:14 99:10 | 125:12,15,19 |
| 191:15 202:9 | 53:10 58:16 | 105:7,16 | 132:16 135:24 |
| 211:1 | 105:24 108:17 | 107:19,23 | 136:5,18,24 |
| certainty 77:22 | 109:4 112:4 | 139:5 145:10 | 137:5,6,17 |
| 81:11 212:15 | 127:9 129:5 | 148:15 149:1 | 146:8 154:4,11 |

[ckd - confidence] Page 12

| 155:15,18 | 1 7 7 1 7 1 0 | TT 1 F0 15 | 00. | 1 |
|--|-----------------------|-----------------------|----------------|-----------------------|
| clarification 118:11 61:15,17,21 compliment 19:9 184:8 collection 45:1 63:18 83:13,19 67:24 clasify 67:15 column 163:11 85:10,21 86:16 component class 144:8 combination 87:9,23 88:6 86:7 classified 60:1 83:22 88:12 112:14 con 143:6 60:4 come 42:2 51:4 129:1 142:23 concern 110:13 clear 19:24 75:13 106:19 191:23 192:6 175:7 concern 110:13 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 105:23 175:6 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 105:23 175:6 concerns 98:12 53:19 129:7 167:19 comparatively 173:22 184:17 conclude 171:2 clinic 137:14 43:15 64:2 151:24 156:6 conclude 215:11 171:2 commencem 196:24 215:7 216:6 compensate | 155:15,18 | collect 50:16 | comor 88:5 | complications |
| 19:9 184:8 collection 45:1 63:18 83:13,19 67:24 clarify 67:15 column 163:11 85:10,21 86:16 component class 144:8 combination 87:9,23 88:6 86:7 classified 60:1 83:22 88:12 112:14 con 143:6 60:4 come 42:2 51:4 129:1 142:23 concern 110:13 clear 19:24 75:13 106:19 191:23 192:6 175:7 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 214:2 213:24 comorbidity concerns 98:12 clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 cleared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable 188:10 215:11 192:2 202:1,4 43:15 64:2 188:10 215:11 clinical 21:18 113:18 comparatively 215:7 clinicians 52:9 216:6 compensate 215:7 close 113:11 1:15 | | | | |
| clarify 67:15 column 163:11 85:10,21 86:16 component class 144:8 combination 87:9,23 88:6 86:7 classified 60:1 83:22 88:12 112:14 con 143:6 clear 19:24 come 42:2 51:4 129:1 142:23 concern 110:13 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 214:2 213:24 comorbidity 105:23 175:6 clearance comes 14:22 62:9 concerning 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 cleared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable compared conclude conclude 192:2 202:1,4 43:15 64:2 151:24 156:6 conclude 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 | | | | _ |
| class 144:8 combination 87:9,23 88:6 86:7 classified 60:1 83:22 88:12 112:14 con 143:6 60:4 come 42:2 51:4 129:1 142:23 concern 110:13 clear 19:24 75:13 106:19 191:23 192:6 175:7 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 214:2 213:24 comorbidity 105:23 175:6 clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 clinic 137:14 comfortable compared conclude 171:2 192:2 202:1,4 43:15 64:2 151:24 156:6 concluded 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparison concludes 171:2 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 140:21 150:9 188:16 complete 17:23 78:17 closely 186:20 188 | 19:9 184:8 | collection 45:1 | 63:18 83:13,19 | 67:24 |
| classified 60:1 83:22 88:12 112:14 con 143:6 clear 19:24 75:13 106:19 191:23 192:6 175:7 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 214:2 213:24 comorbidity 105:23 175:6 clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 clainic 137:14 comfortable compared conclude conclude 192:2 202:1,4 43:15 64:2 151:24 156:6 concluded 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 comment 34:1 conclusion 140:21 150:9 comment 34:1 conclusions closely 186:20 tas:16 complete 17:23 78:17 close | clarify 67:15 | column 163:11 | 85:10,21 86:16 | component |
| 60:4 come 42:2 51:4 129:1 142:23 concern 110:13 clear 19:24 75:13 106:19 191:23 192:6 175:7 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 214:2 213:24 comorbidity concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 clainic 137:14 comfortable compared conclude 171:2 clinical 21:18 113:18 comparison concludes 171:2 216:6 compensate concludes 59:15 commencem 127:8 127:12,16 close 113:11 1:15 compensate 127:12,16 closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | class 144:8 | combination | 87:9,23 88:6 | 86:7 |
| clear 19:24 75:13 106:19 191:23 192:6 175:7 173:8 204:19 213:24 194:10 213:18 concerning 214:2 213:24 comorbidity 105:23 175:6 clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 concert 83:6 clinic 137:14 comfortable compared conclude conclude 171:2 clinical 21:18 113:18 comparison concludes 215:11 clinicians 52:9 216:6 compensate concludes 171:2 216:6 compensate conclusion 59:15 216:6 compensation 127:12,16 close 113:11 1:15 compensation 129:22 197:2 closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 collaborate c | classified 60:1 | 83:22 | 88:12 112:14 | con 143:6 |
| 173:8 204:19 113:6,9 117:17 194:10 213:18 concerning 214:2 213:24 comorbidity 105:23 175:6 clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 cleared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable compared conclude 171:2 192:2 202:1,4 43:15 64:2 151:24 156:6 conclude 21:11 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 closely 186:20 t188:16 complete 17:23 conclusions closer 120:3 comments 18:4 33:12 condition 62:7 collaborate common 65:16 84:18 112:18 conditions | 60:4 | come 42:2 51:4 | 129:1 142:23 | concern 110:13 |
| 214:2 213:24 comorbidity 105:23 175:6 clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 clared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable compared conclude 171:2 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 closely 186:20 188:16 complete 17:23 closer 120:3 comments 18:4 33:12 condition collaborate common 65:16 84:18 112:18 conditions | clear 19:24 | 75:13 106:19 | 191:23 192:6 | 175:7 |
| clearance comes 14:22 62:9 concerns 98:12 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 cleared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable compared conclude 171:2 192:2 202:1,4 43:15 64:2 151:24 156:6 concluded 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 | 173:8 204:19 | 113:6,9 117:17 | 194:10 213:18 | concerning |
| 53:19 129:7 75:18 77:15 comparatively 173:22 184:17 cleared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable compared conclude 171:2 192:2 202:1,4 43:15 64:2 151:24 156:6 concluded 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparatively conclude 171:2 clinical 21:18 113:18 comparatively conclude 171:2 clinical 21:18 113:18 comparatively conclude 171:2 clinical 21:18 113:18 comparatively conclude 215:11 171:2 commencem 196:24 215:71 clinicians 52:9 216:6 compensate conclusion 127:8 127:12,16 129:22 197:2 close 113:11 1:15 complete 17:23 78:17 closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 conditions collaborate common 65:16 84: | 214:2 | 213:24 | comorbidity | 105:23 175:6 |
| cleared 53:17 167:19 54:6 185:10 concert 83:6 clinic 137:14 comfortable compared conclude 171:2 192:2 202:1,4 43:15 64:2 151:24 156:6 concluded 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 conditions | clearance | comes 14:22 | 62:9 | concerns 98:12 |
| clinic 137:14 comfortable compared conclude 171:2 192:2 202:1,4 43:15 64:2 151:24 156:6 215:11 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 closely 186:20 34:1 conclusions closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 conditions collaborate common 65:16 84:18 112:18 conditions | 53:19 129:7 | 75:18 77:15 | comparatively | 173:22 184:17 |
| 192:2 202:1,4 43:15 64:2 151:24 156:6 concluded 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | cleared 53:17 | 167:19 | 54:6 185:10 | concert 83:6 |
| 203:24 204:9 coming 113:4 188:10 215:11 clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | clinic 137:14 | comfortable | compared | conclude 171:2 |
| clinical 21:18 113:18 comparison concludes 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | 192:2 202:1,4 | 43:15 64:2 | 151:24 156:6 | concluded |
| 171:2 commencem 196:24 215:7 clinicians 52:9 216:6 compensate conclusion 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | 203:24 204:9 | coming 113:4 | 188:10 | 215:11 |
| clinicians 52:9 216:6 compensate conclusion 59:15 127:12,16 127:12,16 close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | clinical 21:18 | 113:18 | comparison | concludes |
| 59:15 commencing 127:8 127:12,16 close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | 171:2 | commencem | 196:24 | 215:7 |
| close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | clinicians 52:9 | 216:6 | compensate | conclusion |
| close 113:11 1:15 compensation 129:22 197:2 140:21 150:9 comment 34:1 conclusions closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | 59:15 | commencing | 127:8 | 127:12,16 |
| closely 186:20 188:16 complete 17:23 78:17 closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | close 113:11 | 1:15 | compensation | 129:22 197:2 |
| closer 120:3 comments 18:4 33:12 condition 62:7 cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | 140:21 150:9 | comment | 34:1 | conclusions |
| cmv 184:22 112:3 38:19 39:6 70:15 74:17 collaborate common 65:16 84:18 112:18 conditions | closely 186:20 | 188:16 | complete 17:23 | 78:17 |
| collaborate common 65:16 84:18 112:18 conditions | closer 120:3 | comments | 18:4 33:12 | condition 62:7 |
| | cmv 184:22 | 112:3 | 38:19 39:6 | 70:15 74:17 |
| 68:14 65:18 90:18 177:18 59:10 79:15 | collaborate | common 65:16 | 84:18 112:18 | conditions |
| | 68:14 | 65:18 90:18 | 177:18 | 59:10 79:15 |
| collaborative 167:1 completion 176:20 177:21 | collaborative | 167:1 | completion | 176:20 177:21 |
| 48:4 commonly 195:11 209:23 203:19 208:3 | 48:4 | commonly | 195:11 209:23 | 203:19 208:3 |
| collaboratively 163:23 complex 44:8 conference | collaboratively | 163:23 | complex 44:8 | conference |
| 47:24 communicati complication 12:12 | 47:24 | communicati | complication | 12:12 |
| colleague 6:23 12:13,17,21 183:14 confidence | colleague 6:23 | 12:13,17,21 | 183:14 | confidence |
| 112:15 | | | | 112:15 |

| 60 (0.17 | 4 4 1757 | 4 •1 4 | 46 4 167 10 |
|----------------------|----------------|-----------------------|----------------------|
| confirm 62:17 | constant 175:7 | contribute | 46:4 167:19 |
| 79:13 | consult 135:9 | 112:4 177:20 | 192:19 |
| confirmed | consultants | contributes | converting |
| 109:5 | 4:22 5:3,6 | 127:16 173:23 | 108:19 |
| conjunction | 157:21 158:6 | control 142:14 | cooper 1:9,13 |
| 93:7 | 160:11,24 | 142:20 149:6 | 3:3,9 4:2 5:2 |
| connecting | 162:8 195:1 | 151:22 | 6:9,17,22 7:6 |
| 165:17 169:12 | consulted | controlled | 15:13,18,20 |
| connection | 11:20 | 61:21 62:1,3,7 | 16:7,11,14,15 |
| 14:15 | contact 13:14 | 62:8,15,17 | 16:18,21,22 |
| consider | contacted 13:3 | 91:5,5,10 | 17:1,22 22:1,4 |
| 130:21 186:4 | 13:5,8 | 110:3 139:11 | 23:1 26:23 |
| 213:3 | contain 39:9 | 139:15 152:2 | 28:11,17 31:24 |
| consideration | 75:8 76:7,23 | 152:11,16 | 32:13 33:11 |
| 130:22 | 79:8 | 153:1 154:4 | 34:18,21 37:6 |
| considered | contained 17:7 | 159:10 160:2 | 37:10,12,16,20 |
| 3:11,15,17,19 | 21:2 76:8 | 161:24 163:6 | 38:12 68:20 |
| 15:14,16 16:8 | 88:16 | 195:2 | 69:21 72:24 |
| 16:16,23 17:6 | contains 38:2 | controlling | 74:24 78:20 |
| 17:13,24 18:21 | 75:11 76:12 | 90:19 142:16 | 94:3,9,13,14 |
| 20:4 28:12,13 | 77:3 | 151:24 | 107:2,4 112:22 |
| 28:17 32:1 | content 73:21 | convenient | 112:24 113:20 |
| 84:12,22 | 74:3 | 52:11,14 | 117:23 118:1 |
| 127:23 152:23 | contents 33:20 | 117:19 | 122:2,5 123:3 |
| 199:17 204:9 | continue 134:6 | conversation | 123:5 124:7,9 |
| 205:16 213:2 | 161:24 194:8 | 10:10,22 13:15 | 131:16,18 |
| considering | continues | 14:7,8 62:13 | 134:16,18 |
| 41:16 | 150:17 | 75:14,21 76:2 | 138:3,5 144:19 |
| consistent | continuum | 76:15 77:4 | 146:17 153:6,8 |
| 51:19 110:8 | 170:19 | 90:18 92:8 | 157:13,15 |
| 111:15 128:17 | contradict | 106:2 | 160:9,15 162:5 |
| 147:7 | 133:17 143:3 | conversations | 162:11 164:5 |
| consistently | 143:10 | 10:3 11:19 | 169:16,18 |
| 126:12 | | 21:12 33:15 | 199:3 200:17 |

| 200:19 205:4,7 | 77:10,20 82:3 | 159:20,21 | 141:7 145:20 |
|-------------------|-----------------|-----------------|------------------------|
| 208:20 212:11 | 82:5,8 84:5,6,8 | 161:10,13 | 148:9 149:16 |
| 215:8 217:17 | 95:9,12,23 | 162:2 163:13 | 150:23 166:14 |
| 218:24 219:24 | 96:7 99:19 | 164:17,20 | 170:22 182:10 |
| cooper's 3:12 | 102:21 103:10 | 165:5,14 | corrects 214:6 |
| 3:15 69:21 | 103:13,20 | 166:15,17,20 | cost 197:21 |
| 70:14 | 104:17,20 | 168:9,22 169:2 | 208:4 |
| coordinate | 107:10,16 | 171:11,12,17 | costs 195:20 |
| 68:1 | 109:22 111:8 | 171:18,22,23 | 208:10 |
| copy 17:23 | 111:16 114:4 | 172:2,3,9,10 | counsel 6:10 |
| 196:21 | 114:13,14,20 | 173:6,17,24 | 17:19,20 |
| corner 95:8 | 115:23 116:20 | 174:1 175:2,24 | 216:16,18 |
| 118:9 | 116:24 117:3 | 176:9,10,12,17 | counseling |
| corners 75:12 | 117:15 118:17 | 177:12 181:20 | 65:13 91:14 |
| coronary 83:20 | 118:24 120:11 | 182:11,14,15 | 176:8 180:21 |
| correct 8:22 | 120:12 121:2 | 183:18,21,23 | couple 12:2,2,5 |
| 12:9 13:6,18 | 121:18 122:19 | 184:19 186:1,2 | 12:7 14:10 |
| 13:23 14:8 | 125:2,5,6,10 | 187:2 188:15 | 39:2,2 58:19 |
| 23:8 27:6,8,22 | 131:9 132:24 | 188:20 189:10 | 63:9,10,22 |
| 28:19 29:9 | 133:11,13 | 189:14,19 | 105:10 106:6 |
| 30:8 32:17,20 | 134:14 136:11 | 193:23 194:17 | 190:7 |
| 34:7 35:20 | 136:15 137:14 | 195:2,24 202:1 | course 9:16,17 |
| 41:14 48:10 | 138:24 139:6 | 202:12,17 | 19:3 36:2 |
| 52:5 55:3,6,8 | 140:13,14 | 203:11,15 | 74:18 76:5 |
| 55:12,14,15,18 | 141:17,18 | 204:4,6,7,21 | 89:12 116:6 |
| 55:20,24 56:10 | 144:12 146:9 | 205:21 206:5,8 | 133:14 153:13 |
| 56:12,16,18 | 148:15 149:21 | 206:9,17,18 | 173:7 |
| 57:5 60:2,14 | 149:22,24 | 207:2,9,10 | court 1:1 6:12 |
| 60:17 61:6 | 151:2,19 152:3 | 210:5 | 7:22 8:1 16:1,3 |
| 65:18 66:9,14 | 154:13,16 | corrections | 49:7 |
| 67:17 68:24 | 155:6,7 156:9 | 217:12 | crc1 114:8 |
| 69:1,5,9,14 | 156:11 157:1,5 | correctly 109:8 | creatine 60:4 |
| 71:18,21 72:7 | 157:6 158:14 | 110:15 111:3 | creating 18:18 |
| 73:13,18 76:21 | 158:21 159:1 | 135:14 136:6 | |

[creatinine - dc] Page 15

| creatinine 52:21,22 53:3 53:8,10 54:11 57:11,14,18,22 58:3,8,13,16 59:16,19,22 60:7 63:14,19 63:21 64:18 80:24 81:1,9 81:22 82:6,14 82:16 83:22 87:6 91:16,22 92:1,5,11 93:15,20 96:1 96:9,20,24 97:17,23 100:14 101:14 102:4,16 103:9 103:15,16 104:7,23 105:24 106:2 108:8,22 109:7 | 127:2,17 128:3 128:15,16 129:3,6,6,11 130:15,23 131:7,12 134:10,13 136:1 139:8 140:1 141:23 142:10 143:5 145:17 147:6 147:22 150:13 186:4,5,16,23 187:7,11,14,23 188:3 212:12 212:16 213:3 213:10 214:12 214:21 creatinines 186:12,19 213:5 214:7,7 214:15 critical 49:23 | currently 18:6 42:21 91:24 132:22 143:17 143:18,21 189:17 193:5 195:5 cursory 196:24 cut 93:12,12 201:14 cv 1:4 38:2,14 38:15,21,24 39:13,20 40:2 209:14 d d 3:1 daily 146:2 damage 33:12 105:17 112:12 148:3 194:6 213:17 damaged | 85:19 87:1 89:11,14 93:5 125:21 127:4 141:15 142:3 155:1 188:7 date 1:16 6:4 23:10 29:6 34:1 75:9 76:24 95:17 100:10 101:7 101:12,23 102:24 104:3 118:11 120:7 123:21,22 158:14 162:15 162:17,19,20 181:24 187:15 216:13 218:23 219:23 dated 3:20,21 4:6,9,11,12,14 4:15,17,20,22 |
|---|---|---|---|
| 93:15,20 96:1 96:9,20,24 97:17,23 100:14 101:14 102:4,16 103:9 103:15,16 104:7,23 105:24 106:2 | 188:3 212:12 212:16 213:3 213:10 214:12 214:21 creatinines 186:12,19 213:5 214:7,7 214:15 | d 3:1 daily 146:2 damage 33:12 105:17 112:12 148:3 194:6 213:17 | 123:21,22 158:14 162:15 162:17,19,20 181:24 187:15 216:13 218:23 219:23 dated 3:20,21 4:6,9,11,12,14 |

[dd - determine] Page 16

| dd 182:9 | declining 54:12 | depiction 35:4 | 217:1,9,13 |
|-------------------|-------------------------|---------------------|-----------------|
| deal 45:12 | 105:4 | deponent 6:9 | 218:1 219:1 |
| dealership | decreased | deposed 7:11 | depositions |
| 180:1 | 108:24 155:20 | 30:12,20 31:1 | 11:10 25:8,21 |
| decades 50:12 | decreases | 36:3 | 28:21 32:6,11 |
| 50:12,19,19 | 99:17,20 | deposition 1:9 | 32:15 193:3 |
| 51:18 | defendant 2:7 | 1:13 4:19 6:6 | depression |
| deceased | 35:22 | 8:1 9:13,24 | 79:3 |
| 181:20 182:17 | defense 36:4,5 | 10:7 11:12,14 | describe |
| 183:1 214:14 | defer 68:5,6,8,9 | 11:20,24 12:15 | 207:24 |
| december | define 62:2 | 12:19,23 15:20 | described |
| 22:24 23:10,21 | definition | 16:11,18 17:1 | 193:21 194:16 |
| 29:4 32:14 | 61:24 152:24 | 22:4 24:9 | describes 178:4 |
| 34:3 35:13 | 182:12 183:10 | 26:11,14,16,18 | designation |
| 135:5 136:8 | 213:1 | 29:6,10,15 | 3:10,13 |
| 138:16,19 | degree 77:22 | 31:5,16,20 | despite 164:16 |
| decide 10:6 | 81:11 212:15 | 32:22 33:2 | 173:10 195:15 |
| 21:8 79:14 | 212:19,23 | 34:21 35:16 | detail 54:9 |
| decided 18:14 | degrees 48:9,12 | 37:12,20 75:23 | details 76:14 |
| 167:16 | 48:15,18 | 94:9 107:4,10 | determination |
| deciliter 186:13 | delayed 183:7 | 111:20 112:24 | 33:9 44:13 |
| decision 41:4 | 183:11,15,17 | 118:1 122:5 | 59:4 91:6 |
| 45:2,24 88:18 | demonstrable | 123:5 124:9 | 92:24 127:24 |
| 91:6 93:3 | 154:11 213:19 | 131:18 134:18 | 128:9 |
| 128:8 | demonstrating | 138:5 140:16 | determinations |
| decisions 49:23 | 125:15 186:8 | 144:15,19,24 | 91:18 |
| 84:20 | demonstration | 153:8 157:15 | determine 44:2 |
| declaration | 127:7 142:21 | 160:15 162:11 | 44:5,10,15 |
| 217:6 | dep 4:4 | 169:18 173:14 | 59:2 81:16 |
| declare 217:8 | department 2:8 | 174:3,8 175:23 | 85:12 89:11 |
| decline 58:21 | 6:24 198:5 | 180:17 200:19 | 180:20 185:16 |
| 81:7 82:2,15 | depend 34:8 | 205:7 208:17 | 187:1 193:3 |
| 91:17 92:12 | depends 188:21 | 209:12 210:13 | 196:16 |
| 119:10,19 | | 211:3 215:11 | |

Golkow Technologies, A Veritext Division

Page 236 of 281

| determined | diagnosing | 187:6 188:21 | discovered |
|----------------|-----------------|---------------------|-----------------|
| 96:18 | 58:23 | 198:21,22 | 115:12 |
| determining | diagnosis 43:22 | differential | discuss 42:3 |
| 50:5 58:23 | 43:24 47:24 | 72:1,2 74:12 | 54:23 84:8 |
| 59:7 86:3 87:7 | 49:24 50:4 | 74:13 | 91:16 143:2 |
| 87:24 | 58:6 72:1,2 | difficult 164:16 | 164:1 190:8 |
| develop 45:14 | 74:12,13 79:8 | 173:10 | discussed 9:1 |
| 46:5 183:15 | 176:22 177:1,9 | difficulty | 10:14 18:9 |
| developed 62:6 | 180:14,16 | 165:19 | 25:4 27:20 |
| 159:9 161:9 | 190:1 191:22 | diminished | 39:19 51:2 |
| developing | 202:18 204:6 | 108:24 | 54:19 71:18 |
| 89:4 98:14 | 207:1 | dip 115:22 | 87:11 92:12 |
| 99:12 | dialysis 43:11 | dipstick 133:6 | 107:8 115:22 |
| development | 43:12 46:6 | direct 31:21 | 125:11 134:9 |
| 69:13 171:7 | 56:22 57:7 | directly 38:14 | 137:16 147:5 |
| diabetes 65:17 | 65:21,24 66:7 | 40:20 125:1 | 166:16 180:11 |
| 80:9,12 83:20 | 97:19 150:15 | 216:19 | 191:11 206:6 |
| 90:14 163:23 | 164:15 165:18 | director 40:15 | discussing |
| 189:14,16,18 | 188:6,10 | disabilities | 68:21 73:23 |
| 189:18,20 | 191:13,14,16 | 206:7 208:3 | 109:12 115:16 |
| diagnose 58:11 | 195:16 196:13 | disability | 173:21 |
| 63:6 | 196:14 210:19 | 180:23 | discussion 38:9 |
| diagnosed | 214:22 | disagree | 151:1 |
| 95:21 96:9 | die 63:2 | 114:22 151:2 | discussions |
| 145:10 156:17 | difference | discectomy | 84:20 |
| 156:19 159:1 | 47:17,21 61:1 | 79:3 | disease 41:24 |
| 161:17 168:12 | 131:11 | discharged | 45:10,13,16 |
| 177:10 202:9 | different 44:7 | 137:13 192:12 | 46:5 50:1,6 |
| 203:8 205:19 | 50:10 53:1 | discharging | 56:19 61:9,12 |
| 206:19,20 | 54:24 62:7 | 192:2 | 61:19,20 62:11 |
| diagnoses | 73:24 87:4 | disciplinary | 64:7,17 65:15 |
| 79:11,12,13 | 91:11 96:15 | 49:4,7 | 68:11,12 70:24 |
| 139:4 177:6 | 99:21 138:22 | disclosure 3:10 | 83:18,20,21 |
| | 149:19 175:16 | 3:14 | 89:5 90:3,15 |

[disease - donor] Page 18

| | | 1 | 1 |
|---------------------|----------------|----------------|------------------------|
| 90:17,20 92:6 | 17:15,18 18:20 | 143:1,15 | 76:4 79:24 |
| 98:15 99:10,13 | 20:23 21:7,24 | 144:13 145:2 | 88:11 94:8 |
| 105:7,16 | 22:8,12,23 | 148:19,24 | 107:3 109:19 |
| 107:20,23 | 23:24 24:15 | 150:2,2 151:4 | 112:23 117:24 |
| 111:2 112:16 | 33:24 35:14 | 151:5,21 153:3 | 122:4 123:4 |
| 112:17 128:1 | 37:24 38:12,15 | 153:15,20 | 124:8,18 |
| 134:6 137:8 | 38:20 40:1,19 | 154:7,22 | 131:17 134:17 |
| 139:5 141:3 | 42:4 45:4 | 157:19 158:9 | 138:4 139:2,22 |
| 142:8 145:10 | 46:20 47:1 | 160:20 161:3 | 144:18 153:7 |
| 148:16 149:1 | 48:6 49:3,9 | 163:2,24 164:2 | 157:14 160:14 |
| 152:3 156:21 | 51:2,23 54:7 | 165:24 166:16 | 162:10 169:17 |
| 157:4 168:6 | 59:5,15 60:24 | 167:15 169:6 | 200:18 205:6 |
| 170:20 187:2 | 62:18 63:12 | 169:15,22 | documentation |
| 189:24 190:2 | 66:15 67:5 | 170:12,16 | 15:5 79:13 |
| 194:11,16 | 68:18,21 69:15 | 176:11 178:6 | 171:2 |
| 203:20 210:17 | 71:24 72:8,22 | 180:19 181:12 | documents |
| disorder 176:7 | 73:2 74:23 | 181:19 182:16 | 10:19 17:16,19 |
| 176:23 177:7 | 76:6 78:19 | 184:8 186:22 | 18:5,9,13,22 |
| dispute 111:22 | 84:2 87:18 | 187:10 188:19 | 19:14 20:5,18 |
| dissatisfied | 89:6 91:2,15 | 190:3,17 | 28:24 32:9 |
| 197:21 198:1 | 92:12 93:14,19 | 191:19 192:15 | 78:5,11 140:20 |
| distinction | 94:20 95:3,17 | 195:19 201:1 | doing 24:6 25:3 |
| 184:7 | 96:14 99:22 | 205:14 206:12 | 43:15 110:9 |
| distinguishes | 101:2 106:15 | 207:8 208:16 | 111:16 141:17 |
| 48:1 | 107:8 112:20 | 209:24 211:11 | 146:23 147:8 |
| district 1:1,1 | 113:24 115:15 | 211:14 212:3 | 148:6,22 |
| divide 26:11 | 116:15 118:8 | doctors 41:3 | dollars 20:18 |
| division 2:8,19 | 119:22 122:11 | 52:18 67:7,13 | donate 213:24 |
| 6:3 40:13,14 | 123:11 124:15 | document 1:5 | 214:2,4,10 |
| 197:19 | 128:13 129:9 | 15:19 16:10,15 | donated 151:15 |
| dl 80:24 | 130:2,13 131:3 | 16:17,22,24 | 151:17 |
| doc 73:10 | 131:22 133:14 | 17:7 22:3 23:3 | donor 181:20 |
| doctor 6:13 | 134:24 138:12 | 34:20 37:11,19 | 182:17 183:1 |
| 7:11 9:23 | 139:17 140:19 | 38:21 39:6,9 | |

| donors 213:23 | 145:5,23 146:7 | 132:14 134:9 | 27:21 36:3,4 |
|-----------------------|---------------------|------------------------|-------------------|
| 214:14 | 146:14,21 | 142:19 144:14 | either 18:10 |
| dorotinsky | 147:19 148:21 | 148:13 173:18 | 26:2 30:21 |
| 2:16 | 149:19 150:3 | 194:12 213:21 | 56:21,24 57:3 |
| dotted 139:23 | 150:11 151:2 | early 81:12 | 74:21 128:7 |
| double 139:23 | 151:12 153:8 | 166:13 183:12 | 148:3 155:24 |
| dowling 36:17 | 157:15 160:15 | 185:12 189:16 | 210:12 211:9 |
| doyne 1:15 6:7 | 162:11 169:7 | earned 34:12 | elevated 57:18 |
| dr 3:9 4:2 5:2 | 169:18 171:20 | ease 190:21 | 58:8 60:9,13 |
| 6:9,22 11:12 | 181:2,5 192:13 | easier 162:23 | 81:1 82:6,16 |
| 15:13,20 16:11 | 200:19 205:7 | 169:15 | 131:7,12 |
| 16:15,18,22 | 212:11 215:8 | easily 53:1 | 134:13 142:10 |
| 17:1 22:4 23:1 | draft 25:14 | eastern 1:1 | 143:4,5 |
| 24:11 26:15,17 | 167:16 | easy 52:19 | elevation |
| 28:17 29:7,11 | drafted 38:3,4 | education | 152:13 |
| 29:12,20,22,24 | drafting 25:11 | 51:19 78:18 | elevations 81:8 |
| 30:6,20 31:1,5 | 78:2 130:22 | educational | 152:22 |
| 31:8 34:21 | dropbox 18:6 | 39:7 | em 163:17 |
| 37:6,12,20 | drops 129:6 | effects 59:11 | empagliflozin |
| 69:21 70:14 | due 108:16 | 61:16 | 136:5 149:10 |
| 73:16,16 92:10 | duly 6:14,18 | effort 58:17 | 155:4 163:18 |
| 94:9,13 107:4 | 216:7 | egfr 52:10 54:1 | 163:22 |
| 107:10,13 | dynamic | 54:4 96:5,22 | employee |
| 111:5 112:24 | 179:14,18,24 | 97:1,3,3,5 98:7 | 216:16,18 |
| 114:1,7,12,16 | dysfunction | 98:9,11 100:18 | employment |
| 115:11 118:1 | 57:16 | 101:17 102:7 | 39:7 164:15 |
| 122:5 123:5 | e | 102:20 103:12 | 165:14,21 |
| 124:9 131:18 | e 2:1,1 3:1,8 4:1 | 104:10 106:1 | 172:8,9,12,16 |
| 134:18 135:21 | 5:1 | 117:2,14 | 172:24 173:4,9 |
| 136:17,24 | earlier 9:1 25:5 | 118:17 120:14 | 173:13 |
| 137:12,17 | 41:24 59:14 | 121:5,20 125:9 | ends 52:21 |
| 138:5 140:15 | 78:4 92:19 | 125:11 | endstage 45:16 |
| 141:1,10 | 106:2,6 107:8 | eight 23:3,7,23 | 46:5 56:19,23 |
| 144:15,19,23 | 100.2,0 107.0 | 25:1 26:7 | 61:9,12,20 |

| 50.10.51.15 | . 045440 | | |
|----------------------|-----------------------|----------------------|------------------------|
| 62:10 64:17 | errata 217:1,13 | eventually | excretion 53:15 |
| 68:11 90:3 | 218:1 219:1 | 45:14 83:8 | excuse 22:13 |
| 98:14 152:3 | erratic 83:22 | everybody | 109:6 140:14 |
| 187:1 | especially | 213:9 | 145:1 |
| entire 59:9 | 105:23 | evidence 83:12 | execute 13:19 |
| 207:17 217:9 | esq 2:5,10,11 | 83:23 112:16 | exhibit 3:9 4:2 |
| entirely 110:8 | 2:12 | 125:14 134:13 | 5:2 15:18,20 |
| 111:15 147:6 | esrd 155:15,18 | 137:8 140:5 | 16:11,14,18,21 |
| entirety 41:9 | essential | 142:7 204:10 | 17:1 22:1,4 |
| 88:17 191:9,10 | 149:23 159:19 | 214:8 | 26:23 28:11 |
| entitled 16:15 | 159:23 161:18 | exact 49:17 | 29:3 31:24 |
| 72:17 | 161:21 | 50:7 54:19 | 32:13 33:12 |
| entry 27:10 | essentially 79:9 | exactly 11:2 | 34:19,21 37:10 |
| 33:11 118:14 | 146:1 191:1 | 18:17 46:22 | 37:12,17,20 |
| 121:2 137:12 | estimate 23:22 | 85:23 159:3 | 38:2,13 68:20 |
| environmental | 53:9 57:11 | 208:8 | 69:22 72:24 |
| 48:12 210:13 | 64:16 | exam 3:4,5 | 75:1 78:20 |
| envision 75:16 | estimated | examination | 94:3,9,14 |
| enzyme 108:19 | 52:10 59:11 | 6:20 160:3 | 107:2,4 112:22 |
| epidemiologist | 64:20 83:23 | 212:9 216:6 | 112:24 113:18 |
| 47:4 | eugene 28:22 | examined 6:19 | 113:20 117:23 |
| episode 141:16 | 29:11 | 48:21 | 118:1 122:3,5 |
| episodic 81:8 | evaluate | examiner | 123:3,5 124:7 |
| equally 86:16 | 107:19 | 136:12 | 124:9 131:16 |
| equation 64:11 | evaluated | example 41:23 | 131:18,22 |
| 64:15,23 85:18 | 57:17 | 60:15 70:23 | 134:15,16,18 |
| 143:12 150:4 | evaluating 67:7 | 88:22 91:15 | 138:3,5 139:18 |
| 150:19 | 86:24 142:1 | excellent | 140:16 144:19 |
| erick 2:11 6:23 | 197:14 | 114:18 149:4 | 146:17 153:6,8 |
| 37:15 94:3 | event 62:21 | 149:14,24 | 157:13,15 |
| 107:1 131:15 | 79:24 | except 217:11 | 160:9,10,15 |
| 153:11 205:2 | events 80:1 | excessive 58:8 | 162:5,6,11 |
| erick.marquina | 178:13 | excited 205:3 | 164:6 169:16 |
| 2:12 | | | 169:18 181:13 |

| 199:3 200:17 | 10:3 13:16 | exposures | factors 69:22 |
|-----------------------|-----------------|------------------------|-----------------------|
| 200:19 204:20 | 14:1 15:8 | 73:24 | 70:2,6,11 71:3 |
| 204:21 205:1,5 | 18:19 21:5 | expressed | 73:5 86:10 |
| 205:7 208:20 | 23:13 25:11,14 | 184:17 | 99:12 185:15 |
| exhibits 15:14 | 25:17 33:19,20 | extent 20:15 | 189:8 |
| 17:22,22 19:15 | 33:22 34:12 | 24:13 67:20 | facts 28:16 |
| 19:17 20:11 | 35:21 36:7,10 | 70:12,13,22 | 183:2 |
| 21:2 28:24 | 36:13,17,20,23 | 165:11 192:18 | failure 41:4 |
| 32:10 37:7 | 37:2,2,8,17 | 210:9 | 42:3 45:10,14 |
| exist 157:5 | 88:15,17 89:7 | extremely | 45:17 56:17 |
| existing 170:19 | 89:13,17 93:5 | 153:1 166:11 | 64:10 150:4,19 |
| expect 89:24 | 127:2 129:12 | f | fair 34:4 64:5 |
| 90:6 | 129:21 155:8 | f 1:16 216:3,24 | 86:1 88:3 |
| expectancy | 168:4 169:6,11 | face 214:20 | 195:22 196:17 |
| 145:11,19 | 169:23 170:7 | facility 203:16 | fairly 147:22 |
| 146:9 | 171:13,21 | fact 51:18 | fall 50:2,6 |
| expectation | 181:6,9 192:24 | 52:23 76:2 | 71:17 |
| 45:13,15 98:8 | 198:10,18 | 83:1,13 84:19 | familiarity |
| expected 50:15 | 209:5,8,19,22 | 86:12,17 88:8 | 169:10 |
| 81:9 85:20 | expertise 10:20 | 88:11 89:1 | family 46:4 |
| 151:14 194:12 | 68:2,12 155:2 | 98:11 111:1 | 178:13 |
| expenses | 193:7 | 129:1 136:12 | far 106:12 |
| 199:15,18 | explain 14:24 | 142:9 143:11 | 118:23 163:5 |
| 200:8 204:10 | 47:17 84:24 | 145:15 150:20 | fashion 167:1 |
| experience | 88:5 127:1 | 156:4 171:15 | fatigue 173:24 |
| 51:19 68:2 | 129:9 180:19 | 175:8 184:4 | 175:13,16 |
| 78:18 85:21 | explanation | 191:10 192:5 | fatigued 175:2 |
| 86:24 89:15 | 73:8 74:15 | 194:7 195:15 | 175:21 |
| 90:16 127:15 | 87:12 105:11 | 213:13,16 | favorable |
| 129:22 183:17 | 129:10 | factor 63:17 | 187:24 |
| experienced | explanations | 86:15 87:23 | february 3:17 |
| 178:14 | 76:3,7 77:8 | 89:3 90:2 | 3:19 37:9,18 |
| expert 3:10,14 | exposure 69:12 | 145:15 183:12 | 93:6,6,7 |
| 3:22,23 5:8 | 71:8 | 1.0.10 100.12 | 167:13 |

| | | * * * * * * * * * * * * * * * * * * * | 0 7 11 1 |
|-------------------------|-------------------------|--|-----------------------|
| fee 3:21 34:14 | 141:17 167:21 | fixing 112:15 | focused 11:6 |
| 34:15,17 35:5 | 207:19 | flip 100:12,17 | 21:17 127:14 |
| feel 9:1 43:14 | finish 8:17 | 101:13,16 | folks 154:10 |
| 129:16 162:8 | finished 115:16 | 102:2,6,10,19 | 165:19 183:15 |
| 170:13 | firm 14:12,22 | 103:11 104:9 | follow 92:17 |
| feeling 175:2 | 23:2 24:17 | 117:1,13 | 98:8 109:5 |
| feelings 173:24 | 36:17 | 120:16 121:1,4 | 137:8 166:13 |
| feels 177:17 | first 6:18 13:1 | 121:19 125:7 | 186:21 |
| fellow 132:8 | 13:5,7 15:16 | 132:4,14 | followed 178:2 |
| fellowship 40:6 | 22:16 27:9 | 133:19 135:15 | following 11:8 |
| 209:23 | 37:7 68:20 | 145:2 150:8 | 28:16 31:22 |
| felt 79:17 | 70:17 80:20 | 153:24 159:15 | 35:12,12 53:9 |
| field 49:14 89:2 | 95:3,21 115:12 | 161:15 201:16 | 80:22 81:7 |
| 89:15 | 121:8 123:19 | 206:2 | 83:24 92:16 |
| figure 128:14 | 132:18 158:9 | flipping 136:20 | 129:2 143:11 |
| filter 147:23 | 182:5,7 183:8 | flood 4:5 28:23 | 166:10 171:2 |
| filtering 52:7 | 185:9 199:21 | 29:12,22 30:20 | 173:21 178:1 |
| 52:24 | 201:5,17 | 31:1,8 107:10 | 192:8 193:5 |
| filtrate 83:5 | 209:18,19,20 | 107:13 141:1 | follows 6:19 |
| 214:5 | 209:21 212:18 | 141:10 146:21 | foregoing |
| filtrating | five 9:7 25:6,19 | 147:19 148:21 | 216:10 |
| 142:22 192:9 | 36:5 59:1 | 149:19 150:3 | forever 157:22 |
| filtration 51:24 | 66:19,20 81:12 | 150:11 151:12 | forgot 80:14 |
| 194:9 | 81:18 82:11 | flood's 31:5 | form 50:8 |
| finally 56:14 | 84:15,21 85:13 | 111:5 140:15 | 126:16 165:6 |
| 72:16 74:11 | 88:1,19,24 | 146:14 151:2 | formally 14:3 |
| finances 197:20 | 93:10 97:20 | flow 108:24 | 14:17 |
| find 65:9 87:3 | 98:2,15 130:4 | 110:22 111:2,8 | formed 75:9 |
| 141:15 199:6 | 131:6 143:13 | fluctuations | 76:24 93:8 |
| finding 143:3 | 149:19 150:15 | 105:22 152:12 | forming 28:18 |
| findings 111:23 | 151:22 154:8 | fluids 110:21 | 77:11 84:12 |
| 135:19 | 154:23 163:11 | flying 140:20 | formulating |
| fine 10:13 | 164:20 174:17 | focus 59:1 | 78:14 |
| 66:20 106:20 | 194:13 | | |

[forth - garand] Page 23

| forth 216:13 | 199:15,17 | 183:7,11,15,16 | 10:24 15:9 |
|----------------------|-------------------------|---------------------|----------------|
| fortunate 41:2 | franklin 202:1 | 183:18 184:18 | 16:1,4,14,21 |
| 51:17 | 202:4 203:24 | 186:9,19 | 17:4,10 19:6 |
| fortunately | 204:9 | 188:15 | 19:11,12,19 |
| 50:11 | free 9:1 162:8 | functional | 20:1,3,13,22 |
| forward 79:18 | 170:13 | 188:9 | 21:23 22:7 |
| 93:4 213:24 | frequency | functioning | 24:20,23 26:3 |
| found 30:7 | 198:23 | 66:2,6,6,11 | 28:6 30:18,24 |
| 111:14 114:12 | froedtert 40:14 | 84:3 | 31:12 33:10 |
| 114:16 131:4 | 40:16 | further 57:16 | 34:24 35:2,3 |
| 132:20 135:21 | front 50:13 | 57:19,20 76:3 | 37:15,23 38:11 |
| 136:9,13,17,24 | 78:17 89:11,14 | 212:4 215:2,4 | 39:17,24 44:21 |
| 137:17,23 | 92:9 113:7 | 216:10,15 | 46:7 50:17 |
| 139:15 140:11 | 120:3 127:4 | future 24:18 | 51:1,8 65:6 |
| 171:21 177:3 | 190:18 | 56:6 70:15 | 66:15,20 67:4 |
| 195:1,20 | full 7:4 23:16 | 74:16 87:7,8 | 70:18,20 73:10 |
| foundation | 164:15 173:9 | 98:17 128:1,10 | 73:14 74:18,22 |
| 94:22 95:1 | 176:4 177:18 | 142:24 192:16 | 76:16 81:21 |
| 98:3 126:16 | fully 8:19 38:18 | g | 82:14,20 84:1 |
| 165:6 | 59:12 84:24 | g3 137:17 | 85:6,24 86:9 |
| four 12:1,3,7 | func 186:8 | 139:5 | 87:17 89:23 |
| 17:16,21 25:15 | function 52:10 | g3a 132:16 | 90:8 94:12 |
| 25:16 36:2 | 53:4,7,19 54:2 | 135:24 136:24 | 95:2 97:4 |
| 75:12 81:16 | 54:5 55:1,8,14 | 194:17 | 98:19 99:3,15 |
| 85:8 96:11 | 55:20 56:2,12 | gain 165:21 | 103:20,23 |
| 124:1 149:19 | 57:12 62:10 | gainful 172:8 | 104:17,21 |
| 158:24 163:11 | 64:1,3 86:19 | 172:11,16,23 | 106:18,22 |
| 166:10 171:16 | 87:4 99:17 | 173:12 | 107:1,7 109:11 |
| fourth 137:12 | 105:3 106:4,8 | gallbladders | 111:13,21 |
| 158:20 | 106:9 111:1 | 43:14 | 113:5 115:5 |
| frank 3:12,22 | 114:17,18 | game 131:15 | 116:5 117:22 |
| 5:8 28:18,21 | 139:24 140:6 | garand 2:10 | 118:4,24 119:4 |
| 29:7 37:8 | 143:16 145:17 | 3:4 6:21,22 | 122:10 123:10 |
| 48:21 158:11 | 145:24 146:2 | , | 124:14 126:15 |

[garand - going] Page 24

| 126:21 128:2 | garbarini 32:9 | 104:14 115:17 | 110:17,17,20 |
|----------------|------------------------|----------------------|------------------------|
| 128:12 129:8 | 32:23 | 115:23 119:19 | 115:2 116:2,9 |
| 129:17,24 | gathered 21:20 | 130:14,14,23 | 119:23 124:1 |
| 130:5,12 | general 11:3 | 150:13 186:23 | 126:17 128:19 |
| 131:21 134:3 | 40:4,11 43:5,7 | 214:1 | 134:1 143:8 |
| 134:23 137:22 | 43:18,19 52:8 | gfrs 59:12 | 148:11 152:5 |
| 138:10 143:14 | 105:19 | giles 17:6 | 152:18 155:8 |
| 144:22 146:13 | generally 15:1 | give 8:4 9:20 | 157:11 164:2 |
| 152:9 153:2,4 | 40:24 61:3 | 11:3 21:10 | 168:17 171:13 |
| 153:5,11,13,14 | 84:24 89:6 | 23:22 25:2 | 173:11 183:16 |
| 157:11,12,18 | 131:10 137:7 | 42:23 50:14 | 214:6,16 |
| 160:7,8,18 | 185:13 187:24 | 61:18 90:24 | goal 162:1 |
| 162:18 165:9 | 188:4,8 209:24 | 133:8 | god 140:24 |
| 165:23 168:3 | 211:7 | given 21:7 79:8 | 199:9 |
| 168:10,20 | geneticist 47:6 | gives 53:18 | goes 7:14 69:23 |
| 169:2,4,5,21 | 73:17 | giving 64:6 | 71:7 74:1,8 |
| 170:8,11 | george 32:12 | 70:16 | 105:8 165:18 |
| 175:11,22 | getting 97:8 | glomerular | going 7:13 8:2 |
| 178:5,11,18,24 | 105:8 120:3 | 51:24 68:11 | 8:8,14 9:4,15 |
| 179:6,12,19 | 140:19 | 83:9 155:20 | 10:21 15:13 |
| 180:8,15 | gfr 46:18 51:24 | 156:1 | 21:10,24 24:21 |
| 181:17,18 | 52:6,10,13 | go 7:13 15:16 | 34:17 37:6 |
| 187:9 190:16 | 53:9,11,13,16 | 18:8,24 21:14 | 38:14 41:16 |
| 193:10,17 | 54:12 55:4,10 | 26:6 30:23 | 44:1 46:20 |
| 194:21 195:6 | 55:16,22 56:8 | 31:13,24 32:13 | 66:15,22 70:10 |
| 197:3,10,23 | 56:14 57:11,19 | 33:6 44:18 | 72:8 75:2,2,12 |
| 198:24 199:11 | 57:22 58:3,17 | 45:4,21 50:22 | 79:18 80:20 |
| 200:24 204:17 | 58:21 63:21 | 51:5 65:2 | 83:3 93:3,19 |
| 204:22,23 | 81:7 82:2,15 | 69:15 81:20 | 94:1,2 95:13 |
| 205:12 207:16 | 83:23 91:17 | 85:15 87:16 | 95:15 97:12 |
| 207:23 209:1 | 92:13,20 93:15 | 95:1 97:12 | 99:19 113:17 |
| 211:19 212:3 | 93:20 96:9 | 98:4,24 107:12 | 115:19 117:17 |
| 215:4 | 97:17,24 | 108:2,22 | 123:2 128:10 |
| 213.7 | 77.17,21 | 10012,22 | |
| 213.4 | 103:14,16 | 109:10,17 | 129:24 130:6 |

Golkow Technologies, A Veritext Division

877-370-3377

[going - higher] Page 25

| 131:16 139:17 | graham 36:23 | happy 8:11 9:8 | healthy 151:17 |
|---------------------|----------------------|-----------------------|------------------------|
| 142:24 150:15 | gram 59:22 | 72:10 181:13 | hear 8:7 9:13 |
| 157:10 160:6 | 60:4,7 | harbinger | heard 7:15 |
| 170:6 180:24 | great 20:15 | 57:14 | heather 28:21 |
| 190:3,10 | 146:23 215:5 | harder 83:5 | 29:6 32:8,22 |
| 194:13 199:7,7 | gross 202:11 | 213:14 | 33:3 188:13 |
| 200:11 204:24 | ground 7:13 | harm 194:5 | heavily 86:3,11 |
| 205:4 211:18 | group 13:20 | harms 193:20 | 86:15,20 87:10 |
| 211:20,21 | 36:7 67:21 | 194:1,2 195:7 | 87:23 |
| 214:24 215:6 | guarantee | he'll 84:14 | heimann 36:13 |
| gold 214:11 | 49:13,15 | 194:3 | held 1:14 6:6 |
| golkow 2:19 | guarantees | head 25:12 | help 44:12 |
| 6:3 | 49:10,11 | heading 69:22 | 149:9 155:24 |
| good 49:21 | guess 132:19 | 71:6,14 72:1 | 185:15 |
| 106:3 114:13 | 191:12 194:23 | 72:13,16 73:4 | helping 15:11 |
| 130:1 148:6 | 213:6 | 73:4,16,19,21 | hematuria |
| 149:6 151:22 | guesses 26:5 | 74:4,6,6,11 | 133:6 202:11 |
| 158:8 161:2 | h | 78:21 80:18,21 | hemodialysis |
| 188:3,14 | h 3:8 4:1 5:1 | 80:22 109:19 | 183:8 |
| 211:20 | 32:7 | 124:21 133:20 | hemodynamic |
| gosh 199:6 | half 44:11,15 | 136:17,23 | 108:16 |
| governed 171:9 | 44:24 103:4 | 137:12 139:3 | hereinbefore |
| 171:22 | 182:8 | 139:11 154:3 | 216:13 |
| government's | halfway 109:23 | 159:6,22 161:7 | hereof 217:13 |
| 72:18 | hand 16:2 | 161:17 182:5 | hereunto |
| grade 134:6 | 211:16 216:22 | headings 73:23 | 216:21 |
| 168:12 171:7 | handful 46:21 | health 5:11 | hernia 43:9 |
| 171:10 | handles 47:18 | 48:13 128:10 | hernias 43:10 |
| graft 182:13 | happen 105:15 | 176:16,19 | hesitate 192:1 |
| 183:5,7,11,12 | happened | 177:14,21 | high 171:10 |
| 183:15,17 | 183:21 | 206:3 | 187:18,19 |
| 185:18 186:9 | happens 24:20 | healthcare | higher 54:1,4 |
| grafts 183:3 | 49:14 91:11 | 184:17 | 55:5 87:7 |
| | 12,17 /1,11 | | 110:24 |

| | | I | I |
|----------------------|-------------------|-----------------------|----------------------|
| highest 185:9 | hum 96:13 | 113:1 118:2 | implies 89:13 |
| 185:10 | 163:19 | 122:6 123:6 | important |
| hired 13:16 | hurt 149:7 | 124:10 131:19 | 11:11,13 21:3 |
| histories 11:5 | husband 32:19 | 134:19 138:6 | 31:20 49:23 |
| history 51:17 | hyper 83:5 | 144:20 153:9 | 61:8,11 62:1 |
| 59:9 61:14 | 142:22 192:9 | 157:16 160:16 | 62:19,24 82:24 |
| 65:12 78:24 | 194:9 214:5 | 162:12 169:19 | 83:2 84:23 |
| 79:5 88:13 | hyperfiltration | 195:12 196:4,9 | 86:17 87:2 |
| 98:16 161:4,6 | 81:9 83:16 | 200:20 205:8 | 93:16 128:9 |
| 163:4 174:20 | 85:9 128:24 | identified | 129:4 189:7 |
| 179:2 209:3 | hyperlipidemia | 212:16 | importantly |
| hmm 79:16 | 79:2 | identify 28:16 | 10:2 82:24 |
| hold 186:16 | hypertension | 210:6 | impose 19:22 |
| home 196:13 | 65:17 79:1 | ifs 150:1 | impossible |
| hoog 2:19 6:2 | 83:20 88:8,22 | iii 3:10,14 | 172:9,12,16 |
| hope 56:7 | 90:2,14,19 | illness 149:12 | 173:4,10,13 |
| 135:14 139:18 | 91:4 135:22 | 163:4 176:7,23 | impression |
| 204:24 | 152:1,11 154:4 | 177:6 | 136:16,23 |
| hoping 109:3 | 155:19,22 | immediate | improved |
| hospital 40:15 | 156:17,21,24 | 68:14 | 109:7 110:4 |
| 40:17 198:4 | 157:4,6 159:9 | immediately | improvement |
| hour 9:5 34:6 | 159:20,23 | 173:20 | 110:1 |
| 35:10,10 44:11 | 161:9,18,21 | immunosupp | inability 127:8 |
| 44:11,14,15,23 | 194:22 195:2 | 184:24 195:14 | 175:7 |
| 66:16 114:8 | i | impact 61:22 | inaccuracies |
| 130:1 190:4 | i.e. 58:17 | 62:9,11 70:13 | 213:10 |
| hours 12:2,7 | 213:13 | 91:5,6 145:18 | inaccurate |
| 23:23 24:5,7 | idea 53:11 | 146:1,5,8 | 58:14 87:5 |
| 25:2,3,6,9,15 | identification | 165:13 168:5 | inaudible 93:13 |
| 25:16,19,21 | 15:21 16:12,19 | 171:8 183:22 | incisional |
| 26:10,15,17 | 17:2 22:5 | 192:7 | 43:10 |
| 27:11,13,18,19 | 34:22 37:13,21 | impacts 70:23 | include 35:15 |
| 27:23 33:13 | 94:10 107:5 | 174:10,14 | 39:13 79:15,21 |
| 34:5 | 77.10 107.3 | | 83:19 88:6 |

| | T | | T. |
|----------------------|------------------|-----------------|-----------------|
| 141:20 197:20 | indicate 58:20 | 125:14 128:22 | institution |
| 200:7 204:8 | 119:14 141:21 | 129:19 183:4 | 196:12 |
| included 15:5 | indicated 6:5 | 193:1 201:10 | instruct 10:8 |
| 39:20 79:16 | 217:12 | 213:11,18 | instructing |
| 80:2 84:15 | indicates 54:1,4 | inhibitor | 10:11 192:20 |
| 127:5 128:22 | indicating | 108:18,19 | instruction |
| 193:2 201:7 | 125:19 185:5 | 134:7 154:8,15 | 21:11 |
| 207:3 | indication | 154:23 155:6 | instructs 9:15 |
| includes 35:18 | 61:18 142:17 | inhibitors | 9:16 |
| 44:12 78:24 | indicative | 143:21 | insufficient |
| including 24:12 | 57:19 | initial 13:14 | 57:11 58:3 |
| 59:9 61:15 | indirectly | 15:17 22:14 | interchanged |
| 129:21 143:20 | 216:19 | 28:13 32:1 | 60:22 |
| 174:6 | individual | 51:15 130:17 | interest 164:16 |
| inclusive 20:12 | 30:10,16 44:8 | 131:2 159:12 | 173:10 |
| income 34:11 | 68:3 151:17 | 170:2 199:1,2 | interested |
| incorrect | 194:10 | 205:16 | 127:6 216:19 |
| 204:12,16 | individuals | initially 30:7 | interestingly |
| increase 105:3 | 90:16 213:7 | 44:23 159:11 | 141:5 |
| 108:13 | infections | 159:11 | interface 41:3 |
| increased | 184:21 185:1,6 | injured 192:8 | interferes |
| 155:19,22 | 195:14 | injuries 193:20 | 174:22 |
| 156:5 | infects 90:17 | 194:1,2 195:8 | intermittent |
| increases 88:22 | influence | injury 83:8 | 152:12 |
| 195:14 | 106:21 | 142:17 149:12 | interpreted |
| incred 151:13 | information | 149:13 194:5 | 173:13 |
| incredibly 83:2 | 10:9 13:13 | 214:18 | interrogatories |
| 142:11 | 15:6 17:7 | inside 146:4 | 72:18 |
| incurred | 21:20 24:10 | insomnia | interventions |
| 195:21 | 39:12,15,18 | 173:23 | 53:1 127:9 |
| independent | 49:22 50:14 | instance 126:5 | 196:11 |
| 62:15 | 54:15 77:15 | 126:6 185:2,20 | interview 51:16 |
| independently | 84:17 87:1 | instances 15:7 | intrinsic |
| 171:8 192:22 | 92:10 93:4 | 126:7 | 108:23 111:2,7 |

| 112:16,17 | 48:22 77:1 | 216:22 | 66:1,1,5,6,8,11 |
|-------------------------|-----------------------|-------------------------|-----------------|
| 142:7 | 181:12 | jumping 100:4 | 66:12,13 69:23 |
| inulin 53:17 | jan 122:22 | 126:24 | 70:6,24 71:3,4 |
| invoice 3:20 | janet 28:23 | june 94:15 | 71:16 72:3 |
| 22:16,19,21 | january 32:7 | justice 2:8 6:24 | 74:7,14 79:21 |
| 23:1,7 24:17 | 102:13 108:13 | 77:24 78:8,12 | 81:10 83:2,3,4 |
| 24:21 26:6,22 | 122:22 125:2 | k | 83:8,10,11,17 |
| 27:4,7 29:4,6 | 125:16,20,23 | k 5:8 | 84:4 85:20 |
| 32:14 34:2,5 | 183:24 184:12 | k.v. 32:11 | 86:12,18,19 |
| invoices 200:7 | 184:16,20 | katherine 32:9 | 87:4,7,8 89:4 |
| 200:13 201:22 | jardiance | 32:23 138:23 | 90:15,16,20 |
| 202:24 204:8 | 163:15,16,22 | keep 115:19 | 92:6 97:19 |
| 206:13,16 | jay 135:11,16 | 116:7,13 | 99:10,12,17 |
| 207:4,10 | jayaram 32:8 | 139:19 | 105:2,7,16 |
| involved 41:11 | 32:15 | keller 36:10 | 106:3,7,9 |
| 89:21 211:11 | job 1:24 23:16 | kevin 4:4 28:23 | 107:19,23 |
| irving 73:16,16 | johnstone | kid 45:17 | 108:23,24 |
| island 2:4 | 11:12 24:11 | 178:14 187:1 | 110:9,24,24 |
| issue 211:6 | 26:15 | kidney 3:11,14 | 111:7,8,15 |
| issued 170:2 | johnstone's | 41:20,24 42:21 | 112:11,16,17 |
| issues 41:20 | 26:17 92:10 | 44:2,6,16 | 114:13 127:7 |
| 42:9 68:8 | jones 32:8,22 | 45:10,13,17 | 127:13 128:1 |
| 111:7 154:18 | 33:3 188:13 | 46:3,17 47:18 | 128:10 129:1 |
| 154:19 158:17 | joshua 2:12 | 50:1,6 52:10 | 134:6 137:9 |
| 177:14 184:21 | joshua.g.carp | 53:4,7,17 54:2 | 139:5,24 140:5 |
| iv 78:21 110:21 | 2:13 | 54:5 55:1,7,14 | 141:3,4 142:5 |
| ix 72:1,13 | jr 32:11 | 55:20 56:2,12 | 142:17,21 |
| 73:23 | juliana 1:16 | 56:17,22 57:7 | 143:16,24 |
| j | 6:12 216:3,24 | 57:12,16 59:11 | 144:1,4 145:10 |
| j 3:16 16:9 32:6 | july 1:10 6:4 | 61:9,16,19 | 145:24 147:7 |
| jacqueline 3:16 | 116:20 120:7 | 62:9,10 63:19 | 147:21 148:3 |
| 3:24 16:9 32:6 | 120:18,22 | 63:24 64:6,10 | 148:15,22 |
| 32:19 37:18 | 132:2 133:10 | 64:17 65:15 | 149:1,4,5,7,9 |
| 32.17 37.10 | 136:8 215:11 | 04.17 03.13 | 149:13,14 |
| | I . | | |

[kidney - lack] Page 29

| 150:4,18,19 | kind 42:19 43:3 | 127:7,8 128:10 | knowledge |
|-----------------------|---------------------------------------|----------------|--------------------|
| 151:15,18 | 59:6 87:2 | 129:21 130:20 | 18:4 36:11,15 |
| 154:19 156:1,4 | 151:18 176:17 | 133:16 140:19 | 36:18,21,24 |
| 156:21,22,24 | 210:1 | 142:1,8,15 | 178:6,12,19 |
| 157:4 158:16 | know 7:15 8:8 | 143:23 144:6 | 179:1,7,13,24 |
| 158:18 159:1 | 8:11 9:7 10:20 | 149:12,18,23 | 180:3,9 203:23 |
| 166:19 167:6 | 14:9 18:11,18 | 150:3 151:13 | known 71:15 |
| 168:5 181:20 | 20:16 22:9 | 150.3 151.13 | 74:7 89:1 |
| 182:18 183:6 | 23:17,20 24:15 | 155:18 154:17 | 189:23 |
| 184:18 185:21 | · · · · · · · · · · · · · · · · · · · | 156:18 157:24 | knows 163:5 |
| | 25:2,6,10 26:4 | | |
| 186:3,8,9,10,11 | 26:4 29:18,20 | 158:1 159:2 | 213:9 |
| 186:14,18 | 29:22 30:1,3,6 | 160:19 162:9 | krick 138:23 |
| 187:2 188:5,9 | 30:9,20 31:9 | 164:22,24 | 1 |
| 188:14,20 | 33:16,18 35:11 | 165:10,17,21 | l 140:8 |
| 191:12,15 | 38:1,15 41:20 | 167:10 169:10 | lab 4:7,12 |
| 192:8 194:3,8 | 44:9 45:7 48:4 | 170:14 172:23 | 45:18 59:1,2 |
| 194:9,11,13,16 | 50:18 54:7,9 | 174:15 175:6,8 | 61:16 63:7 |
| 202:4,8 203:8 | 58:24 59:10 | 178:10 179:20 | 64:7 94:15 |
| 203:12,19,20 | 61:15 62:4 | 179:22 180:16 | 108:7 109:24 |
| 203:24 205:20 | 64:8,19 67:7 | 181:17 183:4 | 118:6,15 |
| 206:7,20 207:1 | 70:3,22 72:10 | 186:8,12,22 | 119:13,17 |
| 210:17 213:13 | 75:4,20 78:7 | 190:1 191:16 | 120:22 125:21 |
| 213:14,15,19 | 78:10 79:18 | 192:1,6,14 | 126:2 127:19 |
| 213:21,22,24 | 83:10,18 84:23 | 193:6 194:11 | 130:14 |
| 214:4,5,10,11 | 85:17,18,19 | 195:10,15 | labile 159:9 |
| 214:16 | 87:10 88:10 | 196:4,6,23 | 161:9 |
| kidney's 52:23 | 89:22 90:1,6 | 198:1,14,16,21 | laboratory 4:3 |
| 53:19 | 91:13,24 98:7 | 198:23 199:7 | 95:10 |
| kidneys 43:1 | 98:9,21,21 | 199:24 200:9 | labs 109:19 |
| 52:7 83:5 | 100:4,24 105:9 | 201:2 202:21 | 110:5 119:20 |
| 98:18 110:23 | 112:11,17,18 | 203:19 211:2 | 147:20 |
| 144:11 155:23 | 113:14 115:21 | 214:13,24 | lack 94:22,24 |
| 195:9 213:15 | 116:12 123:13 | knowing | 98:3 |
| 214:19,21 | 125:24 126:9 | 166:23 | |

Golkow Technologies, A Veritext Division

Page 249 of 281

[laid - llp] Page 30

| laid 129:5 | levels 60:9,13 | 135:16 139:23 | 205:16 209:2 |
|------------------------|------------------------|------------------------|-------------------------|
| language 78:13 | 69:11 71:15 | 148:11,18,23 | 209:11 210:8 |
| lastly 110:17 | 74:7 91:22 | 150:11,16,23 | listed 19:14 |
| late 46:1,8 | 92:1,5 93:15 | 161:23 163:4 | 69:18 80:13 |
| 98:22 99:4,5 | 93:20 97:23 | 166:7 171:1 | 85:8,8 86:2 |
| 203:9 | 130:15 187:11 | 172:6 182:7 | 127:1 128:15 |
| law 23:2 | 212:12,16 | 218:2,5,8,11,14 | |
| lawyers 11:19 | lexi 2:16 | 218:17,20 | 209:20,21 |
| lead 61:20 | licensing 49:4 | 219:2,5,8,11,14 | listen 167:18 |
| leadership | lieff 36:13 | 219:17,20 | lists 17:23 20:5 |
| 13:20 | life 39:16 | lines 29:5 | 171:3 |
| leads 196:6 | 145:11,18 | 102:16 110:18 | literature |
| leaves 25:20 | 146:8 182:8 | 116:22 124:1 | 27:10,14 51:20 |
| leaving 82:18 | 213:22 | 125:4 132:19 | 150:20 |
| lectures 39:2,3 | lifelong 149:11 | 141:1,10 145:7 | liti 13:21 |
| 39:19 | lifespan 195:16 | 145:23 146:3 | litigation 1:4 |
| led 196:10 | lifetime 176:8 | 146:19 147:4 | 6:8 12:18 13:2 |
| left 95:8 118:9 | 180:21 | 147:18 164:9 | 13:5,21 14:16 |
| 158:13 163:10 | likelihood 61:8 | lipomas 43:13 | 89:22 211:12 |
| 163:11 | 62:20 63:1 | lisino 154:13 | 217:4 |
| legal 36:7 | likely 60:19 | lisinopril | little 35:6 37:1 |
| lejeune 1:4 6:8 | 77:17 131:4 | 108:18 110:3 | 42:16 63:5 |
| 12:18 13:2 | 166:12 183:5 | 110:22 112:2 | 66:16 97:12 |
| 14:16 15:7 | limit 188:19,23 | 136:4 149:10 | 100:4 114:16 |
| 69:8 71:9 74:1 | limitation | 154:13,15,18 | 165:13 180:11 |
| 77:24 78:8,12 | 189:2 | 158:21,24 | 187:5 |
| 217:4 | limited 42:17 | 163:12 | live 188:5 |
| lesions 166:24 | limits 57:23 | list 3:11,15,17 | 213:22 |
| level 52:3 57:18 | 188:22 | 3:19 15:15,16 | liver 166:13 |
| 105:23 118:21 | line 28:15 | 15:17 16:8,16 | 172:1 |
| 119:14 141:11 | 40:16 78:23 | 16:23 17:6,13 | living 213:23 |
| 186:4,16 | 100:13 108:2 | 18:21 28:12,13 | llc 36:10 |
| 187:14 | 109:16,17 | 32:1 199:18 | llp 36:14 |
| | 133:2 134:4 | 200:6 204:9 | |

Golkow Technologies, A Veritext Division

www.veritext.com

Page 31 [locations - make]

| locations | 103:7 108:1,2 | 214:16 | low 57:19 |
|-----------------|----------------|------------------------|--------------------|
| 208:12 | 108:6 109:10 | looked 11:10 | 108:17 150:14 |
| lone 66:6,11 | 109:16,18 | 32:24 96:14 | 168:12 171:7 |
| long 25:13 | 110:20 112:8 | 126:20 138:20 | 187:24 |
| 43:21 44:3 | 112:20 114:15 | 147:20 149:18 | lower 126:8 |
| 66:18 78:9 | 116:17,22 | 207:15,18 | 128:3,16 |
| 137:7 170:14 | 117:4,16 120:9 | 208:7 | lumps 43:13 |
| 185:14,16,18 | 120:13 123:19 | looking 17:21 | lungs 166:13 |
| 194:13 195:13 | 125:1 128:11 | 26:22 51:23 | 172:1 |
| 211:4,10 | 134:15 136:16 | 63:6,7,8,8,9 | lutheran 40:15 |
| longer 68:15 | 139:4,17,21 | 69:22 81:15,22 | luxenberg |
| 71:20 72:14 | 140:15,18 | 96:22 115:19 | 36:20 |
| 73:6 110:21 | 141:1,9,9 | 136:18 147:18 | m |
| 147:22,24 | 142:4,8 145:7 | 148:7 151:10 | m 2:10 |
| 182:22 188:5 | 145:23 146:14 | 161:4 164:6 | m.d. 4:5 |
| longevity | 146:18,19 | 166:3 171:14 | madam 16:1 |
| 127:12 | 147:2,4,10 | 175:23 208:21 | made 45:2 |
| longstanding | 148:18 151:5,6 | 209:13 | 127:12 202:18 |
| 141:4 | 153:3 154:2 | looks 20:17 | main 164:14 |
| look 18:3 28:11 | 155:12 159:4 | 27:9 38:19 | 170:17 |
| 28:14 29:3 | 162:20 163:2 | 148:6 214:11 | maintain |
| 32:2,4 38:12 | 163:10 165:24 | loss 156:1,1 | 164:14 165:14 |
| 40:1 43:8 | 170:16,24 | 183:12 | 173:4,9 |
| 45:18 50:13 | 172:4 173:19 | lost 156:4 | major 26:2 |
| 58:24 59:6,8 | 181:5,12 182:4 | 194:13 | 62:20 90:2 |
| 63:10,15 64:7 | 186:21 187:1 | lot 8:9 18:1,16 | 183:11 |
| 68:18,19 71:6 | 188:24 189:11 | 32:3 90:6,24 | majority 26:13 |
| 71:14 72:23 | 190:18,20 | 113:14 126:10 | 57:2 213:4 |
| 74:24 75:3 | 193:1 197:20 | 127:5 130:13 | 214:15 |
| 76:17,19 78:19 | 199:1,12,14,21 | 140:19 150:1 | make 7:14,16 |
| 78:20 80:17,20 | 202:6,20 203:1 | 177:24 178:3 | 8:3 17:11 33:9 |
| 85:20 93:19 | 206:10,12 | 213:20 | 38:2 44:12 |
| 95:3,14 99:23 | 207:7,8 208:19 | love 77:6 | 45:24 49:23 |
| 100:21 102:22 | 208:19 210:24 | | 10.2 : 17.23 |

[make - mary] Page 32

| 59:4 70:21 | mandell 2:3,3,5 | 129:23 130:4 | marital 179:2 |
|--------------------|------------------------|----------------|-----------------------|
| 84:22 91:18 | 2:16,16 3:5 | 134:1 137:19 | mark 2:5 15:13 |
| 101:3 105:18 | 9:14 10:4,8,16 | 143:7 146:10 | 15:17 16:7,7 |
| 110:23 129:22 | 11:17,21 13:3 | 152:4,17 | 16:14,21 22:1 |
| 157:7 161:4 | 13:4,8 14:21 | 162:17 165:6 | 33:16 34:18 |
| 163:24 169:15 | 15:24 17:9 | 165:15 167:17 | 37:6,9,16 94:2 |
| 173:5 191:5,8 | 18:24 19:8,12 | 168:7,14,17,24 | 112:21 117:22 |
| 191:19 199:23 | 19:15,19,20,22 | 169:3 175:3,17 | 117:23 122:2 |
| makes 63:23 | 20:2,8,21 | 177:22 178:8 | 123:3 124:6 |
| 64:2 86:7 | 21:10 22:17,20 | 178:15,21 | 131:16 134:16 |
| 173:3 | 23:1,6 24:21 | 179:3,9,15 | 138:2 153:6 |
| making 78:17 | 25:23 28:2 | 180:5,12 | 157:13 160:9 |
| 88:18 93:3 | 30:13,22 31:11 | 181:16 187:3 | 162:4 169:16 |
| 109:4 172:8,11 | 33:6 38:8 | 192:17 193:14 | 200:16 205:4 |
| 172:15 177:2 | 39:14,21 44:17 | 194:18 195:3 | marked 3:9 4:2 |
| male 135:22 | 45:20 50:8,21 | 196:19 197:6 | 5:2 15:20 |
| malignancies | 51:5 65:1 | 197:16 198:19 | 16:11,18 17:1 |
| 195:15 | 66:18,21 68:22 | 199:8 204:14 | 22:4 28:24 |
| malignancy | 70:12,18 73:7 | 204:19,22 | 32:9 34:21 |
| 170:21 | 73:11 74:15,19 | 207:14,19 | 37:12,20 94:9 |
| mall 135:23 | 76:10 81:19 | 208:22 211:16 | 107:4 110:1 |
| malpractice | 82:12,18,22 | 211:18 212:7 | 112:24 118:1 |
| 210:2,4,7,11 | 85:2,14 86:4 | 212:10 215:2,5 | 122:5 123:5 |
| man 11:17 | 87:14 89:19 | mandell's | 124:9 131:18 |
| 150:12 | 90:4,10 94:21 | 14:12 22:14 | 134:18 138:5 |
| man's 186:18 | 96:24 98:3,24 | 24:17 | 144:19 153:8 |
| manage 41:8 | 99:7 103:18 | march 4:8 | 157:15 160:15 |
| managed 136:4 | 104:15 106:17 | 103:1,15 | 162:11 169:18 |
| management | 106:20 111:9 | 104:13,22 | 200:19 205:7 |
| 150:22 191:24 | 111:17 115:1 | 108:9,14 110:5 | marker 186:20 |
| 196:15 | 115:24 118:22 | 118:6,6,20 | marquina 2:11 |
| manages 198:5 | 126:14,16 | 119:7,18 | 6:23 |
| managing | 127:20 128:5 | 160:23 167:13 | mary 32:8,22 |
| 90:14 | 128:18 129:14 | 167:14 187:20 | |

Page 33 [mass - medicine]

| mass 115:12 | mccarthy 32:8 | 186:18 214:1 | 177:5,15 |
|-----------------------|----------------------|----------------------|----------------|
| 136:2 137:1 | 32:16 | measured | 184:11 191:7,9 |
| 155:20 156:1 | mcl 199:2,4 | 51:23 53:11 | 191:10,20 |
| material 21:4 | md 1:9,13 3:3 | 59:12 62:16 | 192:16 193:2 |
| materials 3:11 | 4:19 5:8 6:17 | 91:10 | 193:12 196:17 |
| 3:15,17,18 | 28:23,23 32:8 | measurement | 196:21 197:5 |
| 10:2,6 15:14 | 32:8,12 217:17 | 87:6 | 197:15 198:5 |
| 15:16 16:8,16 | 218:24 219:24 | measurements | 198:11,11 |
| 16:23 17:5,12 | mean 19:15,22 | 58:18,19 59:4 | 199:15,18 |
| 17:24 18:21 | 24:3 39:15 | 63:14 64:18 | 200:8,12 |
| 20:4 21:19,22 | 46:9 59:8 84:4 | measures 54:13 | 203:19 204:2 |
| 25:8,10 28:12 | 90:21 93:12 | 62:15 106:7 | 204:10 210:2,4 |
| 28:13 32:1 | 133:15 139:14 | measuring | 210:7,10 |
| 201:11 204:9 | 149:14 151:12 | 52:12,12 | 212:15,19,23 |
| 205:16 | 155:21 168:24 | mechanism | medically |
| math 20:14 | 174:5 181:1 | 52:24 | 190:24 191:18 |
| 26:2 90:22 | 182:8,15 186:6 | median 182:13 | 195:22 196:18 |
| 165:8,11 | 189:11 191:9 | 182:15 | 198:11 |
| matter 6:8 7:1 | 213:18 | medical 4:22 | medication |
| 13:17 14:20 | meaning | 5:3,5,9,11 11:5 | 61:22 112:9,15 |
| 15:11 30:21 | 146:22 147:23 | 15:5 31:21,22 | 141:6 144:6 |
| 31:2 46:24 | 206:24 | 33:9 35:18 | 152:14,21,24 |
| 142:20 144:16 | meaningful | 47:21 51:17 | 189:17 |
| 169:7 217:10 | 165:21 | 54:16,20 59:9 | medications |
| matters 142:20 | means 134:9 | 61:14 70:15 | 62:5 91:9,12 |
| matthew 1:9,13 | 156:5 | 75:22,22 77:22 | 105:19 127:10 |
| 3:3,12,15 6:9 | meant 97:1 | 78:16,24 79:5 | 142:13,16 |
| 6:17 7:6 16:15 | 163:6 169:3 | 79:14 81:11 | 143:15,20,23 |
| 16:22 217:17 | 207:10 208:5 | 88:12 89:10 | 143:24 144:2,3 |
| 218:24 219:24 | measure 52:6 | 91:19 92:15 | 144:7,10 |
| maximum | 52:10 53:2,7 | 98:16 106:14 | 158:20 163:10 |
| 182:14 | 53:13,16,18 | 125:18 133:3 | medicine 48:16 |
| mbmjustice.c | 58:17 59:15 | 141:20 160:3 | 49:16,21 50:7 |
| 2:5 | 106:3,7,9 | 174:4,6 177:3 | 109:2 |

| | 1 | | |
|---------------------|-----------------------|-----------------------|----------------|
| medicines | mg 80:24 140:8 | misprint 200:4 | 4:17,21,23 5:4 |
| 149:9 | microalbumin | missed 97:21 | 5:7,8,10,11 |
| meet 41:5 | 140:6,12 | missing 17:11 | 15:17 20:19 |
| 43:21 44:3,4,9 | microphone | misstate 45:6 | 26:24 28:13,18 |
| 44:23 | 208:22 | mistake 192:3 | 28:21,22 29:7 |
| meetings 12:11 | microscope | mistakenly | 29:7 33:18 |
| meets 167:5 | 214:17 | 60:23 | 37:9 38:13 |
| members | mid 209:23 | mixed 97:9 | 48:22 54:10,21 |
| 178:13 | middle 95:18 | mmandell 2:5 | 68:18 69:21 |
| memorial | 103:8 114:6 | moderate 55:19 | 70:14 75:10 |
| 40:15 | 124:22 125:8 | 56:1 | 76:9 77:3,18 |
| mental 176:16 | 132:12 133:1 | modify 8:24 | 79:19 80:23 |
| 176:19 177:14 | 139:3,23 161:7 | moment 110:19 | 81:10 82:10 |
| 177:21 | 164:8 166:3 | monday 157:22 | 91:20 93:3 |
| mention 93:17 | mild 55:13 | monitor 161:24 | 94:19 95:21 |
| 194:1 | milligrams | monitored | 106:12 113:23 |
| mentioned | 59:21 60:3,6 | 57:24 | 122:16 123:17 |
| 40:19 53:20 | 81:2,2 110:2 | monitoring | 123:18 124:19 |
| 54:9 65:20 | 186:13 | 57:20 | 126:2 131:4 |
| 67:5 80:15 | milwaukee 7:9 | month 58:19 | 132:2,3 135:6 |
| 87:22 93:11,14 | 37:3 | 105:4 | 135:7,21 136:9 |
| 98:9 106:5,6 | mind 16:5 | months 14:10 | 136:18,24 |
| 110:19 | 75:18 116:8 | 19:3 23:3,7,23 | 137:13 138:3 |
| mercer 28:22 | 128:9 165:20 | 25:1 26:8 | 138:18 142:2 |
| 29:11,18 | minimal 129:5 | 27:21 39:2,4 | 143:16 145:9 |
| met 11:16,24 | 145:15,18 | 58:9 68:16 | 146:22 150:5 |
| 48:24 | minute 9:7 | 103:3 132:21 | 153:22,23 |
| metastatic | 106:16 157:24 | moore's 181:6 | 154:12,17 |
| 166:12,24 | 160:12 202:21 | morning 212:5 | 155:3,9,13,19 |
| 171:24 | 211:15 | motrin 149:8 | 156:8 158:5,7 |
| methodology | minutes 66:19 | mounds 116:13 | 158:10,17,23 |
| 196:16 | 66:20 83:14 | mousser 3:12 | 160:23 161:1 |
| methods 54:18 | 114:9 130:4 | 3:22 4:3,6,8,10 | 164:5,18,19,22 |
| | 181:15 | 4:11,13,14,16 | 165:1,1 166:9 |

| 167:7 168:11 | 145:5 146:8,8 | nagesh 32:7 | 93:9 97:19 |
|----------------|----------------------|----------------------|----------------|
| 169:24 171:14 | 148:24 149:20 | name 6:2,22 | 129:16 157:24 |
| 171:15 172:5,7 | 149:20,24 | 7:4 11:22 30:9 | 160:11 164:19 |
| 173:2 174:9,21 | 152:1,10 168:4 | 30:16 31:15 | 183:7 186:20 |
| 175:5,20 176:5 | 170:3,18 171:8 | 89:13 95:7 | 186:20 193:8 |
| 178:1,13,20 | 171:20 172:13 | 118:8 181:4,8 | 195:17 |
| 180:20 181:10 | 172:17 174:3,8 | named 60:22 | needed 44:5 |
| 181:14 191:2 | 174:13,16 | 92:18 | needing 154:9 |
| 191:20 192:11 | 175:16 176:6 | names 54:20 | needs 44:2,16 |
| 193:4,21,24 | 177:19 178:7 | 169:12,13 | 53:11 57:16 |
| 195:20 196:1 | 179:14 180:4 | national 37:4,5 | 87:8 149:4 |
| 199:3 201:6 | 180:10 192:15 | nature 45:19 | negative 133:6 |
| 202:3,7 203:8 | 193:19 194:15 | 88:6 | negatively |
| 205:16,17,19 | 199:15,17 | nearing 45:10 | 183:22 185:17 |
| 206:19 208:4 | 200:8 204:3,10 | necessarily | neither 216:15 |
| 212:16 213:8 | 206:6 208:1,20 | 33:8 84:4 | 216:17 |
| mousser's 4:7 | 208:24 212:12 | 183:13 | nephrectomies |
| 12:22 18:22 | 213:4 | necessary | 195:11,11 |
| 24:3 29:24 | mouth 45:6 | 21:19 46:15 | 196:11 |
| 30:7,17 31:8 | move 72:9 | 58:10,11 84:19 | nephrectomiz |
| 31:17,22 68:20 | moving 113:15 | 130:24 180:24 | 83:11 |
| 69:4,20 71:8 | mueller 28:23 | 190:24 191:18 | nephrectomy |
| 72:3 75:1 | 29:7 181:2 | 195:12,22 | 11:9 33:17 |
| 78:19 81:7 | multidiscipli | 196:12,18 | 46:19 80:23 |
| 87:22 88:22 | 45:2 | 198:12 | 81:8 83:1,15 |
| 91:21 92:15 | multiple 92:17 | necessity | 83:24 85:9 |
| 93:1,20 94:15 | 92:18 142:23 | 193:12 | 87:11 88:9 |
| 95:7 100:13 | 194:10 196:10 | need 9:5 43:5 | 92:16 112:10 |
| 102:4 107:15 | musculoskele | 44:3,4 45:23 | 115:10 128:24 |
| 110:4 111:6 | 174:14 | 46:6 56:5,24 | 136:2,3 137:1 |
| 114:4,22 115:7 | n | 57:7,19,24 | 137:5 142:11 |
| 115:17 118:6,8 | n 2:1 3:1 | 70:15 74:16 | 142:22 143:12 |
| 120:10 125:15 | 11 2,1 J,1 | 75:15 76:3,14 | 156:7 167:3 |
| 126:11 140:12 | | 1 | |

| 192:8 193:5 | 101:10 103:4 | 122:15 123:17 | 127:5 148:8 |
|-----------------|------------------------|----------------------|-----------------|
| 196:5 212:12 | 135:24 171:11 | 132:2 135:5 | 151:18 199:18 |
| 212:17 | 203:14 205:23 | 137:21 138:1 | 201:13 204:11 |
| nephrologist | neurologist | 138:17 139:16 | 207:6,13,22 |
| 31:9,14,17 | 31:17 | 153:21 158:4 | 0 |
| 33:4 47:12,14 | never 194:3 | 160:22,23 | oath 7:18,22 |
| 47:19,20,22 | new 170:18,20 | 202:6 | 217:15 |
| 48:2 53:7 | newer 155:1 | noted 6:10 | object 9:14 |
| 67:19,23 68:5 | nicely 129:5 | notes 4:11,20 | 94:21 |
| 68:6,7,10 | night 174:17 | 108:8 137:4 | objection 14:21 |
| 89:24 107:15 | nine 25:20 | 178:1 180:22 | 18:24 20:8,21 |
| 107:18,18 | 26:10 | november | 25:23 28:2 |
| 114:23 132:9 | nocturia 80:6 | 94:16 121:12 | 30:13,22 31:11 |
| 135:17 142:7 | 174:16 | 123:16,21 | 33:6 39:14 |
| 148:13 188:13 | nodding 25:12 | 140:10,11 | 44:17 45:20 |
| 192:12 | non 89:24 | 153:21 | 50:8,21 51:5 |
| nephrologists | 183:16 | number 10:1 | 65:1 73:7 |
| 64:24,24 | normal 46:18 | 25:3 32:10 | 76:10 81:19 |
| 149:21 186:24 | 55:7 57:23 | 59:3 68:23 | 85:2,14 86:4 |
| 194:15 | 59:21 98:10 | 86:17 90:14 | 87:14 89:19 |
| nephrology | 99:14 108:21 | 98:16 112:15 | 90:4,10 94:24 |
| 68:16 81:3 | 108:22 146:2 | 139:4,7,10 | 98:3,24 99:7 |
| 132:8 135:8 | 151:14,16 | 159:19,23 | 103:18 104:16 |
| 137:7,13 | 152:23 212:13 | 161:17,20 | 111:9,17 115:1 |
| 153:21 192:2 | 212:17 213:1,2 | 171:6 183:2 | 115:24,24 |
| nephrosclero | 213:22 214:6 | 187:16 189:13 | 118:22 126:14 |
| 83:12,17 84:9 | 214:12,15,20 | 190:22 199:14 | 126:16 127:20 |
| 85:10 112:18 | normalize 87:3 | 213:12 214:14 | 128:5,18 |
| nephrosclerotic | normally 83:6 | numbered | 129:14,23 |
| 112:12 | north 1:1 189:3 | 124:19 161:1 | 137:19 143:7 |
| nephrotoxins | notary 217:24 | numbers 32:4 | 146:10 152:4 |
| 149:7 | note 4:6,9,14 | 58:22 63:16 | 152:17 165:6 |
| nephroureter | 4:15,17 109:13 | 95:5 97:8 | 165:15 167:17 |
| 79:22 81:23 | 112:21 113:22 | 116:7 126:23 | 100.10 107.17 |

Golkow Technologies, A Veritext Division Document 507-9 Filed 08/26/25 Page 256 of 281

| 167:23 168:7 | offer 49:9 | 72:16 73:3,9 | 135:19 136:16 |
|---------------------|-----------------------|----------------|----------------|
| 168:14 175:3 | 217:14 | 74:17,19,23,24 | 136:21,22 |
| 175:17 177:22 | offering 70:11 | 76:17 78:19 | 138:2 139:1,17 |
| 178:8,15,21 | office 10:4,11 | 79:9 80:12,17 | 139:21 140:15 |
| 179:3,9,15 | 17:6 21:13 | 80:19 81:15 | 140:17 141:12 |
| 180:5,12 187:3 | 22:14 33:16 | 82:18,22 84:2 | 144:5,5,13 |
| 192:17 193:14 | 146:4 167:20 | 84:23 85:7,7 | 145:7 146:14 |
| 194:18 195:3 | 192:20 198:7 | 91:15 93:19,22 | 146:20 147:17 |
| 196:19 197:6 | oftentimes | 93:23 94:5,7 | 148:12 150:10 |
| 197:16 198:19 | 23:18 | 95:7,13 96:4 | 150:11,12 |
| 204:14 | oh 18:15 28:7 | 97:11,16 99:23 | 151:4,9,11 |
| obstructed | 164:24 199:6 | 100:3,6,21 | 153:3,20 154:1 |
| 174:10 | 209:13 | 101:20,22 | 154:7,22 155:8 |
| obstructive | okay 7:11,13 | 102:10,12,23 | 155:11,11 |
| 80:3 180:10 | 8:5,11,15,16,20 | 103:24 104:2 | 156:20 157:7,9 |
| obtain 52:19 | 8:21 9:2,11 | 106:15,24 | 157:10 158:2,8 |
| obtained | 10:14 11:1,16 | 107:12 108:1,5 | 158:19 159:4 |
| 157:21 | 11:23 13:11 | 109:10,16 | 160:6,21 161:2 |
| obvious 39:15 | 15:2,13 17:9 | 112:1,20 | 161:3,5 162:4 |
| obviously | 17:15,18,21 | 113:10,19,19 | 162:22 163:1,2 |
| 114:13 200:4 | 18:12 20:2,20 | 113:21 115:16 | 163:24 164:2,4 |
| occasional | 21:10 22:23 | 116:11,16,18 | 164:7 166:2 |
| 46:16 | 24:6,20 25:20 | 117:5,16,18 | 170:1,5,15 |
| occupational | 26:22 27:9,9 | 119:24 120:5 | 172:4 173:15 |
| 48:15 | 27:16,17 28:11 | 120:16,17 | 173:19,19 |
| occurred | 30:11 31:24 | 121:8,23,23 | 175:1,12,23 |
| 167:11 181:22 | 33:11 34:17 | 122:1,14,20 | 176:3 177:9 |
| occurs 183:14 | 37:6 38:12,19 | 123:15 124:6 | 179:23 181:12 |
| october 101:7 | 39:3 40:1 45:8 | 124:17 125:22 | 181:19 182:4 |
| 101:10 103:14 | 46:20 51:12 | 126:4 129:24 | 182:16,16 |
| 115:18 135:24 | 52:17 54:23 | 130:21 131:3 | 185:1 186:14 |
| 179:21 203:13 | 58:11 62:2 | 131:14,14 | 189:23 190:3,6 |
| 205:24 | 66:17 69:15 | 132:1,7 133:1 | 190:9,20,22 |
| | 71:6,14 72:12 | 134:15 135:4 | 193:18 199:1 |

[okay - page] Page 38

| 200:3,10,16 | 69:11 73:6 | opioids 180:4 | p |
|------------------------|----------------|------------------------|-----------------------|
| 201:12,20,21 | 76:13 77:4 | opportunity | p 2:1,1 4:19 |
| 202:20,23 | 84:12,14 86:8 | 172:8,11,15 | 28:22 |
| 204:12,18,24 | 88:17 89:14 | 173:12 | p.a. 36:23 |
| 205:18 206:2 | 91:21 92:4 | opposed 128:16 | p.m. 190:11,13 |
| 206:10,15 | 93:5,9 97:24 | options 46:4 | 190:15 211:22 |
| 207:7,19 | 108:12 111:5 | order 21:4 59:4 | 211:24 212:2 |
| 208:16,19 | 111:12 114:21 | 167:5 191:6 | 215:7,10 |
| 210:12,21 | 129:21 131:1 | ordered 109:5 | p.o. 2:9 |
| 211:14 214:23 | 145:11,14 | ordinarily | page 3:2 7:17 |
| old 35:7 127:18 | 146:7,12 | 197:14 | 28:14 32:2 |
| 135:21 150:12 | 156:20 157:3 | organ 41:4,5,20 | 40:1 69:16,20 |
| 182:2 | 164:18 168:2,4 | 42:3,8 105:17 | 69:23 70:22 |
| older 141:15 | 169:11 170:2,3 | 214:3 | 71:7,7,14,24 |
| once 41:6 | 172:13,17 | original 166:10 | 72:13,17,24,24 |
| oncologist | 173:2,15,17 | 171:22 | 73:4,15,15 |
| 47:10 166:17 | 174:2 177:13 | outcome 34:8 | 74:6,8,11 75:3 |
| ones 79:16 | 181:6 194:12 | 216:20 | 76:19,20 78:21 |
| 94:17 119:21 | 200:14 210:17 | outcomes | 80:18,19,19 |
| 139:18 175:20 | 212:14,19,22 | 185:14,16 | 82:17 95:4,18 |
| 210:21 | 212:24 | outlook 33:17 | 95:24 96:5,23 |
| ongoing 173:23 | opinions 28:18 | outset 97:16 | 100:9,12 101:6 |
| 191:12,23 | 31:18 33:5 | outside 58:21 | 101:13,17 |
| open 190:19 | 46:24 69:18 | 203:3 | 102:2,6,17 |
| operating | 70:5,11,14,16 | outstanding | 103:1,7,8 |
| 186:9 | 71:3,10,20 | 149:11 200:13 | 108:1,7,6 |
| operations 41:8 | 72:19,20 73:19 | overactive 80:6 | 109:10,11,16 |
| operative 11:7 | 73:20 74:3,9 | overall 171:8 | 109:18,23,24 |
| opine 148:14 | 75:9,24 76:8 | 175:13 | 110:17 114:6 |
| 192:15 193:11 | 76:24 77:9,12 | oversee 198:7 | 116:17 114:0 |
| opined 108:15 | 77:18,21 78:14 | overseeing | 117:13 120:6,9 |
| 198:10 | 78:15 80:4,7 | 40:17,19 | 120:19 121:1,8 |
| opinion 10:3 | 80:10 85:1 | own 179:8 | 121:15 122:22 |
| 15:8 21:5 69:7 | 171:3 211:7 | | 121.13 122.22 |

| 123:19,20 | pancreas 42:21 | particles | 50:11,13 61:8 |
|-------------------|--------------------|------------------------|------------------|
| 124:23 125:7,9 | pancreatic 43:2 | 184:23 | 62:8,20 63:2 |
| 132:4,12,14 | papers 113:7 | particular | 64:16 65:12 |
| 133:19,21,24 | papillary | 67:15 | 67:8,9,16,17 |
| 135:9,15,19 | 168:12 | particularly | 68:3 97:18 |
| 136:17,20 | para 166:8 | 24:10 41:7 | 99:5 186:11 |
| 139:1,4,21,24 | paragraph | 43:10 105:16 | 187:6 |
| 140:18,22 | 80:17,18,21 | 154:11 | patient's 21:20 |
| 141:9 145:2,7 | 81:6 114:16 | parties 11:6 | 58:23 59:9 |
| 145:22 146:18 | 132:19 133:2 | 216:17 | 61:14 |
| 147:2,10 | 140:4 159:8 | parts 49:20 | patients 40:20 |
| 148:11 150:8 | 161:8 163:4 | 129:20 | 41:3,15,19 |
| 151:6 155:12 | 164:8 166:3 | party's 198:10 | 42:2 43:3,4,9 |
| 155:13,16 | 170:17 172:4 | passages | 44:9 45:9,12 |
| 159:5,15,17 | 176:4 182:5 | 149:19 | 45:23 46:1,11 |
| 161:7,15 163:2 | paragraphs | passing 32:24 | 46:16 48:1 |
| 164:6,9,10 | 82:17 173:18 | past 17:17 23:7 | 49:10,22 51:3 |
| 165:24 171:14 | pardon 97:21 | 51:17 61:14 | 51:16,21 53:9 |
| 172:5 173:20 | parentheses | 78:24 79:5,6 | 56:5 57:3 |
| 176:4 182:4 | 110:2 | 192:16 195:21 | 58:15 62:4 |
| 190:20 191:4 | parents 178:7 | 196:2,7 198:23 | 85:23 86:24 |
| 193:19,19 | park 2:3 | 200:8 | 91:14 105:15 |
| 195:19 199:12 | part 10:2,9 | path 50:14 84:8 | 137:5 155:24 |
| 208:21 209:2 | 18:18 25:10 | pathology 11:7 | 164:15 168:21 |
| 218:2,5,8,11,14 | 52:2,3 53:19 | 83:11,16 84:9 | 176:19 177:16 |
| 218:17,20 | 54:10 62:13 | 85:9 142:8 | 178:3 186:21 |
| 219:2,5,8,11,14 | 80:21 85:4,18 | 213:16 | 188:4,5,8,10 |
| 219:17,20 | 91:13 92:7 | pathophysiol | 197:21 198:1,5 |
| pages 4:18 | 93:2,15 127:23 | 166:23 | payment 34:8 |
| 20:19 27:24 | 128:8 131:3 | patient 21:17 | pc 36:20 |
| 38:16 74:1 | 143:12 170:19 | 21:18 24:8 | pediatric 40:17 |
| 201:17 206:10 | 172:12,16 | 41:23 42:1 | peek 72:5 |
| pain 79:2 | 174:15,19 | 43:22,23 44:2 | penalties 7:23 |
| 174:14 | 198:17 | 44:4,16 45:18 | |

[penalty - position]

| | | | T |
|------------------------|----------------------|-----------------------|------------------------|
| penalty 217:6,8 | persistently | picture 93:16 | 75:4 82:13 |
| people 56:23 | 58:7 | piece 128:8 | 84:7 87:18,21 |
| 57:24 90:6,17 | person 12:11 | pieces 11:4 | 88:4,20 98:20 |
| 90:23,24 99:9 | 13:4 21:13 | 18:17 75:14,16 | 100:24 101:20 |
| 166:19 213:20 | 58:7 65:24 | 87:1 113:15 | 103:24 121:8 |
| 213:21 214:9 | personal | 131:15 | 122:17 125:17 |
| 214:14,22 | 177:19 211:12 | place 70:17 | 139:1 145:3 |
| percent 34:13 | personally | 72:14 216:12 | 146:19 147:2 |
| 42:18 43:20 | 63:10 | placed 129:20 | 158:1 160:12 |
| 90:23 150:16 | persons 12:10 | 154:17 156:9 | 162:8 170:13 |
| 201:7 | perspective | places 73:24 | 192:22 206:13 |
| percentage | 148:7 | plaintiff 3:12 | 207:4 |
| 27:12,13 34:11 | pertinent 10:19 | 3:16 16:8 | pllc 36:17 |
| 42:14 43:17 | 11:11 79:17 | 28:21 32:6 | plus 27:23 |
| perfect 66:21 | peterson 5:11 | 36:5 | 213:10 |
| perfectly 8:10 | 206:3 | plaintiffs 2:2 | po 101:11 |
| perform 14:15 | pharmacology | 3:10,13 11:9 | podocytes 83:9 |
| 40:22 42:20 | 48:9 | 12:18 13:20,21 | point 9:8 19:21 |
| 46:3 48:3 | phase 3:10,14 | 15:6 28:16 | 24:17 51:13 |
| performing | phone 12:11 | plan 24:19 | 56:23 75:17,20 |
| 41:8 | physically | 133:20 139:3 | 75:24 76:7 |
| period 56:24 | 48:21 | 139:10 154:3 | 77:12 79:6 |
| 58:20 119:19 | physician | planned 10:5 | 103:4 118:19 |
| 126:3 214:5 | 90:13 | planning 77:11 | 130:1 133:10 |
| peripheral | physicians | play 69:19,24 | 152:11 163:9 |
| 83:21 | 12:22 47:23 | 71:11,21 73:6 | 165:18 169:13 |
| peritoneal | 67:19,20 92:18 | 78:13 | points 91:10 |
| 43:12 191:14 | physiologic | played 69:13 | poor 166:11 |
| 196:13 | 189:7 | pleading 165:2 | 186:18 |
| perjury 7:23 | physiology | please 6:13,16 | portion 144:23 |
| 217:6,8 | 105:20 | 7:4,5,7 8:8,17 | portions 31:19 |
| permanent | picked 129:11 | 9:1,7 22:8,9 | position 59:13 |
| 193:22 194:1,5 | picking 70:23 | 41:22 45:6 | 148:14 |
| 195:7 | | 50:3 66:3 72:5 | |

| positive 186:4 | 64:13 65:5,8 | preparation | pretty 14:9,11 |
|----------------------|-----------------------|----------------|-----------------------|
| 186:5 | 85:22 86:23 | 10:4,7 22:15 | 52:24 53:1 |
| possess 46:23 | 88:14 167:3 | 25:6 | 131:13 151:13 |
| possession | 197:4,11 | preparations | 151:14 |
| 138:15 153:19 | 198:17 | 24:14 | prevent 23:18 |
| 201:11 | practicing | prepare 9:23 | previous 159:5 |
| possibility | 42:15 | 11:24 12:14,23 | 161:3,6 |
| 182:21 | pre 41:14 43:4 | 17:18,19 | previously 67:5 |
| possible 175:1 | 44:10 68:8,10 | prepared 17:20 | 84:3 96:14 |
| post 33:4,17 | preclinical | preparing | 115:22 136:2 |
| 41:9,10,12,14 | 109:6 | 11:20 | 172:18 |
| 43:5 68:9,13 | predate 206:24 | prescribed | primarily |
| 68:14,15 79:1 | predates | 144:10 158:23 | 21:17 47:21 |
| 79:2 115:10,10 | 156:24 | 163:21 | 48:1 55:1 |
| 135:22,23 | prediabetes | present 2:15 | 68:16 176:21 |
| 137:1 187:5,6 | 80:12 189:16 | 69:8 93:21 | primary 42:8 |
| 187:11 188:13 | 189:21 | 163:4 | 68:10 90:13 |
| 191:24 196:5 | predict 62:23 | presentation | 183:16 |
| postman 36:10 | predicting | 159:12 | printed 38:17 |
| postsurgery | 61:11 | preserved | prior 14:16 |
| 42:7 203:18 | predicts 61:8 | 114:18 147:22 | 36:6,9,12,16,19 |
| postsurgical | 62:19 63:1 | pressure | 36:22 42:3 |
| 176:6 196:11 | predominantly | 108:17 109:1,2 | 79:7,24 120:21 |
| potential 89:12 | 210:1,3 | 127:10 149:6 | 136:3 151:1 |
| 127:9 183:14 | preemptive | 151:22 152:13 | 158:24 171:9 |
| potentially | 46:3 | 152:22 156:3,6 | 198:9 216:5 |
| 45:14 46:6 | preexisted | 163:5 | privileged |
| 61:17,19 64:3 | 156:22 | pressures | 14:23 |
| 112:4 167:3 | preface 94:24 | 160:2 162:1 | pro 78:1 |
| 192:7 | 116:1 | presumably | 141:21,22 |
| practice 13:24 | prefatory | 14:6 25:10 | probably 7:15 |
| 23:12,13 43:18 | 94:23 | 35:18 | 25:18,19 26:15 |
| 49:9,15 51:10 | prepara 78:1 | presurgery | 42:18 108:16 |
| 53:23 57:21 | | 42:7 | 187:17 |

[problem - put] Page 42

| | 110171101 | 01.1.05.1.1 | |
|-----------------------|-----------------------|----------------|-----------------------|
| problem 97:14 | 148:15 149:1 | 81:1 82:6,16 | providers |
| 147:16 | 149:15,24 | 131:7,12 | 142:14 184:17 |
| problems 46:17 | 166:11 168:6 | 134:13 140:6 | providing 14:1 |
| 108:23 142:24 | 171:9,21 | 141:22 143:5 | 17:8 46:24 |
| 158:16 | 183:22 188:14 | 148:2,4 214:2 | 52:12 69:7,11 |
| procedure 48:3 | 210:18 | proteins 61:3 | 70:5 71:2,12 |
| procedures | program | proteinuria | 72:19 73:20 |
| 43:6,8,19 | 189:13 | 60:9,21 61:2,2 | 74:2,8 200:14 |
| 53:21 | programs | 81:1 82:4,15 | psychiatrist |
| proceed 6:16 | 40:18 188:22 | 83:23 131:7,11 | 176:14 |
| process 51:13 | progress 4:6,9 | 133:6,11 136:3 | psychological |
| 170:20 | 4:11,14,15,17 | 136:10,13 | 173:22 176:8 |
| produced | 4:20 61:9 | 137:23 139:11 | 180:21 |
| 24:22 157:22 | 64:17 | 139:15 141:4 | psychologist |
| profession | progressing | 141:13,16,22 | 174:7 176:2,11 |
| 23:18 | 90:3 152:2 | 142:9,14,15 | 177:8 180:23 |
| professional | progression | 143:4,5 | 180:23 181:1 |
| 1:17 39:18 | 50:19 61:11,18 | provide 15:8 | 181:10 |
| 176:16 177:20 | 62:10 63:16 | 21:4 49:22 | psychology |
| 179:24 216:4 | 65:15 | 51:9,14,20 | 81:3 |
| professions | progressive | 89:13 107:22 | psyd 28:23 |
| 169:12 | 99:12 | 210:16 | public 217:24 |
| professor 42:11 | pronouncing | provided 13:13 | publications |
| proffered | 135:14 | 15:4 18:6 24:8 | 28:17 39:10 |
| 155:2 | properly 8:4 | 24:9,10 131:1 | purpose 64:20 |
| profile 124:21 | protect 143:16 | 209:12 210:12 | purposefully |
| prognosis 50:1 | 143:24 144:1,3 | 213:8 | 82:19 |
| 50:5,5 51:9,11 | 144:11 149:9 | providence 2:4 | purposes 144:2 |
| 51:14,21 59:7 | protected | provider | put 19:4 20:12 |
| 61:23 62:11 | 149:5 | 115:12 132:15 | 33:19 43:11 |
| 64:6 65:15 | protective | 136:13 138:22 | 45:1,5 51:16 |
| 84:20 86:3 | 144:9 | 139:24 140:11 | 57:6 78:5,17 |
| 91:7 92:6,6 | protein 52:3 | 160:1 | 79:23 80:14 |
| 93:1 107:23 | 60:10,16,18 | | 84:18 88:14 |

[put - recall] Page 43

| | | | I . |
|-----------------------|---------------------------------|------------------------|---------------------|
| 93:4 106:15 | quick 14:10 | 111:11 136:6 | 219:4,7,10,13 |
| 113:11 117:16 | 69:16 72:5 | 141:7 145:20 | 219:16,19,22 |
| 154:10,20 | 76:18 181:16 | 148:9 149:16 | reasonable |
| 165:22 | 190:4 211:19 | 150:23 162:23 | 77:21 81:10 |
| puts 83:7 | quickly 14:11 | 166:14 170:22 | 190:24 191:18 |
| putting 128:22 | 16:6 72:10 | 173:14 177:24 | 193:12 195:22 |
| q | quite 110:9 | 182:10 217:9 | 196:18 198:11 |
| quadruple | 111:16 147:8 | 217:10 | 212:14,19,23 |
| 156:13 161:12 | 148:7 | reader 89:17 | reasonableness |
| quality 183:3 | quoting 177:10 | readily 213:11 | 193:12 |
| 186:10,14 | r | reads 78:24 | reasons 82:9 |
| question 8:8,13 | r 2:1 | 81:6 164:14 | 99:11 163:21 |
| 8:18,20 9:9,10 | radiotracer | ready 158:1 | 175:1,16,19 |
| 9:16 10:12 | 53:15 | 160:19 162:9 | reassuring |
| 20:10 21:14 | range 199:21 | 170:14 201:19 | 110:14 212:13 |
| 36:4 66:10 | range 199.21 ranges 200:6 | 202:22 | 212:17 |
| 87:20 94:23 | 205:15 | real 69:16 | recall 10:23 |
| 98:13 99:21 | | 76:18 211:19 | 11:1,15 13:7 |
| | rapidly 52:24 rate 34:6 35:9 | reality 166:4 | 14:3,9 18:10 |
| 108:5,12 110:10,12 | 51:24 | really 41:9 | 22:19 25:13 |
| 142:19 143:2 | | 47:23 49:13 | 27:12 29:13,14 |
| | rather 111:2 | 51:15 52:22 | 29:17,23 31:4 |
| 145:9,13 | ratio 59:15,19 | 67:20 87:5,12 | 35:24 78:3 |
| 148:23 167:21 | 59:21 81:1 | 90:13 146:23 | 92:13 107:9,11 |
| 167:22 211:2,6 | 82:6,16 131:7 131:12 134:10 | 146:23 166:23 | 119:16,21 |
| 212:7,18 214:9 | | 213:9 | 124:16 131:23 |
| questions 8:5 | 134:13 141:23 | realtime 1:18 | 144:14,17 |
| 9:14 32:3 | 142:10 143:5 | reason 9:6,6,19 | 150:6 169:8 |
| 33:12,16 46:21 | rationale | 79:20 86:17 | 174:19,24 |
| 70:2,8 75:13 | 127:11 | 111:22 112:9 | 181:9 187:18 |
| 76:18 94:24 | rationales | 141:19 167:15 | 198:13,16 |
| 201:18 212:4 | 84:24 86:1 | 175:6 218:4,7 | 199:24 202:13 |
| 212:11 215:2,4 | read 92:9 109:8 | 218:10,13,16 | 210:21 211:7,9 |
| | 110:15 111:3 | 218:19,22 | 210.21 211.7,9 |
| | | 210,17,22 | |

| | | | 1 |
|----------------------|-----------------|----------------|-----------------------|
| receive 195:17 | 26:16,20 27:10 | 79:7,10 89:10 | 195:16 |
| received 17:5 | 27:13,18,20 | 89:12 91:17,19 | reduction |
| 33:24 34:1 | 28:9,14 35:19 | 92:13,16 94:1 | 55:13,19 56:2 |
| 181:19 183:1 | 38:8,10,15 | 94:18 101:4 | 56:11 |
| 186:11,15 | 44:12,24 66:22 | 103:19,20 | refer 33:14 |
| 190:23 191:17 | 67:2 70:13 | 104:15,18,22 | 61:3 65:21 |
| 196:21 | 94:14,18,22 | 105:1 118:22 | 94:4 |
| receiving | 106:14 112:13 | 118:24 119:7 | reference |
| 110:21 190:24 | 118:5 122:11 | 125:18 126:1 | 150:21 190:21 |
| 192:6 | 122:14 123:12 | 130:16 131:24 | 213:2 |
| recent 63:8 | 123:16 124:15 | 135:2 141:20 | referenced |
| 94:17 128:3,17 | 124:18 130:6 | 155:10 157:20 | 53:22 |
| 141:20 143:3 | 130:10 132:1 | 157:20 174:4,6 | referencing |
| 147:20 185:4 | 133:3,12,15,16 | 176:1,6 177:15 | 61:3,4 92:14 |
| recently 34:16 | 133:17 135:1,4 | 177:24 183:19 | 92:15 133:15 |
| recess 66:24 | 135:20 138:13 | 185:4 187:12 | referred 189:16 |
| 130:8 190:12 | 153:16,20 | 193:2,9 200:5 | referring 41:3 |
| 211:23 | 157:1 158:3 | 200:12 201:2,5 | 79:6 191:7,21 |
| recipient 188:1 | 160:11,22 | 201:7,24 204:3 | 194:2 196:2,8 |
| recitation | 162:8 163:3 | 204:16 206:3 | refers 60:9,12 |
| 173:16 | 173:3 177:4,5 | 206:23 207:9 | 161:12 |
| recognize | 184:11 190:10 | 207:22 208:1,5 | reflected 140:1 |
| 17:15 38:21 | 190:14 201:4 | 208:7 | reflection |
| recognizing | 204:20 211:21 | recur 166:24 | 111:1 148:2 |
| 86:24 | 212:1 215:6 | recurrence | reflections |
| recommendat | records 4:22 | 166:9 171:16 | 63:24 |
| 137:11 | 5:3,5,9,11 11:2 | 175:8 184:14 | reflective 52:22 |
| recommended | 15:5 20:17,19 | 185:5 | 61:17 63:19 |
| 109:4 160:4 | 20:24 21:8,18 | redraft 167:22 | reflects 87:15 |
| record 6:1,11 | 21:21 24:9 | reduce 152:2 | regarding |
| 7:5 8:2,3 16:2 | 25:22 27:24 | 154:8,23 | 13:21 42:8 |
| 17:4 19:10 | 31:22 33:9 | reduced 111:7 | 50:19 73:21 |
| 21:18 22:8,24 | 54:17,20 72:9 | 136:1 137:1 | 74:3 75:9 |
| 23:24 26:11,13 | 75:22 78:16 | 151:22 192:7 | 76:24 77:8,12 |

| 77:18 92:24 | rely 18:14 21:9 | 54:11 56:19 | report 3:12,15 |
|---------------------|----------------------|---------------------|-----------------------|
| 178:7,19 179:1 | 186:24 | 61:12,20 62:10 | 3:22,23 5:8 |
| 179:7,13 180:3 | relying 85:11 | 64:3 65:20 | 25:17 33:19,21 |
| 180:9 | 91:17 | 68:11 73:5 | 33:22 37:8,17 |
| regardless | remainder | 81:11,17 82:10 | 38:3,3,13 54:8 |
| 214:12 | 26:16,20 | 84:5,14 85:12 | 54:9,14 68:20 |
| regards 193:24 | remaining 25:7 | 87:13,24 88:23 | 69:16,18,21 |
| registered 1:17 | 26:10 81:10 | 90:3 93:9 98:1 | 72:23 73:16 |
| 216:3 | 83:3,4,7,9 | 98:15 114:17 | 75:1,3,8 76:6,9 |
| regular 89:16 | 112:11 127:13 | 114:18 131:5 | 76:17,20,23 |
| regulate 155:24 | 128:24 137:9 | 136:1 137:1 | 78:20,21 80:15 |
| regulating | 213:13 | 144:9 145:16 | 83:16 84:7,9 |
| 156:3,5 | remains 81:2 | 151:23 152:3 | 84:10,11,16,22 |
| rejection 184:1 | 132:21 140:1,7 | 154:9,24 | 85:9 86:2 |
| 184:4,10 185:5 | 145:24 171:9 | 164:19 165:3 | 87:11,15,18 |
| 185:9,17,19,21 | remember | 165:12 167:1 | 88:5,21 89:18 |
| relate 74:16 | 11:22,23 13:9 | 195:17 196:10 | 92:10 93:17 |
| related 149:1 | 18:16,17 19:2 | render 43:22 | 127:2,4,13 |
| 206:7 | 21:1,22 30:16 | rendered 23:2 | 128:16 129:10 |
| relates 1:5 | 31:6 33:1 | rendering | 129:12 130:17 |
| relationship | 54:19 96:16 | 77:17 | 130:22 131:2 |
| 178:7 179:8 | 122:12 135:3 | repeat 54:3 | 141:21 142:1 |
| relative 216:16 | 143:19 144:6 | rephrase 8:11 | 155:8,13 164:3 |
| 216:18 | 153:17 181:7 | 39:14 | 166:1 167:13 |
| relevant 10:21 | 181:11 187:16 | replacement | 167:16 169:6 |
| 31:18 33:4 | 188:16 201:9 | 54:11 65:20 | 170:7 171:13 |
| 80:4,7,9 92:2,5 | 208:8,14 210:9 | 81:11,17 82:11 | 172:5,6 176:5 |
| 92:24 | 211:5 | 84:5,14 85:12 | 181:10,13 |
| reliable 54:13 | remove 214:16 | 87:13 88:1,23 | 182:5 193:18 |
| 54:18 | removed 83:2 | 93:10 98:1 | 193:19,22 |
| relied 31:21 | 83:17 86:13,18 | 131:5 151:23 | 208:20 213:16 |
| 33:8 52:17 | 185:24 213:21 | 154:9,24 | reporter 1:17 |
| 115:22 | renal 45:10,14 | 164:19 165:4 | 1:18,18 6:12 |
| | 45:16 46:5 | 165:12 195:17 | 8:1 16:1,3 |

| 216:4,5,24 | requirement | resulting 90:20 | 29:10 32:21 |
|-----------------------|------------------------|----------------------|----------------|
| reporter's | 50:16 | results 4:3,7,12 | 35:7,15,16,19 |
| 216:1 | requires 58:7 | 45:18 57:23 | 38:1,16 44:12 |
| reports 11:7,8 | 77:4 | 59:1 62:5 63:7 | 44:24 51:19 |
| 25:11,14 37:7 | requiring | 63:21,21 64:7 | 54:16 75:22,22 |
| 38:1,4,4 65:21 | 88:23 151:23 | 92:21 94:15 | 75:23 77:24 |
| 68:19 77:16 | 154:24 | 95:10 97:17,19 | 78:15,16 89:10 |
| 78:2 88:15 | reserving 76:2 | 102:13 108:8 | 89:12 116:7 |
| 171:3 190:17 | residency 40:4 | 115:17,20 | 125:24 157:24 |
| 195:19 | residents 42:17 | 116:20 117:6 | 160:12 162:9 |
| represent 7:1 | resides 189:3 | 118:6,15 | 169:6 170:13 |
| 20:14 125:24 | resolved 133:5 | 119:13,17 | 171:1 176:5 |
| 126:10 169:22 | 136:4,13 | 120:18,22 | 197:5,24 201:1 |
| 205:14 | 137:24 141:5 | 121:12 122:23 | 202:21 209:22 |
| representation | 141:22 148:5 | 124:2 126:2 | reviewed 10:1 |
| 39:6 | respect 3:11,14 | 127:19 128:3 | 10:3,13,18 |
| represents 55:7 | respects 156:2 | 129:12 130:14 | 11:2,5,8,12 |
| 55:13,19 56:1 | respond 187:7 | 130:14,23 | 18:13,16,21 |
| 56:11,17 | response 83:3 | 143:3 192:18 | 19:3 20:5 21:2 |
| request 24:21 | 93:13 | retained 14:4 | 21:3 24:11 |
| requests | responses 8:5 | 14:12,17 | 29:6,14,15 |
| 198:22 | 72:17 | retainer 13:19 | 31:5 32:5,15 |
| require 54:11 | responsibilities | retire 164:23 | 78:7 79:10 |
| 56:21 65:24 | 23:17 | 165:3 | 94:13 107:9 |
| 66:7,12 81:11 | responsible | retired 165:14 | 109:24 187:13 |
| 81:17 82:10 | 41:7 197:14 | 179:21 | 196:22 199:16 |
| 84:5 85:12 | rest 207:18 | returns 57:22 | 201:11 211:1 |
| 87:13,24 98:1 | restate 141:14 | review 10:7 | reviewing 16:5 |
| 131:5 137:7 | result 58:3 59:2 | 15:8 20:23 | 18:10 25:9,21 |
| 176:7 180:20 | 68:11 75:13 | 21:9,22 22:8 | 144:14 181:9 |
| 210:18 | 129:6 | 25:7 26:11,12 | 193:9 197:14 |
| required 165:3 | resulted 62:6 | 26:13,16,20 | 206:14 |
| 184:23 | 173:22 | 27:10,13,14,19 | rhode 2:4 |
| | | 27:20 28:9 | |

[richard - says] Page 47

| richard 28:22 | 96:6 98:18 | 166:8 171:4,6 | roc 32:8 |
|-----------------------|-----------------|----------------------|-----------------------|
| 29:11 | 101:7,10,14,18 | 176:3 181:23 | rockwood 4:19 |
| right 13:12,17 | 102:20,22 | 181:24 182:8 | 28:22 29:11,20 |
| 13:22 17:13 | 103:5,6,9,12,17 | 182:19,23 | 29:24 30:6 |
| 18:23 20:7 | 104:7,14,24 | 183:9,12,22 | 114:1,7,12,16 |
| 23:4,7 25:11 | 106:8,13 | 184:18,21 | 115:11 145:5 |
| 25:22 26:1,2 | 109:21 110:6 | 185:18 187:17 | 145:23 |
| 27:5,7,21 28:1 | 113:9 114:19 | 187:22 191:2 | rockwood's |
| 28:18 29:1,8 | 115:14 116:9 | 193:22 195:23 | 144:15,23 |
| 30:12 31:5 | 116:23 117:2 | 199:8,19 | 146:7 |
| 32:16 33:21 | 117:14,17,20 | 200:10 202:14 | roger 181:5 |
| 40:2,7,10 | 118:21 119:11 | 203:2,10,14,21 | role 40:12 |
| 41:13 42:12 | 119:23 120:23 | 205:24 206:4 | 69:12 78:13 |
| 45:11 47:2,4,6 | 120:24 121:17 | 206:21 207:1 | 89:7 192:24 |
| 47:8,10,12,15 | 123:2 125:12 | 207:24 208:17 | 193:9 |
| 48:7,13,19 | 125:13 129:13 | 209:3 212:3,22 | roles 155:23 |
| 51:4 52:1,7 | 130:2 131:8 | rise 80:23 | rotate 42:17 |
| 54:2,5 55:2,5 | 132:16,20,23 | rises 129:3 | routine 124:21 |
| 55:11,17,23 | 133:7 134:7,10 | risk 64:10,16 | 160:3 |
| 56:2,6,9,15,22 | 134:13 135:17 | 69:22 70:1,6 | routinely |
| 57:8 59:16,18 | 136:10,14 | 70:11 71:3 | 197:18,19 |
| 59:23,24 60:4 | 137:2,4,9,10,18 | 73:5 79:18 | row 2:3 |
| 60:7,10,13,16 | 137:24 138:20 | 88:23 89:3 | rules 7:14 |
| 61:5 62:12,21 | 138:21,23 | 90:2 98:14 | S |
| 63:3 65:17 | 139:5,8,9,12,22 | 99:12 145:15 | s 2:1 3:8 4:1 5:1 |
| 66:2,8,13 67:8 | 140:2,8 143:22 | 150:4,15,19 | save 217:11 |
| 72:14 73:6,17 | 146:5 147:8 | 151:23 152:2 | saw 54:21,22 |
| 74:14 75:6,21 | 150:14 154:15 | 154:8,23 | 106:14 148:1 |
| 77:19 79:3 | 156:22 158:10 | 155:14,18,19 | 184:11 185:3 |
| 80:22 81:4,13 | 159:2,13,23 | 155:22 183:11 | 201:21 |
| 81:24 82:2,4,7 | 160:4 161:5,18 | 185:8 195:13 | saying 214:21 |
| 82:22 88:2 | 161:21,22 | risks 90:19 | says 26:23 |
| 90:23 93:17 | 162:20 163:7 | 192:4 | 28:15,20 29:2 |
| 95:8,11,20,22 | 164:9,16 165:8 | | , |

Page 48 [says - session]

| | I | I | T |
|-----------------------|----------------|-----------------|-----------------------|
| 32:10 71:15 | secondarily | 132:5,10,15,17 | sentence 78:23 |
| 81:14 95:10 | 55:1 | 133:3,20 135:8 | 79:23 80:2 |
| 109:19 125:1 | secondary | 135:11,19 | 88:16 132:18 |
| 132:20 133:5,9 | 112:10 142:21 | 139:2 140:3 | 133:8 159:9 |
| 134:4 137:10 | 195:10 | 146:21,22,24 | 161:8 164:10 |
| 137:15 140:9 | sections 69:17 | 151:18 154:3,5 | 166:8 170:17 |
| 146:6 147:9 | 73:9 | 158:10,19,22 | 172:12,17 |
| 148:21 151:20 | see 21:5 27:1 | 159:6,16 | 173:20 176:4 |
| 154:3 161:23 | 34:2 40:20 | 164:12 166:5 | sentences 81:15 |
| 162:3,20 166:8 | 41:15,19 43:3 | 167:2 170:24 | 82:19 |
| 173:9 180:24 | 43:4 45:23,24 | 173:2 178:2 | sentiment |
| 199:17 | 46:11 51:4 | 186:12 200:16 | 149:23 |
| schedule 3:21 | 57:3,13 80:1 | 203:3,7 208:21 | separate 165:2 |
| 34:14,18 35:5 | 81:16 84:7 | 214:18 | 198:4 |
| 172:8,22 173:3 | 95:17,24 96:21 | seeing 51:21 | september |
| 173:12 | 100:10,15,19 | 53:10 56:5 | 100:10 117:6 |
| schedules | 100:20 101:6 | seem 199:22 | 203:9 205:20 |
| 34:15 | 101:15,23 | seems 148:5 | serious 149:12 |
| science 49:17 | 102:3,8,14,18 | 165:8 | serum 80:24 |
| 50:6,7 | 102:24 104:5 | seen 17:17 22:9 | 81:22 82:14 |
| sclerosis 83:9 | 104:11,12 | 101:3 112:12 | 83:22 91:16 |
| scope 68:21 | 105:21,23 | 118:20,20 | 93:14,20 114:7 |
| screen 6:5 | 107:2 108:10 | 119:10 122:11 | 139:7 140:1 |
| second 17:5,12 | 109:11,14 | 123:11 124:15 | served 35:21 |
| 78:23 133:2,8 | 113:24 114:2,6 | 126:2 131:22 | 198:9 209:5,8 |
| 133:8,23,23 | 114:10 116:19 | 134:24 138:12 | 209:18,19 |
| 134:4 135:15 | 117:7,11,22 | 153:15 157:20 | service 40:16 |
| 139:7 147:15 | 118:8,11,14,18 | 157:23 192:12 | 42:18 162:20 |
| 159:8 161:15 | 120:6,19 121:6 | 201:2 | services 14:1 |
| 161:23 167:8 | 121:7,11,13,21 | sense 88:9 | 23:2,14 37:2 |
| 167:10 168:5 | 121:22 122:22 | 199:23 | 46:15 |
| 170:3,16 204:5 | 122:24 123:20 | sent 22:20 23:1 | serving 34:12 |
| 205:15 | 123:21,23 | 23:6 | session 65:13 |
| | 124:2,4,20,22 | | |

Golkow Technologies, A Veritext Division Document 507-9 Filed 08/26/25

www.veritext.com

[set - slave] Page 49

| 4 205 15 | 110.00 | 177 16 | 104161004 |
|-----------------------|------------------------|------------------------|-----------------------|
| set 205:15 | shown 118:23 | similar 177:16 | 124:16 133:4 |
| 216:13,21 | 118:24 119:8 | simply 59:5 | 134:8 135:10 |
| setting 146:5 | 119:12,21 | 65:24 84:3 | 135:18 137:15 |
| seven 27:19 | 126:1 184:1,13 | 112:8,14 | 139:13 140:9 |
| 90:17,21 | shows 83:12,17 | single 57:10,18 | 146:6 147:3,9 |
| several 143:20 | 119:19 135:16 | 58:2,3,18 59:2 | 148:20 154:14 |
| 173:17 | 213:16 | 67:16,17 84:4 | 155:13 158:15 |
| severe 41:21 | side 41:7 | 141:4 142:21 | 158:22 159:7 |
| 56:1,11 80:3 | 106:16 113:12 | 213:14,22 | 159:14,18 |
| 174:9 180:10 | 117:17 166:8 | sir 14:2 33:23 | 160:5 161:11 |
| sglt2 154:23 | sided 38:5 | 34:16 40:3,8 | 161:14,19 |
| 155:6 | sign 187:24 | 40:11 42:13 | 162:3 164:13 |
| share 77:6 | signature 75:6 | 47:5,7,9,11,13 | 166:18 168:16 |
| shared 208:7 | 76:20 135:16 | 47:16 48:8,11 | 168:19 171:12 |
| she'll 183:5 | 216:23 218:23 | 48:14,17,20 | 172:10 176:18 |
| sheet 217:1,13 | 219:23 | 49:5,8 60:5,11 | 181:21 183:10 |
| 218:1 219:1 | signed 132:5,8 | 65:23 67:11 | 184:15 191:3 |
| shocked 213:6 | significant | 71:19 72:7,21 | 199:13,20 |
| short 214:5 | 50:18 57:13,15 | 73:18 74:5,10 | 200:2 201:9 |
| shorthand 1:17 | 58:21 59:10 | 75:7 76:22 | 203:17 205:22 |
| 216:4 | 79:18 80:24 | 77:10 78:22 | 206:1,22 207:2 |
| show 21:24 | 82:4,15 89:3 | 79:4 81:5,14 | 208:18,24 |
| 34:17 87:19 | 105:17,22,24 | 95:6 96:7 | 209:4,10 |
| 88:4,20 122:2 | 127:15,19,24 | 101:1 102:15 | 210:15 211:4 |
| 123:2 124:6 | 128:4 129:3,6 | 103:6 104:6 | site 166:12 |
| 138:2 157:1,10 | 131:6,11 | 109:9 110:16 | 171:24 |
| 160:6 162:4 | 142:12 143:4,4 | 114:5 115:10 | sitting 200:10 |
| 169:16 170:6 | 173:23 176:6 | 116:18,21 | six 25:19 59:1 |
| 184:3 200:3,12 | 176:22 214:18 | 117:8,12 | 68:16 164:9 |
| 204:24 | significantly | 118:13,16 | 174:17 |
| showed 120:22 | 98:6 105:3 | 119:12 120:8 | skills 165:11 |
| 130:13 | 110:5 174:14 | 120:24 121:3 | skip 140:4 |
| showing 114:17 | signs 184:1,3,9 | 121:14 122:12 | slave 172:7,21 |
| 133:5 | 184:13 185:5 | 122:18 123:1 | 173:11 |

[sleep - stage] Page 50

| sleep 80:3 | somewhat | sounds 13:12 | 150:6 169:8 |
|------------------------|--------------------|-------------------------|-------------------------|
| 174:10,11,14 | 46:17 | 26:1,2 103:6 | 174:15,24 |
| 174:23 180:10 | soon 129:1 | 120:24 159:2 | 175:10 180:2 |
| slow 72:10 | 167:12 209:22 | 187:22 | 181:7,11 |
| small 43:12,20 | sorry 11:22 | south 4:22 5:3 | 187:16 188:17 |
| 58:15 187:6 | 14:5 18:15 | 5:5 157:20 | 201:9 206:12 |
| smith 5:8 169:7 | 19:8 26:14 | 158:5 160:10 | 208:15 211:5 |
| 169:9 171:20 | 27:15 29:5 | 160:24 162:7 | specifics 10:22 |
| smoking 70:23 | 35:11 40:9 | 194:24,24 | 13:9 21:1 31:6 |
| smoothly 7:14 | 54:3 62:15 | speak 65:14 | 33:1 35:11 |
| solely 34:2 | 82:13 93:6,11 | speaking 112:3 | 88:18 99:20 |
| solid 41:5 | 98:14 100:1 | 115:14 176:1 | 153:18 |
| solitary 114:13 | 107:11 110:11 | specialties 48:5 | specimen 83:11 |
| somebody | 122:13 123:13 | specialty 46:22 | spent 23:23 |
| 56:20 84:4 | 125:22 132:6 | 46:23 47:22 | 25:3 28:9 |
| 90:2 97:24 | 136:18,19 | specific 3:22,23 | 42:14 |
| 98:20,22 99:4 | 140:21 144:17 | 5:7 37:8,17 | spike 111:6 |
| 99:16 110:8 | 147:14 150:7 | 43:24 60:16 | spoken 48:24 |
| 111:15 147:7 | 150:18 153:17 | 69:18 78:3,6 | spot 117:20 |
| 147:21 151:14 | 153:22 155:15 | 168:22 169:23 | stability 97:20 |
| 167:5 | 156:23 162:19 | 170:7 171:20 | 185:13 |
| somebody's | 169:14 192:14 | 177:1 | stable 51:3 |
| 42:8 52:4 53:3 | 198:13 199:16 | specifically | 57:8 63:22,22 |
| 57:22 66:5 | 200:2 203:1,4 | 10:19 28:16 | 64:3,18 97:16 |
| 91:4,7 105:2 | 208:14 209:15 | 30:16 61:5 | 97:23 132:21 |
| 148:14 | 210:22 211:4 | 70:9 71:5 | 136:18,24 |
| someone's | 213:15 | 75:18 78:10 | 137:5,18 139:8 |
| 53:16 57:12,14 | sort 18:17 | 79:19 93:9 | 140:1,5 194:16 |
| 58:17 59:13 | 65:13 79:24 | 98:12,13 112:3 | staff 15:10 |
| 61:11,19 63:6 | 83:13 112:8 | 122:12 123:14 | 67:21 132:9 |
| 64:6 65:15 | 127:8 197:21 | 131:23 135:3 | 135:16 |
| 87:4 106:3 | sound 18:23 | 138:14 143:2 | stage 46:1,2,9,9 |
| 107:19,23 | 20:7 | 143:19 144:1,7 | 46:12 51:3,3 |
| 112:15 210:17 | | 144:17 146:19 | 55:4,10,16,22 |

[stage - sure] Page 51

| 56:4,8,14,20,24 | state 7:4,7 | stcc 4:23 5:4,7 | 19:9 21:21 |
|----------------------|-----------------------|-----------------------|---------------------|
| 57:3,4,8,9 58:4 | 158:3 193:20 | 158:7 161:1 | 33:22 76:13 |
| 58:7,12,15,24 | stated 56:4 | stenographic | 77:3 |
| 59:2,7 61:7 | 111:19 114:7 | 6:10 38:10 | substantive |
| 62:19,24 96:8 | 137:12 141:2 | stenographic | 11:5 21:4 |
| 96:12,19 97:6 | 146:21 171:19 | 216:12 | successful |
| 97:9,15 98:23 | 174:21 188:13 | stents 156:9,10 | 196:14 |
| 99:6,11 125:12 | 194:12 | step 211:19 | suffered 193:20 |
| 132:16 137:17 | statement | stephan 2:19 | 195:8 |
| 139:5 188:1,2 | 166:22 172:13 | 6:2 | suffers 166:9 |
| 194:17 | 172:17,19 | sticks 165:19 | suggest 57:7 |
| stages 41:24 | 173:8,14,16 | stop 9:8 | 110:24 |
| 54:24,24 96:15 | 191:8,19 | stopped 179:14 | summer 13:11 |
| staging 51:23 | 194:20 | stopping 130:1 | 14:6 |
| 125:19 | statements | story 51:16 | summertime |
| stamped 94:18 | 173:6 | stress 83:7 | 13:10 |
| 122:16 123:18 | states 1:1 7:1 | 176:7,22 177:6 | supplemental |
| 132:3 135:6 | 26:24 29:4 | strike 91:3 | 3:17,18 5:7 |
| 138:17 153:22 | 32:5,14 90:18 | students 42:17 | 16:15,23 17:5 |
| 158:6 205:17 | 137:21 139:24 | studies 114:17 | 17:12 130:22 |
| standard 64:23 | 140:5 159:9 | study 109:5 | 167:16 170:3,7 |
| 77:17 150:21 | 160:1 161:8 | subject 7:22 | supplementary |
| 183:10 186:24 | 163:5 170:17 | 49:3,6 212:20 | 23:20 |
| 188:19 213:2 | 171:6 199:14 | submitted | supplied 91:20 |
| 214:11 | 209:6,9 | 22:13,16,22 | support 15:10 |
| start 37:7 | stating 79:9 | 23:19 38:18 | 21:19 67:21 |
| 69:16 72:24 | statistics 48:18 | submitting | 76:8 176:8 |
| 201:12 | status 79:1,2 | 24:16 | 180:21 |
| started 88:12 | 105:19 135:22 | subscribed | supporting |
| 156:18 159:3 | 135:23 137:1 | 217:20 | 79:13 |
| 159:12 | 188:10 | subset 50:6 | supports 188:7 |
| starting 95:14 | stay 23:15,19 | 201:5 | sure 7:14,16 |
| starts 164:10 | 211:18 | substance | 8:3,17 16:3 |
| | | 11:15,18 19:4 | 17:11 19:10 |
| | 1 | 1 | 1 |

[sure - testify] Page 52

| 38:3 41:23 | 48:3 68:8 | taken 19:21 | 188:18 191:17 |
|-----------------------|----------------------|---------------------|------------------------|
| 70:21 72:6 | surprising | 216:11 217:9 | 191:24 194:23 |
| 80:15 87:22 | 142:6 | takes 68:17 | 194:24 |
| 91:14 101:3 | surrounding | 85:22 | teams 67:23 |
| 128:13 130:3,5 | 15:7 33:17 | talk 8:23 21:5 | technologies |
| 142:20 147:16 | survival 85:20 | 37:1 46:2 54:8 | 2:19 |
| 157:8 161:4 | 182:8,13 | 75:12,19 83:6 | tell 7:19 11:19 |
| 163:24 165:24 | 185:18 | 88:7,8 99:20 | 40:24 113:17 |
| 173:5 179:20 | susceptible | 131:14 173:11 | 162:15 203:4 |
| 188:17 189:4 | 105:18 | 194:8 | 207:3,9 |
| 189:11 191:5 | suspicion | talked 24:14 | temporally |
| 197:11 200:5,9 | 108:20 109:6 | 25:5 58:22 | 63:7 |
| 201:7 | swear 6:13 | 59:13 63:5,14 | ten 25:20 26:10 |
| surgeon 40:2 | sworn 6:15,19 | 63:20 78:4 | 120:21 140:17 |
| 41:1 42:15 | 216:7 217:20 | 86:7 88:10 | 146:16 |
| 47:18 48:2 | symptoms | 89:4 91:8 93:8 | term 137:7 |
| 67:18,23 90:1 | 45:19 | 99:9 112:7 | 185:14,16,18 |
| 197:4,8,13 | t | 127:6 128:23 | 195:13 |
| surgeon's 41:7 | t 3:8 4:1 5:1 | 142:3 172:24 | terms 14:24 |
| surgeons 47:23 | tab 107:1 | 173:18 186:17 | 45:18 69:12 |
| 47:24 | 136:23 153:4 | 186:23 192:3,7 | 146:4 167:18 |
| surgeries 40:22 | 157:11 159:16 | 193:2 196:3,23 | 186:7 188:14 |
| 42:19,24 43:13 | 160:7 161:20 | 213:7 | 199:23 212:13 |
| surgery 40:4,7 | table 68:2 | talking 58:14 | test 92:20 |
| 40:10,11 41:6 | take 7:22 9:4,5 | 67:16,19 98:18 | 141:13 |
| 41:12,17 42:11 | 9:7,10,18 | 105:5 115:13 | testified 6:19 |
| 42:15 51:13 | 66:16 72:5 | 172:18 183:2 | 84:2 141:10 |
| 56:6,6 93:21 | 140:18 148:18 | 189:9 204:20 | 147:19 150:12 |
| 115:18 129:2,2 | 157:24 160:12 | 207:14 | 151:12 164:22 |
| 156:14 161:13 | 189:12 190:4 | taught 90:13 | 165:1 208:16 |
| 166:10 171:16 | 202:21 206:13 | teaching 42:15 | testifies 145:24 |
| 183:9 | 211:14 213:20 | 42:16,16 | 148:21 |
| surgical 43:6,7 | 214:17 | team 45:2 67:6 | testify 30:22 |
| 43:18,19 47:22 | | 67:6,14 93:3 | 216:7 |

| | I | I | I |
|-------------------|---------------------|--------------------|---------------------|
| testifying 46:24 | 65:19 67:12 | thereof 90:19 | third 3:18 |
| 68:24 69:3,7 | 70:18 71:24 | thing 10:8 | 16:22 17:5 |
| 69:11 71:23 | 72:22 73:10,10 | 149:8 183:21 | 28:15 100:13 |
| 72:15 73:20 | 74:23 83:19 | 191:1,15,16 | 118:14 121:2 |
| 74:21 | 94:7 99:22 | 209:13 | 163:4 166:7 |
| testimony 8:23 | 106:18,22 | things 7:15 | 172:6 |
| 9:21 10:5 | 107:14,17 | 10:20 43:14 | thirds 123:20 |
| 11:11 18:19 | 113:13,16,19 | 45:19 62:22 | thomas 32:12 |
| 24:10,11 45:6 | 115:15 116:15 | 63:1 70:24 | 32:15 |
| 68:22 71:12 | 117:19 119:22 | 82:19 86:6 | thought 10:21 |
| 72:19 74:2,9 | 122:9,20 123:9 | 93:8 105:18 | 11:12 19:23 |
| 114:22 174:3 | 124:13 134:22 | 108:22 112:6 | 21:19 84:18 |
| 209:3,12 | 138:9,11 | 116:4 128:23 | 108:16 112:19 |
| 210:12 215:7 | 146:17 153:11 | 149:7 175:10 | 169:3 |
| 216:11 | 153:12 158:2 | 194:8 213:9 | thoughts 77:5 |
| testing 58:16 | 160:13 162:24 | think 18:7 | three 12:1,3,7 |
| 159:6 | 169:4 170:8,10 | 24:13 25:5 | 25:15,16 26:15 |
| tests 57:19 | 182:16 199:9,9 | 49:20,22 50:10 | 26:17 36:5 |
| 109:24 214:1 | 200:23 204:22 | 50:10,11 57:24 | 58:9,19 64:8 |
| texas 4:22 5:3,5 | 205:11,13 | 58:10 62:1 | 81:12,18 82:11 |
| 157:21 158:5 | 211:17 212:6,6 | 76:1 82:9 85:4 | 84:15,21 85:13 |
| 160:10,24 | 215:3 | 87:14 91:13 | 88:1,19,24 |
| 162:7 194:24 | thankfully | 93:2 96:24 | 93:10 97:20 |
| 194:24 | 121:24 | 97:8 98:13 | 98:1,15 124:1 |
| thank 8:12 | thanks 184:7 | 109:4 110:19 | 125:4 127:18 |
| 10:16 15:23,24 | therapy 54:11 | 112:5 129:4,24 | 131:5 132:19 |
| 17:9 19:12,17 | 65:20 81:12,17 | 144:13 149:3,3 | 137:2 143:13 |
| 19:19 20:1 | 82:11 84:5,14 | 158:8 161:2 | 158:20 164:20 |
| 21:24 30:2 | 85:13 87:13 | 163:6 167:12 | 165:4 171:3,3 |
| 34:24 35:1,2 | 88:1,23 98:1 | 167:14 190:3 | 194:13 |
| 35:14 37:15 | 131:5 151:23 | 191:14,18 | thursday 1:10 |
| 38:20 39:21 | 154:9,24 | 192:2,3,5,9 | 215:10 |
| 45:4 59:20 | 164:19 165:4 | 207:21 208:2 | time 6:4 8:23 |
| 60:24 62:18 | 165:12 195:18 | 208:11 | 12:2,8 23:16 |

| 20.0 42.14 10 | titled 16:22 | tonia 70.6 | transition |
|------------------------------|---------------------|---------------------------------------|-----------------|
| 28:8 42:14,18 51:21 62:16 | 71:8 72:17 | topic 70:6 topics 68:23 | 191:14 |
| 75:20 76:7 | today 6:9 7:15 | 71:17 190:7 | |
| 77:13 78:10 | 7:19 8:9 9:21 | tort 210:14 | transplant 33:4 |
| | | | 40:2,6,18 41:1 |
| 79:6,7 91:10 | 9:24 10:22 | total 20:16 | 41:5,9,10,12,14 |
| 93:21 95:20 | 11:20,24 12:15 | 25:16 | 41:16 42:3,19 |
| 97:22 99:2 | 21:6 24:14 | totality 18:5 | 42:24 43:5 |
| 100:1 115:17 | 31:18 45:5 | 19:2 59:6,8 | 44:3,6,10,16 |
| 119:3,18,18 | 72:9 75:12 | 98:16 142:2 | 45:24 46:3 |
| 125:17 126:3 | 85:5 180:11,17 | 193:1 | 47:14,18,19,22 |
| 127:3 128:21 | 196:6 | towards 95:14 | 47:23,23 50:12 |
| 134:5 140:18 | today's 6:4 | 122:21 133:21 | 51:13 56:6,22 |
| 141:17,24 | 10:4 160:2 | toxic 210:13 | 57:7 64:24 |
| 142:11 149:2 | 215:7 | toxicologist | 66:12 67:6,9 |
| 152:16 156:19 | together 45:1 | 47:8 | 68:9,10,13,14 |
| 156:23 160:4 | 51:16 84:18 | toxins 69:7,12 | 68:15 70:24 |
| 164:15 167:2 | 88:15 128:22 | 69:13 71:15 | 90:1 97:19 |
| 167:14 172:14 | 165:22 | 74:7 | 167:4 181:20 |
| 173:9 182:2 | told 30:3 | training 68:2 | 181:22 182:22 |
| 186:5 197:9 | 139:19 | 78:18 | 183:6,8,12,14 |
| 202:10,14,17 | took 7:18 25:13 | transcribe 8:2 | 184:2,18 |
| 202:19 206:13 | 157:22 | transcribed 8:4 | 185:12,21 |
| 209:18,19 | tools 53:21 | transcript 4:4 | 186:1,3,15 |
| 211:10 212:4 | top 28:15,15 | 4:19 31:5 33:3 | 187:5,6,11,15 |
| 214:6 216:12 | 83:13 95:8,11 | 35:16 107:10 | 188:1,13,22,24 |
| timeframe | 101:17 102:3,7 | 108:2 140:16 | 189:9 191:15 |
| 88:19 119:14 | 104:3 108:6 | 144:15,24 | 191:17 193:8 |
| timeline 80:1 | 113:24 116:19 | 146:15,18 | 196:5,14 197:4 |
| times 11:23 | 118:9 120:10 | 175:24 216:11 | 197:8,13 |
| 12:1,3,7 36:3,4 | 121:15 133:2 | 217:9 | 210:18 |
| 44:4 152:22 | 133:21,21 | transcripts | transplantation |
| 174:17 195:5 | 135:9,15 | 28:20 29:10,16 | 40:14 42:22 |
| tinnitus 174:22 | 158:10 159:17 | 31:16 32:5,10 | 66:10 167:6 |
| | 162:20 | 32:22 75:23 | 188:20 |

| transplanted | 192:16 193:13 | 76:17 77:1,12 | 213:15 |
|--|--|---|--|
| 193:6 | 195:12,21 | 77:18 181:13 | type 42:1 45:17 |
| transplants | 196:2,7 201:24 | 181:19 182:4 | 146:4 149:8 |
| 43:11 47:19 | 203:12,18 | 182:21 183:17 | 168:22 |
| 65:22 89:2 | 204:3 208:1,2 | 184:1,13,16,20 | typical 13:24 |
| 182:9,18 188:5 | trial 2:8 70:7 | 185:21 186:15 | 23:12,13 105:2 |
| 188:9 | 208:17 209:12 | 187:10 188:12 | 105:5 198:17 |
| traumatic | 210:13 211:3 | 188:14 189:3 | typically 37:3 |
| 178:12 | tribunal 49:7 | 189:14 190:19 | 41:15,19 46:10 |
| treat 45:9 | true 30:19 52:9 | 190:20,23 | 46:11 51:2,9 |
| 166:19 168:21 | 106:3 182:17 | 191:8 192:16 | 51:14 52:14 |
| 168:24 176:19 | 186:16 189:6 | 193:4,21 195:8 | 53:22 54:1,4 |
| treated 61:22 | 213:12 217:11 | 195:9,21 196:8 | 56:5,21 57:6 |
| 62:1,2,4,8,14 | truly 106:9 | tukes's 193:19 | 58:24 67:13 |
| 157:5 202:3 | truth 7:19 | tumor 170:18 | 68:15 94:4 |
| 203:24 | 216:8,8,9 | turn 38:14 | 107:19 193:11 |
| treater 42:8 | truthful 9:20 | 95:13 96:3 | 197:5 |
| treaters 115:7 | try 9:4 23:15 | 101:20 103:24 | u |
| treating 12:22 | 46:21 113:17 | 120:1 121:8 | u.s. 2:8 |
| | | | |
| 42:1 67:7 | 189:12 | 122:17 139:1 | |
| 42:1 67:7 142:18 149:21 | 189:12 trying 26:6 | 122:17 139:1 145:22 | ua 133:3 |
| | | | ua 133:3 uacr 134:4,9,12 |
| 142:18 149:21 | trying 26:6 | 145:22 | ua 133:3 uacr 134:4,9,12 uas 133:5 |
| 142:18 149:21 177:16 | trying 26:6 45:5 116:13 | 145:22 two 25:18 38:5 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 |
| 142:18 149:21 177:16 treatment | trying 26:6 45:5 116:13 128:14 140:21 | 145:22 two 25:18 38:5 48:5 53:21 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 |
| 142:18 149:21 177:16 treatment 31:22 49:24 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 63:17 74:16 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 12:22 16:9 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 81:15 82:17,19 83:5 90:15 98:17 101:9 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 30:15 |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 63:17 74:16 109:12 112:21 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 12:22 16:9 20:6,19 24:4 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 81:15 82:17,19 83:5 90:15 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 30:15 uncertain 18:5 |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 63:17 74:16 109:12 112:21 113:22 122:15 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 12:22 16:9 20:6,19 24:4 27:5 32:2,6,11 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 81:15 82:17,19 83:5 90:15 98:17 101:9 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 30:15 uncertain 18:5 uncontrolled |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 63:17 74:16 109:12 112:21 113:22 122:15 123:17 132:2 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 12:22 16:9 20:6,19 24:4 27:5 32:2,6,11 32:16,18,19,19 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 81:15 82:17,19 83:5 90:15 98:17 101:9 123:20 131:15 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 30:15 uncertain 18:5 uncontrolled 152:8 |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 63:17 74:16 109:12 112:21 113:22 122:15 123:17 132:2 135:5 138:17 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 12:22 16:9 20:6,19 24:4 27:5 32:2,6,11 32:16,18,19,19 32:23 33:3,18 37:18 48:22 68:19 69:3 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 81:15 82:17,19 83:5 90:15 98:17 101:9 123:20 131:15 132:19,19 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 30:15 uncertain 18:5 uncontrolled 152:8 under 8:14 |
| 142:18 149:21 177:16 treatment 31:22 49:24 50:1,4 62:6 63:17 74:16 109:12 112:21 113:22 122:15 123:17 132:2 135:5 138:17 138:20 158:4 | trying 26:6 45:5 116:13 128:14 140:21 tubules 148:4 tukes 3:16,24 12:22 16:9 20:6,19 24:4 27:5 32:2,6,11 32:16,18,19,19 32:23 33:3,18 37:18 48:22 | 145:22 two 25:18 38:5 48:5 53:21 54:18 64:8 65:16,18 77:16 81:15 82:17,19 83:5 90:15 98:17 101:9 123:20 131:15 132:19,19 158:20 165:18 | ua 133:3 uacr 134:4,9,12 uas 133:5 um 96:13 163:19 unable 9:20 unaware 30:11 30:15 uncertain 18:5 uncontrolled 152:8 |

[under - various] Page 56

| | | | , |
|----------------|------------------------|---------------------|------------------------|
| 137:11 139:7 | undetectable | 60:10,13,19 | 186:18 |
| 139:10 141:12 | 140:7,13 | 61:4 64:18 | utuc 69:23 70:6 |
| 144:8 154:2 | 141:23 150:14 | 108:21 114:8 | 71:4 171:10,22 |
| 158:19 159:8 | undetected | 134:10 140:6,7 | 204:3 |
| 159:19,22 | 134:5,12 | 140:12 141:11 | v |
| 161:3,16,20 | unfamiliar | 142:10 148:6,6 | v 26:24 80:18 |
| 163:3 182:5 | 143:22 | 151:14 184:23 | 80:21,22 182:5 |
| 214:16 217:6,8 | unforeseen | 214:2 | va 29:24 31:8 |
| 217:15 | 149:11 | urologist 30:1 | 31:17,17 92:18 |
| underlined | unfortunately | 30:7,17 48:6 | 94:15 95:10 |
| 27:1 | 117:21 | 114:4,23 145:5 | 107:15 113:22 |
| underlying | unilateral 81:8 | urothelial | 114:4,22,23 |
| 87:5 213:17 | 83:1 85:8 | 135:23 168:12 | 115:7 122:15 |
| understand 7:2 | 87:10 88:9 | 170:20 | 123:17 135:5 |
| 7:18,21 8:6,7 | 112:10 128:23 | usdoj.gov 2:11 | 135:17 138:17 |
| 8:10 9:3 26:7 | united 1:1 7:1 | 2:12,13 | 138:22 145:5 |
| 30:1 31:9,14 | 26:24 90:18 | use 49:15 52:9 | 149:20 174:6 |
| 46:22 70:19 | 209:6,9 | 53:15,16,23 | 191:24 194:15 |
| 89:2,6 90:1 | units 147:23 | 54:14 59:3 | 194:23,23,23 |
| 95:5 107:13 | unrelated | 64:13 65:4,7 | 203:16,16,20 |
| 114:3 115:6,9 | 170:20 204:3,5 | 65:12 108:17 | 206:8 208:4,11 |
| 115:11 128:14 | unsure 78:5 | 174:17 180:4 | valuable 65:9 |
| 139:14 145:4 | untoward | 186:19 196:16 | value 57:10 |
| 163:17 177:16 | 59:10 61:16 | 213:1 214:18 | 58:2 127:17 |
| 178:3 179:23 | upcr 134:5,12 | used 18:18 | values 64:21 |
| understanding | updated 39:1 | 34:15 77:16 | 126:19 127:2 |
| 68:22 72:2 | 114:7 130:23 | 84:17,19 | 128:15,16 |
| 74:12 99:16 | 171:1 | usual 131:15 | 213:2 |
| 177:19 217:14 | uptrend 132:21 | utilize 53:8 | variable 153:1 |
| understood | uremia 184:22 | 91:14 213:11 | variables 61:10 |
| 8:14 9:12 | urinalysis | utilized 64:19 | 61:13 |
| 10:15 157:8 | 133:3 | 88:17 150:4 | various 99:11 |
| 170:19 | urine 52:4 55:2 | utilizing 63:13 | 213:7 |
| | 58:8 59:16,22 | 64:20 85:19 | |

[vas - witness] Page 57

| | I | | 1 |
|----------------------|-------------------------|--------------------|------------------------|
| vas 92:17 | vii 71:6 73:16 | wauwatosa | 211:2 |
| vascular 83:21 | 73:20,21 | 1:15 6:7 | west 1:14 6:7 |
| vast 57:2 | viii 71:15 73:23 | way 52:11 | 7:9 |
| vba 4:8 | viral 184:22 | 88:14 95:15 | whereof 216:21 |
| verbal 8:5 | virtue 141:3 | 123:20 166:7 | willie 32:11,23 |
| verbatim | volume 105:18 | 177:17 178:4 | wisconsin 1:15 |
| 216:11 | 127:9 155:24 | 182:7 198:14 | 6:7 7:9,10 37:3 |
| veritext 2:19 | voluminous | ways 53:13 | witness 3:2 |
| 6:3 | 10:1 21:8 | 87:4 | 6:14,18 10:15 |
| version 38:23 | W | we've 18:9 | 10:17 13:16 |
| versus 42:15 | w 3:12 28:18,21 | 27:20 39:19 | 15:3,23 19:1 |
| 47:21 91:12 | 199:15,17 | 66:15 75:21 | 19:13,16,21 |
| 189:12 | wake 174:17 | 112:5,7,12 | 20:9 21:16 |
| vha 4:6,10,11 | wallace 36:23 | 119:12 125:11 | 25:24 28:3 |
| 4:13,14,16,17 | want 8:24 9:6,7 | 126:20 129:24 | 30:14 33:7 |
| 4:21 113:23 | 19:23 23:19 | 149:18 166:16 | 34:12 35:1,21 |
| 122:16 123:18 | 38:2 63:15 | 167:19 180:11 | 36:7,10,13,17 |
| 124:19 132:3 | 69:15 101:3 | 186:17,22,22 | 36:20,23 39:22 |
| 135:7 138:18 | 158:9 163:9 | 186:23 190:3 | 44:19 45:22 |
| 153:23 | 173:5 213:1,23 | 191:11 192:3 | 50:9,23 51:6 |
| vi 69:22 73:5 | 213:24 214:10 | 192:19 | 65:3 73:12 |
| video 6:5,6 | wanted 19:23 | week 12:4 | 74:20 76:11 |
| 12:12 | 106:21 157:7 | 183:8 | 82:23 85:3,16 |
| videographer | 164:1 | weekly 162:1 | 86:5 89:20 |
| 2:18 6:1,2,16 | wants 19:11 | weeks 12:5 | 90:5,11 97:2 |
| 66:22 67:2 | 165:20 | 105:10 | 98:5 99:1,8 |
| 130:6,10 | warrants 58:16 | weight 87:7 | 103:21 104:19 |
| 190:10,14 | washington 2:9 | weighted 86:2 | 106:23 111:10 |
| 208:22 211:21 | water 1:4 6:8 | 86:10,15,20 | 111:18 113:3 |
| 212:1 215:6 | 12:18 13:2 | 87:9,23 | 115:3 116:3 |
| videotaped 1:9 | 14:16 69:8 | weitz 36:20 | 119:1 122:8 |
| 1:13 | 217:4 | went 96:14 | 123:8 124:12 |
| viewed 187:24 | <u> </u> | 104:14,23 | 126:18 127:21 |
| | | 126:9 155:9 | 128:6,20 |

Golkow Technologies, A Veritext Division

877-370-3377

[witness - zoom] Page 58

| 100 15 100 0 | 165 20 155 5 | 170.00 | 26262 |
|----------------|----------------------|------------------------|---------------------|
| 129:15 130:3 | 165:20 175:7 | 172:20 | years 36:2 63:9 |
| 134:21 137:20 | 175:13 179:14 | X | 63:11,23 64:8 |
| 138:8 143:9 | 179:18 194:10 | x 3:1,8 4:1 5:1 | 81:12,18 82:11 |
| 146:11 152:6 | 201:14 213:14 | 72:16 74:6 | 84:15,21 85:13 |
| 152:19 153:12 | worked 36:6,9 | xi 74:12 | 85:22 88:1,19 |
| 162:14 165:7 | 36:12,16,19,22 | | 88:24 93:10 |
| 165:16 167:24 | 179:21,22 | y | 97:20 98:2,15 |
| 168:8,15,18 | working 13:5 | yeah 15:4 16:5 | 127:18 131:6 |
| 170:9 175:4,18 | 23:23 95:15 | 19:20 20:11 | 137:2 143:13 |
| 177:23 178:9 | 146:4 179:14 | 24:2 26:19 | 150:15 158:24 |
| 178:16,22 | works 89:15 | 66:20 82:24 | 164:20 165:4 |
| 179:4,10,16 | workup 167:4 | 90:21 91:5,8 | 166:10 171:16 |
| 180:6,13 187:4 | 196:4 202:14 | 97:3 109:22 | 182:2,9,12,18 |
| 192:23 193:15 | worried 97:11 | 113:11,16 | 182:22 183:6 |
| 194:19 195:4 | 97:18 98:6,17 | 119:6 127:3 | 185:10 194:14 |
| 196:20 197:7 | worsen 157:6 | 128:13 131:13 | 202:8 |
| 197:17 198:10 | 171:8 194:11 | 132:6 133:14 | yep 97:13 |
| 198:20 199:9 | worsening | 141:13 147:16 | 147:15 |
| 200:22 204:15 | 110:24 | 157:7 162:19 | Z |
| 204:21 205:10 | worst 183:20 | 165:8 172:23 | |
| 207:15,18,20 | wrap 190:5 | 173:5 175:15 | zajicek 1:16 |
| 208:23 212:6 | 211:15 | 181:17 186:7 | 6:12 216:3,24 |
| 216:6,7,21 | write 80:22 | 186:23 191:4,6 | zero 146:1,5 |
| witnesses 3:11 | 155:14 172:6 | 194:23 197:12 | zoom 2:12,16 |
| 3:14 | 173:21 176:5 | 207:15,21 | 12:12 |
| wonderful | 182:8 190:22 | 208:6 215:4 | |
| 141:6 | 191:1 | year 13:10 | |
| word 49:15 | wrong 84:8 | 42:24 43:2 | |
| worded 8:9 | 96:23 204:11 | 68:16 103:3 | |
| words 45:5 | 207:5,12,22,22 | 135:21 150:12 | |
| work 14:15 | 209:13 | 151:22 154:8 | |
| 22:14 23:9 | wrote 109:24 | 154:23 185:9 | |
| 27:4 47:24 | 127:3 130:17 | 185:24 198:3 | |
| 48:4 83:5,6 | 141:14 142:1 | | |
| TU.T UJ.J,U | 171.17 172.1 | | |

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted

fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions'
confidentiality and security policies and practices
should be directed to Veritext's Client Services
Associates indicated on the cover of this document or
at www.veritext.com.